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Abstract 
The strategy of suicide gene therapy in cancer is based on the idea of enabling tumour 
cells, by gene transfer, to convert a non-toxic pro-drug into a toxic product. Previous 
work has shown that the combination of herpes simplex virus type 1 thymidine kinase 
gene (HSV1-tk) transfer with the pro-drug ganciclovir (GCV) to be a promising suicide 
gene therapy in cancer. Unlike several other gene therapy systems, early-phase clinical 
trials of this strategy have shown encouraging results. Therefore, methods to improve its 
therapeutic efficacy are urgently sought.  
The  thymidine  analogue  5-iodo-2’-fluoro-2’-deoxy-1-ß-D-arabino-furonosyluracil 
(FIAU) is an alternative substrate of the HSV1-TK enzyme. The iodine atom of FIAU 
can  be  substituted  with  radioactive  iodine,  for  example;  [
123I]-iodine,  and  thereby 
utilised for the delivery of ionising radiation into tumour cells expressing the viral tk 
gene. The aim of this study was primarily to investigate the therapeutic potential of 
combining HSV1-tk gene transfer and [
123I]FIAU for the targeted radiation cytotherapy 
of prostate cancer cells alone or in combination with GCV. 
The HSV1-tk gene was cloned into the plasmid vector pcDNA3.1. This plasmid, driven 
by the ubiquitous promoter of CMV, was then used to transfect the prostate cancer cell 
line DU145 and the glioma cell line UVW. A viral TK positive, commercially available 
cell line derived from osteosarcoma (143B-TK) along with its TK-negative clone were 
also used for comparison.  
The viral tk gene transfection efficiency was assessed by three independent methods. 
Firstly,  the  uptake  of  [
123I]FIAU  normalised  to  the  uptake  of  tritiated  thymidine 
([methyl-
3H]TdR); secondly, GCV sensitivity, assessed by the MTT assay; and thirdly, 
by  the  detection  of  HSV1-tk  gene  by  RT-PCR.  The  highest  specific  activity  of 
[
123I]FIAU was obtained by the use of a no-carrier added method of synthesis.  
The  cytotoxicity  of  [
123I]FIAU  was  assessed  by  clonogenic  assay  after  incubating 
monolayers of parental and TK-positive clones of the cell lines with a range of doses of   XV 
[
123I]FIAU for the periods of 4 h, 8 h  and a period equal to their doubling times. The 
effect of this treatment on cell cycle progression was assessed by FACS analysis after 
staining the cellular DNA with propodium iodide.  
Combination therapy using GCV and [
123I]FIAU for the treatment of TK-positive clones 
of  the  prostate  cancer  cell  line  DU-145  and  the  osteosarcoma  cell  line  143B  was 
assessed by the method of median effect analysis and combination index. Monolayers 
were treated with a constant ratio of various doses of [
123I]FIAU for 4h or GCV for 72h. 
The  combination  therapy  followed  three  different  timing  schedules  of  GCV-before-
[
123I]FIAU, [
123I]FIAU-before-GCV, or simultaneous therapy. 
The expression of HSV1-tk gene by the three cell lines was confirmed by the three 
methods described above. For instance, the TK positive clone of the cell line DU145 
exhibited 4.25 ± 0.15 times higher [
123I]FIAU/ [methyl-
3H]TdR uptake ratio and 43 
times higher sensitivity to GCV compared with the parental cell line. 
The  three  cell  lines  demonstrated  sensitivity  to  radiolabelled  FIAU,  which  was 
significantly enhanced by HSV1-tk gene expression. This sensitivity was time-, dose-, 
and  proliferation-dependent.  Maximum  cell  kill  was  achieved  when  the  monolayers 
were exposed to [
123I]FIAU for a period equavelant to the cellular doubling time. For 
example,  the  sensitivity  enhancement  factor  by  tk  gene  expression  of  the  cell  line 
DU145 increased from 5.2 to 7.6 when the treatment period was prolonged from 4 h to 
26 h (doubling time of DU145). 
Following the treatment with [
123I]FIAU for a period equal to the doubling time, cells 
were arrested at G2/M phase of the cell cycle. For instance, 49% of DU145-TK cells 
treated  with  1  MBq/ml for  26  h  were  at  G2/M  phase  compared  with  21.9%  of  the 
untreated cells. In contrast, incubation of DU145-TK or 143B-TK cell lines with lethal 
doses of [
123I]FIAU for 4 h and GCV for 72 h had no significant effect on cell cycle 
progression.   XVI 
Comparison of the effectiveness of [
123I]FIAU in the monolayer and spheroid cultures 
indicated  that  clonogenic  cell  kill  resulting  from  Auger  electron  bombardment  was 
restricted to targeted rather than bystander cells. 
The combination therapy of [
123I]FIAU and GCV of the cell line DU145-TK resulted in 
antagonistic  effect  throughout  the  examined  dose  range  of  the  schedules  of  FIAU-
before-GCV and simultaneous therapy and the low toxicity concentration range (lower 
surviving fractions) of the GCV-before-FIAU schedule. The high toxicity concentration 
range of the latter schedule has shown evidence of additive effect. For the osteosarcoma 
cell line 143B-TK, synergistic effect was observed at the high toxicity concentration 
range  of  the  three  combination  schedules  and  antagonism  at  the  low  toxicity 
concentration range of the combinations. 
We concluded from this in vitro study that the combination of HSV1-tk gene transfer 
and the delivery of radiolabelled FIAU is a promising strategy for targeted radiation 
cytotherapy  of  prostate  cancer.  This  proliferation-dependent  therapy  has  caused 
significant  cell  cycle  arrest  that  warrants  further  investigation.  Furthermore,  the 
combination  of  GCV  and  radiolabelled  FIAU  for  the  treatment  of  tumour  cells 
expressing the gene of viral TK resulted in a dose- and schedule-dependent synergism. 
We  believe  that  these  encouraging  results  should  be  substantiated  by  in  vivo 
experiments in the near future.   1 
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1.1 Prostate cancer epidemiology and risk factors 
1.1.1 Incidence 
There were 679,000 new cases of prostate cancer worldwide in 2002, making this the fifth 
most common cancer in the world and the second most common in men (11.7% of new 
cancer  cases  overall;  19%  in  developed  countries  and  5.3  %  in  developing  countries) 
(Parkin  et  al.,  2005).  In  comparison  with  the  previous  global  estimates  this  shows  an 
increased incidence of prostate cancer (Parkin et al., 1999). 
Prostate cancer is a disease of the elderly. Around the world, three quarter of cases occur in 
men aged ≥ 65 years. It is therefore more common in countries with a higher proportion of 
elderly men in their population (Parkin et al., 2001). Prostate cancer is unique among solid 
tumours in that it exists in two forms: a histologic or latent form, which can be identified in 
approximately 30% of men older than 50 years and 60% to 70% of men older than 80 
years, and a clinically evident form which affects approximately one in six American men. 
Latent  prostate  cancer  is  believed  to  have  similar  prevalence  worldwide  and  among 
different ethnicities, whereas the incidence of clinical prostate cancer varies dramatically 
between and within different countries (Reiter & deKernion, 2002). 
Incidence  rates  are  now  influenced  by  the  diagnosis  of  latent  cancers  by  screening 
asymptomatic individuals, so that where this practice is common, the incidence may be 
very high (124.8 per 100,000 in United States, for example, where it is now by far the most 
commonly diagnosed cancer in men (Parkin et al., 2005). 
   3 
1.1.2 Mortality  
The prognosis is relatively good; prostate cancer is a less prominent cause of mortality with 
221,000 deaths in 2002 (5.8 % of cancer death in men and 3.3% of all cancer deaths) 
(Parkin et al., 2005). Mortality is affected by survival and survival is significantly better in 
high-risk countries, but much of this is a consequence of more latent cancer being detected 
by screening procedures. As a result, mortality rates are probably a better guide to the risk 
of invasive prostate cancer in different populations. 
 
1.1.3 Risk Factors 
Although  the  specific  causes  of  prostate  cancer  initiation  and  progression  are  not  yet 
known, considerable evidence suggests that both genetics and environment play a role in 
the evolution of this disease. The most convincing evidence for the role of the environment 
comes from migration studies showing an increased incidence of prostate cancer in first 
generation US immigrants from Japan and China (Muir et al., 1991; Shimizu et al., 1991). 
    
1.1.3.1 Age, race and family history 
Age  is  a  strong  risk  factor  for  prostate  cancer,  white  US  men  aged  75-79  years  have 
approximately 130 times the risk of men aged 45-49 years (Parkin et al., 1997). Numerous 
genetic  alterations  have  been  demonstrated  in  prostate  cancer  tissue,  suggesting  that 
cumulative damage to DNA with age may partially explain this trend (Chan et al., 1998c).   
Race  is  one  of  the  few  well-established  risk  factors  for  prostate  cancer  incidence  and 
mortality. In the US, the disease is 66% more common and twice more likely to be fatal 
among African-Americans than Caucasians (1997). In contrast, blacks in Africa have some   4 
of  the  lowest  rates  of  prostate  cancer  worldwide,  although  this  may  partially  due  to 
incomplete disease recording (Parkin et al., 1997). Japanese and Chinese men appear to 
have lower rates of prostate cancer than their ethnic counterparts. 
A number of case-control studies have demonstrated familial clustering of prostate cancer, 
suggesting that some prostate cancers may be inherited (e.g. (Carter et al., 1992a; Carter et 
al., 1993; Carter et al., 1991; Steinberg et al., 1990). One study of 1085 prostate cancer 
patients found that a history of prostate cancer in any first or second degree relative was 
associated with a threefold excess risk. Risks tend to rise with the increasing number of 
relatives with a history of prostate cancer, especially if they had cancer at a young age 
(Carter et al., 1992a).  
 
1.1.3.2 Hormones 
Several lines of evidence support a role for sex hormones as initiators or promoters of 
prostate cancer (Wilding, 1995).  Prostate tumours are exquisitely sensitive to androgens 
and  regress  after  medical  or  surgical  castration.  Men  castrated  at  an  early  age  rarely 
experience prostate cancer (Hovenanian & Doming, 1948) and prolonged administration of 
high level of testosterone can produce prostate cancer in rats (Noble, 1977; Pollard et al., 
1982). 
Young African American men have 15% higher total circulating testosterone level than 
white men (Ross et al., 1986). Therefore, the high incidence of prostate cancer observed in 
African Americans may be related to the elevated levels of circulating androgen. A meta-
analysis  of  previously  published  studies  on  hormonal  predictors  of  prostate  cancer 
concluded that men whose total testosterone level is in the highest quartile are 2.34 times 
more likely to develop prostate cancer (Shaneyfelt et al., 2000).   5 
1.1.3.4 Diet 
Fat consumption has long been suspected to be a risk factor for prostate cancer and prostate 
cancer mortality rate correlates highly with the average level of fat consumption around the 
world  (Reiter  &  deKernion,  2002).  Fat-free  diet  has  reduced  the  growth  of  androgen-
dependent tumours in the Dunning model of prostate cancer (Clinton et al., 1988). Other 
studies have shown that a high-fat diet promotes the growth of LNCaP prostate cancer cells 
(Aronson  et  al.,  1999;  Wang  et  al.,  1995).  Gann  et  al  reviewed  several  mechanisms 
whereby fatty acid levels may influence prostate cancer (Gann et al., 1994):  first, fat can 
act as a precursor to eicosanoids, which play a critical role in tumour cell proliferation, 
immune  response  invasion  and  metastasis;  second,  membrane  phospholipids  fatty  acid 
composition  can  affect  permeability  and  receptor  activity;  third,  low  levels  of 
polyunsaturated  fatty  acids  can  inhibit  5￿ -reductase  activity;  and  fourth,  free-radical 
formation from fatty acid oxidation can damage DNA. 
A number of studies have found an association between high calcium consumption and 
increased prostate cancer risk (Chan et al., 1998a; Giovannucci et al., 1998; Rodriguez et 
al., 2003). Chan et al found that calcium intake was an independent predictor of prostate 
cancer risk (RR, 1.91). Although the mechanism by which calcium could increase prostate 
cancer risk is not known, it is hypothesised that high levels of calcium may down-regulate 
vitamin D production, thereby promoting cell proliferation (Chan et al., 1998a). 
Lycopene is a carotenoid present at high concentrations in tomatoes. Lycopene is a potent 
antioxidant which has been studied extensively as a potential negative risk factor for cancer 
(Di Mascio et al., 1989). In the health Professional Follow-up Study, high lycopene intake 
was related to a 21% lower risk of prostate cancer. Tomato sauce, the strongest dietary   6 
predictor of reduced prostate cancer risk in the cohort (36% for high versus low intake) was 
also the major predictor of serum lycopene levels (Giovannucci et al., 1995).  
Selenium is a trace mineral component of the antioxidant glutathione peroxidase. The most 
provocative evidence linking selenium to prostate cancer risk comes from a prospective 
randomised study to determine if selenium supplementation could reduce the risk of skin 
cancer  (Clark  et  al.,  1998).  Although the  trial found  no  influence  of  selenium  on  skin 
cancer, it did incidentally find a dramatic reduction in the incidence of prostate cancer.  
 
1.2 Aetiology and Molecular genetics of prostate cancer 
Although only approximately 10% of prostate cancers are believed to be inherited by rare, 
highly penetrant genes, it is more likely that multiple common low-penetrance genes also 
contribute  to  prostate  cancer  development  (Carter  et  al.,  1992a).  These  genes  may 
predispose  to  prostate  cancer  by  modulating  the  response  of  the  host  to  certain 
environmental factors or by interacting with other genes. 
1.2.1 Inherited susceptibility to prostate cancer 
Inherited forms of prostate cancer tend to develop at an earlier age compared with sporadic 
cases, although differences in terms of biological potential between inherited and sporadic 
forms of disease are less apparent (Bova et al., 1999).  
 
1.2.1.1 Hereditary prostate cancer genes 
A genome wide scan of prostate cancer families found strong evidence for a prostate cancer 
susceptibility  locus  on  chromosome  1q24-25  (Smith  et  al.,  1996).  This  region  was 
designated Hereditary prostate cancer 1 (HPC1) and it is the most extensively studied   7 
prostate cancer predisposition locus to date. Recombination mapping has localised the gene 
encoding  2’-5’-oligoadenylate  (2-5A)  dependent  ribonuclease  L  (RNASEL)  to  the 
critical region of 1q24-25, thus implicating this gene as a candidate for HPC1. At lease two 
mutations inactivating RNASEL have been identified that are potentially responsible for 
prostate cancer cases in families showing linkage to HPC1 (Carpten et al., 2002).  
 
A number of germline variants and mutations have also been identified in a gene located in 
chromosome 17 designated HPC2/ ELAC2. Variant alleles of ELAC2 were found to be 
associated with increased risk of prostate cancer (Tavtigian et al., 2001). 
Another  candidate  susceptibility  gene  for  prostate  cancer  is  the  macrophage  scavenger 
receptor  1  gene  (MSR1)  located  in  chromosome  8p22.  Family  based  linkage  and 
association  tests  have  demonstrated  that  mutations  in  MSR1  co-segregate  with  prostate 
cancer cases in men of African and European descent (Xu et al., 2002).  
Another gene called BRCA2 has been implicated as a prostate cancer susceptibility locus 
primarily due to its analysis in breast cancer families which suggests that male carriers of 
mutations are at an increased risk for prostate cancer, particularly at an early age(1999).  
 
CHEK2 is a gene encoding an upstream regulator of p53 in the DNA damage signalling 
pathway. Recently, studies of CHEK2 showed germline mutations in patients with sporadic 
and hereditary prostate cancer (Dong et al., 2003). Importantly the majority of CHEK2 
mutations identified were not detected in 423 unaffected men, suggesting a pathological 
effect of CHEK2 mutations in prostate cancer development. 
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1.2.2 Genetic Polymorphism 
Molecular  epidemiologic  studies  have  uncovered  a  number  of  intriguing  associations 
between specific gene polymorphisms (i.e., inherited sequence variants of a given gene that 
may alter its function) and risk of developing prostate cancer (Reiter & deKernion, 2002).  
1.2.2.1 Androgen receptors 
Androgen receptors (AR) mediate testosterone and diydrotestosterone (DHT) activities by 
initiating  transcription  of  androgen-responsive  genes.  The  AR  gene  contains  two 
polymorphisms that may play a role in prostate cancer initiation and progression. Exon 1 
contains a polymorphic trinucleotide (CAG)n repeat encoding polyglutamine (Kantoff et al., 
1998). The length of the polymorphism is inversely related to transcriptional activity of the 
AR gene (i.e., it modulates the response of AR to androgens) (Wieacker et al., 1998). 
Giovannucci and associates (1997) reported that men with CAG repeat length less than 18 
had a 1.5-fold relative risk (RR) of prostate cancer compared with those with repeat lengths 
greater than 26. Shorter CAG length were associated with a higher risk of advanced stages 
(RR, 2.2) and high-grade (RR, 1.9) disease (Giovannucci et al., 1997).  
1.2.2.2 5￿ -Reductase type 2 enzyme 
5￿ -Reductase type 2 enzyme converts testosterone to the more potent DHT. It has been 
hypothesised that its gene polymorphisms that confer a greater degree of enzymatic activity 
might be associated with increased risk of prostate cancer (Henderson & Feigelson, 2000; 
Ross et al., 1998). 
1.2.2.3 Vitamin D receptor 
1,25-dihydroxyvitamin D (1,25D), also known as calcitriol, is the active form of vitamin D. 
1,25D has been shown to promote differentiation and inhibit the proliferation and invasive   9 
potential of human prostate cancer cells. Prostate cells express vitamin D receptors (VDR), 
which mediate the function of 1,25D. Ingles and associates (Ingles et al., 1997) found that 
the presence of a single “long” poly A allele (i.e., L) conferred a 4.6-fold increased risk of 
prostate cancer. 
1.2.2.4 Insulin-like growth factor -1 
The insulin-like growth factor -1 (IGF-1) is part of the IGF axis, which consists of IGF 
hormones, IGF binding proteins (IGFBP), IGF receptors, and IGFBP protease. IGFs play 
important roles in cell proliferation and metabolism (Cohen et al., 1994).  IGF-1 is one of 
the strongest risk factors identified to date for prostate cancer (Chan et al., 1998c). Two 
case controlled studies in Greece (Mantzoros et al., 1997) and Sweden (Wolk et al., 1998) 
found an association between circulating IGF-1 levels and prostate cancer risk. Results 
from these retrospective studies were confirmed in the prospective Physician Health Study, 
in  which  a  direct  association  was  found  between  IGF-1  levels  measured  in  samples 
collected before subsequent development of prostate cancer (Chan et al., 1998b). Men with 
IGF-1 levels in the highest quartile had a 4.3-fold higher risk of prostate cancer compared 
with men in the lowest quartile. Together these studies provide provocative evidence that 
IGF-axis plays an important role in the development of prostate cancer. 
 
1.2.3 Somatic gene alterations in prostate cancer 
Loss of heterozygosity (LOH) involving chromosome 8p is perhaps the most common 
deletion event in prostate cancer (Gonzalgo & Isaacs, 2003). LOH of chromosome 8p is 
believed  to  be  an  early  event  in  prostate  carcinogenesis  that  is  found  in  prostatic 
intraepithelial neoplasia (PIN) and also in prostatic inflammatory atrophy (PIA) lesions.   10 
The existence of a tumour suppressor locus on 8p is supported by LOH and a comparative 
genomic  hybridisation  study  that  demonstrated  loss  of  8p  in  approximately  80%  of 
metastatic prostate cancers (Cher et al., 1996).  
LOH  at  chromosome  10q  is  frequently  associated  with  metastatic  prostate  cancer.  The 
Phosphatase and tensin homologue (PTEN) gene is located in chromosome 10q23 and is 
frequently mutated or deleted in prostate cancer cell lines and tumours (Li et al., 1997).  
Absent PTEN expression has been correlated with higher Gleason score and advanced stage 
of prostate cancer (McMenamin et al., 1999).  
The  CDKN1B  gene  is  located  on  chromosome  12p12  encodes  the  cyclin-dependent 
kinase inhibitor p27. The p27 protein regulates cell cycle progression from G1 to S phase 
by its inhibitory interaction with the cyclin E/cdk2 complex. Decreased p27 is common in 
early stage invasive prostate cancers and it has also been associated with an increased risk 
of biochemical recurrence in patients following radical prostatectomy (Cote et al., 1998). 
Expression of p27 in prostate biopsy specimens was found to be predictive of expression 
levels in radical prostatectomy specimens and it correlated with Gleason score and final 
pathological stage (Thomas et al., 2000).  
 
The  Retinoblastoma  Susceptibility  (Rb)  gene  located  on  chromosome  13q  has  been 
implicated in prostate cancer development. Mutations in Rb and loss of expression have 
been reported in 20% to 50% of prostate cancers (Cunningham et al., 1996). The lack of Rb 
expression  has  also  been  observed  in  approximately  22%  of  prostate  cancers,  although 
LOH  at  Rb  was  not  significantly  associated  with  absent  Rb  expression (Cooney  et  al., 
1996). 
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The ￿ -Methylacyl-CoA racemase (AMACR) gene was identified on chromosome 5p13 
and  found  to  be  consistently  up-regulated  in  prostate  cancer.  Approximately  88%  of 
prostate  cancer  cases  analysed  by  immunohistochemistry  demonstrated  higher  AMARC 
staining than normal prostate tissue (Luo et al., 2002). An evaluation of AMACR protein 
expression in prostate needle biopsy specimens demonstrated 97% sensitivity and 100% 
specificity for detecting prostate cancer, thus, providing further support for the diagnostic 
usefulness of this newly discovered marker (Rubin et al., 2002).  
 
Telomerase: Telomeres are repetitive non-coding DNA sequences located at the ends of all 
eukaryotic  chromosomes  that  shorten  with  each  cell  division.  The  loss  of  genetic 
information at telomeres is a fundamental component of the normal aging process.  
The enzymatic activity of telomerase functions to maintain telomere length and it has been 
associated with cellular immortalisation and cancer. Telomerase activity is increased in PIN 
lesions and prostate cancer but absent or low in benign disease and normal prostate tissue. 
Prostate epithelial cells within high grade PIN and invasive prostate cancer lesions were 
found  to  have  significantly  shorter  telomere  lengths  compared  with  adjacent  normal 
epithelial cells (Meeker et al., 2002). Telomere shortening is believed to occur at or before 
the development of PIN lesions and may precede the up-regulation of telomerase activity 
that is frequently observed in prostate cancer (Meeker et al., 2002).  
Increased Prostate stem cell antigen (PSCA) expression has been observed in greater than 
80% of prostate cancer specimens, including high grade PIN. (Reiter et al., 1998). Higher 
PSCA  expression  is  associated  with  increasing  Gleason  score,  disease  stage  and 
progression to androgen independence (Gu et al., 2000b).  
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The Kruppel-like factors 6 (KLF6) gene located on chromosome 10p encodes a zinc 
finger  transcription  factor  of  unknown  function  and  it  has  been  recently  implicated  in 
prostate carcinogenesis (Narla et al., 2001).  LOH of KLF6 was observed in approximately 
77% of prostate tumours with concomitant mutation of the retained allele occurring in 71% 
of tumours.  
 
1.2.4 DNA methylation and prostate cancer 
DNA methylation is one of the epigenetic events that can effect gene expression without 
altering  the  actual  sequence  of  DNA.  Abnormal  methylation  of  genes  such  as  those 
involved with the control of cellular growth or detoxification is believed to have a critical 
role in the early stage of prostate cancer progression (Lee et al., 1994). 
1.2.4.1 The ras association domain family protein 1, isoform A (RASSF1A) gene 
 Abnormal methylation of the RASSF1A gene is common in other cancers like lung cancer 
(Dammann  et  al.,  2000).  The  RASSF1A  promoter  is  unmethylated  in  normal  prostate 
tissue,  whereas  RASSF1A  methylation  has  been  reported  to  occur  in  60%  to  70%  of 
prostate carcinomas (Kuzmin et al., 2002). RASSF1A methylation is also a more frequent 
event in high grade prostate cancers compared with less aggressive tumours (Liu et al., 
2002).  
1.2.4.2 GSTP1 
Glutathione-s-transferase proteins (GSTPs) represent a superfamily of enzymes responsible 
for detoxifying a wide range of xenobiotics. These enzymes catalyse the nucleophilic attack 
of reduced glutathione on electrophilic compounds and they have evolved as a cellular 
protection system against their toxic effects. Aberrant methylation of regulatory sequences   13 
at the GSTP1 locus is the most common somatic genome alteration reported for prostatic 
cancer and it represents an early event in neoplastic transformation (Jeronimo et al., 2001; 
Lee et al., 1994) . 
GSTP1  methylation  occurs  in  approximately  70%  of  PIN  lesions  and  in  the  majority 
(Greater than 90%) of prostate carcinoma but not in normal prostate tissue and benign 
prostatic hyperplasia (Lee et al., 1994). Abnormal gene methylation has been associated 
with  poor  clinical  outcomes  in  patients  with  prostate  cancer  and  it  may  serve  as  a 
potentially useful tool for disease diagnosis and prognostication (Maruyama et al., 2002). 
Recent studies have reported measurement of GSTP1 methylation in cells in the urine and 
urine sediment after prostatic message of men with prostate cancer (Cairns et al., 2001; 
Goessl  et  al.,  2001).  Enokida  et  al.  have  lately  reported  a  novel  method  of  using 
methylation score (M score) as a diagnostic and staging biomarker for prostate cancer. For 
prostate cancer detection the M score had 75.9% sensitivity and 84.1% specificity, which is 
much higher compared with that reported with PSA. Furthermore, the M score showed 
significant  correlation  with  clinicopathologic  features  such  as  high  Gleason  score, 
involvement of seminal vesicle, and higher preoperative PSA (Enokida et al., 2005). 
1.3 Pathology of prostate cancer 
1.3.1 Prostatic intraepithelial neoplasia 
Prostatic intraepithelial neopalsia (PIN) consists of architecturally benign prostatic acini or 
ducts lined by cytologically atypical cells.  The presence of high-grade PIN in prostate 
biopsy samples prompts repeated biopsy according to several studies. The largest studies 
reported 23% to 35% risk of cancer on subsequent biopsy (Davidson et al., 1995; Kronz et 
al., 2001; Schlesinger et al., 2005). More and larger foci of high-grade PIN were found in   14 
prostate glands with cancer compared with those without cancer and the amount of high-
grade PIN is proportional to the number of multifocal carcinomas (McNeal & Bostwick, 
1986).  
1.3.2 Adenocarcinoma 
1.3.2.1 Tumor location and volume 
In clinical stage T2 carcinoma and in 85% of non-palpable tumours diagnosed on needle 
biopsy (stage T1c), the major tumour mass is peripheral in location (Byar & Mostofi, 1972; 
Epstein et al., 1994; McNeal, 1969). In the remaining cases, tumours are predominantly 
located in the transitional zone. Tumours that appear to be unilateral on rectal examination 
are  bilateral  in  approximately  70%  of  cases  when  examined  pathologically. 
Adenocarcinoma of the prostate is multifocal in more than 85% of cases (Byar & Mostofi, 
1972). In general, the size of a prostate cancer correlates with its extent. Extraprsotatic 
extension is uncommon in tumours of less than 0.5 cm
2. Tumours that are less than 4 cm
2 
uncommonly reveal lymph node metastases or seminal vesicle invasion (McNeal, 1992). 
1.3.2.2 Grading of prostate cancer  
The Gleason grading system is the most widely accepted grading system for the evaluation 
of prostatic adenocarcinoma (Gleason & Mellinger, 1974). The Gleason system is based on 
the glandular pattern of the tumour as identified at relatively low magnification. Cytologic 
features play no role in the grade of the tumour. Both the primary (predominant) and the 
secondary (second most prevalent) architectural patterns are identified and assigned a grade 
from 1 to 5, with 1 being the most differentiated and 5 being the least differentiated.  Since 
both the primary and the secondary patterns are influential in predicting prognosis, their   15 
resultant Gleason sum (Gleason grade or score) is obtained by the addition of the primary 
and secondary grades. 
 
1.4 Prostate cancer diagnosis and staging 
1.4.1 Diagnosis  
Prostate cancer rarely causes symptoms until it is advanced. Thus, suspicion of prostate 
cancer  resulting  in  a  recommendation  for  prostatic  biopsy  is  most  often  raised  by 
abnormalities  found  on  digital  rectal  examination  (DRE)  or  by  serum  prostate-specific 
antigen (PSA) elevations (Carter & Partin, 2002).  
1.4.1.1 Digital rectal examination 
Prostate biopsy is recommended for all men who have DRE abnormalities, regardless of 
PSA level, because 25% of men with cancer have PSA levels less than 4 ng/ml (Carter & 
Partin, 2002). A recent study by Philip et al, concluded that if patients are appropriately 
counselled before PSA testing, a DRE may not be essential for patients with a PSA level of 
2.5-10 ng/ml (Philip et al., 2005). 
1.4.1.2 Prostate specific antigen  
Prostate specific antigen (PSA) is a 33 kD serine protease of the kallikreine family that is 
produced primarily by prostatic luminal epithelial cells (Carter & Partin, 2002). PSA is 
secreted  in  high  concentrations  (mg/ml)  into  seminal  fluid,  where  it  is  involved  in 
liquefaction of the seminal coagulum (Lilja, 1997; McGee & Herr, 1988) and it is normally 
found in low concentration in sera (ng/ml). Most PSA in sera is bound to the antiproteases   16 
alpha  1-antichymotrypsin  (ACT)  and  alpha  2-macroglobulin  (MG)  (Christensson  et  al., 
1990; Lilja et al., 1991; Stenman et al., 1991). 
Since the discovery of PSA (Nadji et al., 1981; Wang et al., 1979) and its detection in the 
sera of prostatic cancer patients (Papsidero et al., 1980), PSA has become one of the most 
widely used tumour markers in medicine. Early study performed by Myrtle and Ivor in 
1989 established a reference range of 0-4 ng/ml to define normal PSA levels (Myrtle & 
Ivor, 1989). While several studies have attempted to refine the sensitivity and specificity of 
these  levels,  to  date,  these  values  remain  the  standard  against  which  elevations  are 
compared (Catalona et al., 1994b; Catalona et al., 1997; Ellis et al., 2001). Nevertheless, in 
the absence of prostate cancer, serum PSA levels vary with age, race and prostate volume 
(Carter & Partin, 2002).  Initial examination of the use of PSA as a diagnostic tool of 
prostate  cancer  has  uncovered  its  low  sensitivity  and  specificity  (Polascik  et  al.,  1999; 
Reissigl  et  al.,  1995).  Methods  to  improve  these  values  have  evolved  with  the  goal  of 
increasing the positive predictive value of PSA in early cancer detection, while limiting the 
number of unnecessary biopsies.  
Firstly, the use of different PSA thresholds depending on age and race (e.g. (Catalona et al., 
1994a; Catalona et al., 1997; Oesterling et al., 1993)). The recommended reference range 
for serum PSA (95
th percentile) for men aged 40 to 49 years is 0.0 to 2.5 ng/ml; for 50 to 59 
years, 0.0 to 3.5 ng/ml; 60 to 69 years, 0.0 to 4.5 ng/ml and 70 to 79 years, 0.0 to 6.5 ng/m 
(Oesterling et al., 1993).  
Secondly, the prostate specific antigen density (PSAD), which refers to the value of PSA 
divided by the volume of the prostate gland. A PSAD of 0.15 or greater has been proposed 
as a threshold for recommending prostate biopsy in men with PSA levels between 4 and 10 
ng/ml and no suspicion of cancer on DRE or TRUS (Bazinet et al., 1994; Seaman et al.,   17 
1993). PSAD of the transitional zone better enhances the specificity of serum PSA for 
prostate cancer detection in patients with PSA of 4.0 to 10.0 ng/ml (Djavan et al., 1998). 
Thirdly, the rate of change of PSA (PSA velocity PSAV) has been found to be specific in 
predicting the presence of prostate cancer. A velocity of  > 0.75 ng/ml per year was 72% 
sensitive and 95% specific in predicting prostate cancer in men with PSA values under 10 
ng/ml (Carter & Pearson, 1994; Carter et al., 1992b).  
Fourthly, men with prostate cancer have lower percentage of unbound or free to total PSA 
in sera (Stenman et al., 1994; Stenman et al., 1991). Cristensson and coworkers found that a 
free/total PSA cutoff of 0.18 (18% free/total PSA) significantly improved the ability to 
distinguish between cancer and non-cancer subjects as compared with the use of total PSA 
alone (Christensson et al., 1993). In two prospective multicenter clinical trials, Complexed 
or bound PSA was found to be superior to total PSA in discriminating between benign 
disease and prostate cancer (Djavan et al., 2002; Partin et al., 2003). 
1.4.1.3 Transrectal ultrasound-directed prostate biopsy  
A  number  of  studies  have  confirmed  the  inability  of  transrectal  ultrasound  (TRUS)  to 
localise early prostate cancer (Ellis et al., 1994; Flanigan et al., 1994). The major role of 
TRUS is to ensure accurate wide-area sampling of prostate tissue in men at high risk of 
harboring  cancer  (Carter  &  Partin,  2002).  Hodge  et  al,  were  the  first  to  report  that 
systematic  sampling  of  the  prostate  guided  by  TRUS  improved  the  detection  rate  of 
prostate cancer over merely sampling hypoechoic or other lesions (Hodge et al., 1989). This 
sextant  technique  was  accepted  as  the  standard  of  care  until  subsequent  literatures  has 
demonstrated it to be undersampling. In one study, for example, when the sextant biopsies 
were repeated in a single sitting, the initial biopsies revealed cancer in 22% of men while 
10% had cancer diagnosed only on the second set of biopsies (Levine et al., 1998). Chen et   18 
al used a computer simulation model of reconstructed radical prostatectomy specimens to 
compare the ability of biopsy regimens published in the literature to detect prostate cancer. 
The highest cancer detection rate of 94% was found by using 11-core multisite-directed 
scheme (Chen et al., 1999). 
1.4.2 Staging of prostate cancer  
The main goals in staging prostate cancer are to predict prognosis and to rationally select 
therapy based on the predicted extent of disease (Carter & Partin, 2002). The first clinical 
staging classification system for prostate cancer was introduced by Whitmore in 1956 and 
later  modified  by  Jewett  in  1975  (Jewett,  1975). The  tumour,  node,  metastases  (TNM) 
system for staging prostate cancer was adopted in 1975 by the American Joint Committee 
for Cancer Staging and End Result Reporting (AJCC) (Collins, 1975; Wallace et al., 1975) 
and was modified in 1997 to combine clinical stages T2a and T2b (Flemming et al., 1997). 
Table 1.1 compares the Whitmore-Jewett and TNM classifications.  
Clinical staging refers to the assessment of the extent of the disease determined by DRE, 
serum tumour markers, tumour grade, and imaging modalities. The determination of local 
extent of the disease, primarily by DRE, is referred to as the T stage. However, because 
DRE is subjective and poorly reproducible, both understaging and overstaging are often 
found when the pathologic extent of disease is correlated with DRE findings (Carter & 
Partin, 2002).  
Pathologic staging after histological examination is more useful than clinical staging in the 
prediction  of  prognosis  because  it  can  accurately  determine  tumour  volume,  surgical 
margin  status,  extent  of  extracapsular  spread,  and  involvement  of  seminal  vesicle  and 
pelvic lymph nodes (Carter & Partin, 2002)..  
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Table 1.1: Prostate cancer staging systems  
 
TNM 
     
1997  1992  Description 
whitmore-
Jewett  Description 
TX  TX  Primary tumour cannot be assessed   None   None  
T0  T0  No evidence of primary tumour  None  None 
T1  T1  Nonpalpable  tumour  not  evident  by 
imaging 
A  Same as TNM 
T1a  T1a  Tumour found in tissue removed at TUR; 
5% or less is cancerous with histological 
grade ≥7 
A1  Same as TNM 
T1b  T1b  Tumour found in tissue removed at TUR; 
>5% is cancerous or histological grade >7 
A2  Same as TNM 
T1c  T1c  Tumour  identified  by  prostate  needle 
biopsy owing to elevation in PSA  
None  None 
T2  T2  Palpable tumour confined to the prostate   B  Same as TNM 
T2a    Tumour involves one lobe or less  B1  Same as TNM 
  T2a   Tumours  involves  less  than  half  of  one 
lobe 
B1N  Tumour  involves  half  of  lobe 
surrounded by normal tissue on all 
sides 
T2b    Tumour involves more than one lobe  B2  Same as TNM 
  T2b  Tumour involves more than half of a lobe 
but not both lobes 
B1  Same as TNM 
None   T2c  Tumour involves more than one lobe  B2  Same as TNM 
T3  T3  Palpable tumour beyond prostate  C1  Tumour < 6cm in diameter 
T3a  T3a  Unilateral extracapsular extension   C1  Same as TNM 
T3b  T3b  Bilateral extracapsular extension   C1  Same as TNM 
T3c  T3c  Tumour invades seminal vesicle(s)  C1  Same as TNM 
T4  T4  Tumour  is  fixed  or  invades  adjacent 
structures (not seminal vesicles) 
C2  Same as TNM 
T4a  T4a  Tumour  invades  bladder  neck,  external 
sphincter and/or rectum 
C2  Same as TNM 
T4b  T4b  Tumour invades levator muscle and/or is 
fixed to pelvic wall 
C2  Same as TNM 
N(+)  N(+)  Involvement of regional lymph nodes  D1  Same as TNM 
None  None  None  D0  Elevated  prostatic  acid 
phosphatase  
NX  NX  Regional lymph nodes cannot be assessed   None   None 
N0  N0  No evidence of lymph node metastasis  None  None 
N1  N1  Metastases in single regional lymph node, 
≤ 2cm in dimension  
D1  Same as TNM  
N2  N2  Metastases  in  single  (>2  but  ≤  5cm)  or 
multiple lymph nodes with none >5cm 
D1  Same as TNM 
N3  N3  Metastases in regional lymph node > 5cm 
in dimension  
D2  Same as TNM 
M(+)  M(+)  Distant metastatic spread  None  Same as TNM 
MX  MX  Distant metastases cannot be assessed   None   None 
M0  M0  No evidence of distant metastases  None  None 
M1  M1  Distant metastases  D2  Same as TNM 
M1a  M1a  Involvement of nonregional lymph nodes  D2  Same as TNM 
M1b  M1b  Involvement of bone  D2  Same as TNM 
M1c  M1c  Involvement of other distant sites  D2  Same as TNM 
None  None  None  D3  Hormonal refractory disease   20 
1.4.2.1 Serum tumour markers 
Before PSA was available, prostate acid phosphatase (PAP) was the most often used serum 
marker for staging prostate cancer. However, a normal enzymatic PAP level is not highly 
predictive of the absence of extraprostatic disease. Several studies have shown that serum 
PSA  correlates  directly  with  advancing  clinical and  pathologic  stage  of  prostate  cancer 
(Oesterling et al., 1988; Partin et al., 1990; Stamey et al., 1987).  However, in most cases, 
PSA  level  alone  does  not  provide  accurate  enough  staging  information  for  individual 
patients because of overlap of PSA levels between stages (Carter & Partin, 2002). As a 
general guide, most men (80%) with PSA values less than 4 ng/ml have pathological organ 
confined disease (Catalona et al., 1997) , two of three men with PSA levels between 4 and 
10 ng/ml have organ-confined cancer, and more than 50% of men with PSA levels above 
10 ng/ml have disease beyond the prostate. Pelvic lymph node involvement is found in 
nearly 20% of men with PSA levels greater than 20 ng/ml and in most men (75%) with 
serum PSA levels greater than 50 ng/ml (Partin et al., 1990; Partin et al., 1993b). 
1.4.2.2 Histologic grading 
The Gleason system of histological grading has been shown to correlate with the pathologic 
extent  of  disease  (Gleason  &  Mellinger,  1974). Numerous  studies  have  shown  that  the 
presence of Gleason grade 4 (primary or secondary) or Gleason sum of 7 or greater is 
predictive of a poorer prognosis (Epstein et al., 1993; Partin et al., 1993a; Stamey et al., 
1999). 
1.4.2.3 Combined use of clinical data to predict pathologic stage 
Staging  accuracy  of  prostate  cancer  can  be  significantly  enhanced  by  combining  the 
parameters of local disease extent (T stage), serum PSA level, and Gleason grade from the   21 
prostate  biopsy  specimen  (Humphrey  et  al.,  1991).  Probability  tables,  based  on  these 
parameters  have  been  constructed  based  on  large  number  of  men  who  have  undergone 
radical prostatectomy with precise determination of pathological stage (Partin et al., 1997; 
Partin  et  al.,  1993b).  The  information  extrapolated  from  these  tables  can  be  useful  in 
counselling men with newly diagnosed prostate cancer. 
1.4.2.4 Imaging 
Modern  imaging  modalities  such  as  magnetic  resonance  imaging  (MRI)  have  been 
employed  to  obtain  more  precise  local  staging  of  porstate  cancer.  This  is  benifical 
particularly for patients with intermediate risk disease and those suspected of having gross 
extracapsular extension, or seminal vesicle involvement. Recent advances in MRI such as 
the use if endorectal coil (Nakashima et al., 2004) and spectroscopy (Yuen et al., 2004) 
have improved its accuracy compared with pathological analysis.  
Positron emission tomography (PET) using 
11C has been used to evaluate patients for local 
tumour recurrence and regional metastasis(Fricke et al., 2003). 
The ProstaScint (
111In capromab pendetide) scan uses a radiolabeled monoclonal antibody 
targeted to the intracellular epitope of the PSMA molecule. It is approved by the United 
States Food and Drug Administration (FDA) for the diagnostic imaging and staging of 
newly  diagnosed  patients  who  are  deemed  high  risk  for  pelvic  lymph  node  metastases 
(Brassell et al., 2005). One multicentre study reported sensitivity, specificity, and overall 
accuracy of 75%, 86%, and 81%, respectively(Hinkle et al., 1998). 
Whole body skeletal scintigraphy (radionuclide bone scan) is the standard technique for 
detecting  bone  metastases  from  prostate  cancer  (Gerber  &  Chodak,  1991;  Schaffer  & 
Pendergrass,  1976).  However,  new  evidence  suggests  that  whole  body  MRI  is  more   22 
sensitive than bone scan in detecting bone metastases from solid tumours(Lauenstein et al., 
2004).  
1.4.2.5 Staging lymphadenectomy 
Surgical removal and histological examination of the pelvic lymph nodes provide the most 
accurate  staging  information  relative  to  pelvic  lymph  node  status.  Many  investigators 
advocated  that  in  patients  with  clinically  localised  and  low  risk  prostate  cancer, 
lymphadenectomy need not be undertaken  (e.g. (Alagiri et al., 1997; Bluestein et al., 1994; 
Narayan et al., 1994). However, this has been challenged by a recent study based on the 
gamma probe-guided sentinel lymph node identification in patients with prostate cancer 
(Wawroschek et al., 1999). In patients with PSA ≤ 10 ng/ml and biopsy Gleason score ≤ 6, 
positive lymph nodes were identified by radio-guided surgery in 6.8% (positive biopsies in 
one lobe) and 10.7% (positive biopsies in both lobes) and therefore, these authors suggest 
performing an operative lymph node staging, even in low risk disease (Weckermann et al., 
2005). 
 
1.5 Treatment of early prostate cancer  
In recent years, increasing numbers of patients with prostate cancer have been diagnosed 
while their disease is still clinically localised (Mettlin et al., 1998). Patients with clinically 
localised disease (T1-3 NX M0) and good life expectancy are generally offered radical 
prostatectomy or radiotherapy (external beam and/or brachytherapy). However, observation 
and  watchful  waiting  might  be  a  better  option  for  many  patients  with  prostate  cancer, 
particularly  elderly  patients  with  low  grade  tumours  or  those  with  multiple  severe  co-
morbidities. For example, the probability that a patient with Gleason score of 2-4, who has   23 
not been treated, will die of prostate cancer within 15 years is only 4-7% (Albertsen et al., 
1998). 
1.5.1 Radical prostatectomy 
Since it was first described by Hugh Young one century ago (Scott, 1983), radical surgery 
for prostate cancer has gone through several stages of modernisation,  starting from simple 
perineal approach up till the high tech robotic prostatectomy. Most of the efforts were to 
minimise the unacceptable morbidity, including urinary incontinence, erectile dysfunction 
and major blood loss. Undoubtedly, the meticulous work by Walsh and Reiner has made 
major contribution to the modern anatomical radical prostatectomy, particularly the control 
of the dorsal venous plexus (Reiner & Walsh, 1979) and the nerve-sparing approach (Walsh 
& Donker, 1982) to eliminate major bleeding and preserve sexual function, respectively.  
A  study  of  1000  patients  treated  with  radical  prostatectomy  showed  that  10-year 
biochemical disease-free survival was closely associated with T stage, Gleason score, and 
PSA concentration. Remarkably, the 10 year cause-specific survival was 95-100% for all 
patients treated with surgery except for those with Gleason score of 8-10 whose survival 
dropped to 82% (Hull et al., 2002). Another observation in this study is that whilst 85% of 
patients with PSA <10 ng/ml had 10-year biochemical disease-free survival, only 46% of 
patients with PSA >20 ng/ml had similar survival. 
Several series demonstrated very low mortality and intraoperative and postoperative events. 
Less than 10% of patients are left with urinary incontinence. About 31 % and 52% of 
patients  will  become  impotent  after  bilateral  and  unilateral  nerve-sparing  procedures, 
respectively (Catalona et al., 1999; Lepor et al., 2001). 
Enthusiasm  for  using  laparoscopic  surgery  in  urology  has  led  to  the  development  of 
laparoscopic radical prostatectomy (Guillonneau et al., 1998; Guillonneau & Vallancien,   24 
1999). Short term studies on disease control and complication rates showed similar results 
compared  to  open  surgery  (Rozet  et  al.,  2005;  Stolzenburg  et  al.,  2005).  Furthermore, 
innovative robotic laparoscopic prostatectomy is at the focus of leading prostate surgery 
centres in the world (Abbou et al., 2000; Abbou et al., 2001). 
 
1.5.2 Radiotherapy of prostate cancer 
Radiation therapy, the use of ionising radiation to destroy malignant tissue, has been used 
in the treatment of the prostate cancer since the 1960s. Radiation acts at the cellular level to 
cause breakage of the DNA, leading to a loss of reproductive integrity and cell death.  
Radiation can be produced by naturally occurring isotopes such as cobalt-60 or artificially 
created isotopes. In a linear accelerator, high frequency electromagnetic waves accelerate 
charged particles through a linear tube. The high-energy electron beam can then be made to 
strike a target to produce high-energy X-rays for treating deep tumours. Radiation can also 
be introduced into the prostate directly using interstitial implantation of radioactive isotope 
in the prostate itself, a technique referred to as brachytherapy.  
 
1.5.2.1 External Beam radiation 
Conventionally  planned  radiation  therapy  of  prostate  cancer  involves  using  plain  film 
images to define the prostate, its location and the field size and shape. Simulation images 
are then created using bony landmarks and intravesical contrast. This method has two major 
disadvantages.  First,  this  approach  has  been  insufficiently  accurate  to  include  the  total 
prostate volume thereby leading to tumour underdosing (Ten Haken et al., 1989). Second, 
the proximity of the prostate to critical normal structures, such as the bladder and rectum   25 
has limited the ability to deliver effective dose levels in excess of 70 Gy by means of 
conventional radiotherapy techniques (Greskovich et al., 1991; Smit et al., 1990). 
 
1.5.2.1.1 Three dimensional CT-guided treatment planning 
Three dimensional conformal radiation therapy (3D-CRT) was developed to correct some 
of  the  shortcomings  of  the  conventionally  planned  radiation  therapy.  This  technique 
describes any multiple-beam arrangement that uses computer-aided devices to plan and 
deliver prescribed radiation doses conforming to the three dimensional configuration of the 
tumour whilst minimising the dose to the normal tissues (Porter & Hart, 1999).  
The minimum therapeutic gain with 3D-CRT of reduced morbidity has been confirmed in 
several  studies.  In  a  prospective  randomised  clinical  trial,  Dearnaley  and  co-workers 
reported  a  significant  reduction  in  rectal  complications  after  3D-CRT  compared  with 
conventional radiotherapy for patients with early prostate cancer (Dearnaley et al., 1999). 
Furthermore, 3D-CRT has allowed the escalation of the dose to the tumour beyond that 
possible with conventional systems, with a reasonable rate of normal tissue complications 
(Leibel et al., 1991). In a prospective randomised trial, a conventional dose of 70 Gy was 
compared with a dose escalation to 78 Gy using 3D-CRT (Pollack et al., 2000). While there 
was no benefit with dose escalation for patients in the favourable prognosis group (PSA < 
10 ng/ml), the trial found very significant benefit for patients in the intermediate and poor 
groups (PSA > 10 ng/ml or T3 disease).  
 
1.5.2.1.2 Intensity modulated radiotherapy (IMRT) 
IMRT is a technological advance in conformal radiotherapy in which there is variation of 
the quantity of radiation (fluence) across the beam. The potential advantages include more   26 
control of the shape of the high dose envelope, for example to include a concavity around 
an adjacent critical normal tissue, and also the ability to deliver heterogeneous doses to 
boost the dose to sub-targets in the tumour volume (Leibel et al., 2002).  
Zelefsky  and  colleagues  reported  the  early  toxicity  and  biochemical  outcome  in  772 
patients treated with a dose of 81 Gy or more using IMRT. At three years, grade 2 or more 
toxicity was reported in just 4%. The three-year actuarial PSA relapse-free survival rates 
among  patients  with  low-,  medium-  and  high-risk  for  biochemical  relapse  treated  with 
81Gy were 93%, 84% and 81%, respectively (Zelefsky et al., 2002). Moreover, 3D-CRT 
has allowed dose escalation to the whole prostate, but IMRT can be used to escalate the 
dose to other targets also, such as the pelvic lymph nodes and intraprostatic tumour nodules 
(Nutting et al., 2002). 
 
1.5.2.2 Brachytherapy  
Brachytherapy is the targeted delivery of radiation through implants directly to the prostate 
gland.  This  is  either  through  permanent  implants  of  iodine-125  (
125I)  or  palladium-103 
(
103Pd) seeds, or temporary implantation with iridium-192 wires through shallow needles. 
Modern prostate brachytehrapy is performed under TRUS guidance and may be used as 
monotherapy, as a boost to another primary therapy such as EBRT, or as a primary therapy 
with another treatment such as EBRT used as a boost, with or without adjuvant/ neoadjvant 
androgen deprivation therapy (ADT). 
Not  all  patients  with  localised  prostate  cancer  are  suitable  for  brachytherapy  as  a  sole 
modality of treatment. Selection criteria include patients with organ-confined disease who 
are at low risk of developing metastatic disease (PSA <10 ng/ml, stage <T2a, and Gleason 
score <7), and those who are likely to have a good functional outcome (Mangar et al.,   27 
2005).  Studies have shown that patients with prostate volume of less than 35 cm
3 have a 
relatively low incidence of acute urinary retention and urinary morbidity (Gelblum et al., 
1999).  Similarly,  patients  with  minimum  urinary  symptoms,  as  determined  by  the 
International  Prostate  Symptom  (IPS)  score,  have  a  low  risk  of  acute  retention  and 
prolonged urethritis (Terk et al., 1998). 
In a retrospective study, Zelefsky et al, compared the 5-year outcome and morbidity of 3D-
CRT  versus 
125I
 brachytherapy  for  early  prostate  cancer.  The  5-year  PSA  relapse-free 
survival rates for 3D-CRT and brachytherapy groups were 88% and 82%, respectively (P = 
0.09). Urinary toxicities were more prevalent in the brachytherapy group and subsequently 
resolved  or  improved  (Zelefsky  et  al.,  1999).  Another  study  by  Ragde  and  colleagues 
reported a 70% 10-year disease-free survival for 229 patients treated with brachytherapy 
+/- EBRT, of which 147 received brachytherapy alone (Ragde et al., 2000). These figures 
are comparable to surgery or EBRT.  
 
1.5.2.3 Combining external beam radiotherapy with androgen deprivation 
1.5.2.3.1 Neo-adjuvant hormonal therapy (NHT) 
The role of NHT in the management of localised prostate cancer is to reduce the volume of 
the prostate tumour before definitive therapy. This might result in an additive effect on cell 
kill and also allows for a reduction in radiotherapy volume by 20-50% (Forman et al., 1995; 
Zelefsky et al., 1994). 
In phase III Radiation Therapy Oncology Group (RTOG) trial 86-10, 471 patients with T2-
4  primary  tumours  treated  with  combined  androgen  blockade  for  2  months  before  and 
continuing  during  radiotherapy,  were  compared  with  a  group  treated  with  radiotherapy 
alone. The most significant difference was seen in a subgroup of 129 cases with Gleason   28 
score 2-6, in which 8-year survival was 70% versus 52% for those receiving radiation alone 
(Pilepich  et  al.,  2001).  It  is  now  widely  accepted  that  patients  who  receive  radical 
radiotherapy  for  locally  advanced  disease  should  have  at  least  short-term  neoadjuvant 
hormone therapy (Mangar et al., 2005). 
 
1.5.2.3.2 Adjuvant hormonal therapy (AHT) 
The  rational  for  the  adjuvant  treatment  is  to  eradicate  residual  tumour  clonogens  that 
remain  after  radiotherapy,  either  within  the  prostate  or  at  distant  metastatic  sites.  The 
survival benefit of the AHT in patients with locally advanced disease has been confirmed in 
two RTOG trials (Hanks et al., 2003; Pilepich et al., 1997). 
In a very recent update of the RTOG trial 85-31, the conclusion was that, in a population of 
patients  with  unfavourable  prognosis  carcinoma  of  prostate,  AHT  after  definitive 
radiotherapy was associated not only with a reduction in disease progression but also with 
statistically  significant  improvement  in  absolute  survival  (Pilepich  et  al.,  2005).  The 
improvement in survival appeared preferentially in patients with a Gleason score of 7-10. 
 
1.5.3 Other novel treatment modalities for early prostate cancer 
Several innovative technologies are being evaluated for the treatment of organ confined 
prostate  cancer. These  include  cryotherpy,  high intensity  focused  ultrasound,  interstitial 
microwave  therapy,  transperineal  radiofrequency  interstitial  tumour  ablation  and  laser 
photocoagulation. With the exception of cryotherpy, there is as yet no sufficient evidence to 
draw conclusions regarding the effectiveness of these new therapies (Hummel et al., 2003).  
   29 
1.5.3.1 Cryotherapy  
Cryosurgical ablation aims to reduce the prostate tumour by the application of sub-zero 
temperature,  administered  via  the  perineum  using  cryoprobes.  Although  this  treatment 
modality  is  not  yet  widely  practised,  potential  advantages  of  its  use  include,  focal 
application with sparing of normal tissues, treatment of cancers that are not amenable to 
surgical resection, and minimal bleeding (Shinohara & Carroll, 2002). The use of TRUS for 
real-time  monitoring  of  the  freezing  process,  improved  cryoprobes,  and  better 
understanding  of  cryobiology  have  all  contributed  to  the  resurgence  of  interest  in 
cryosurgery. In addition to treating organ-confined cancer, cryotherapy has been proposed 
as a treatment for patients with more locally advanced, T3 disease or for patients with 
residual or recurrent cancer after radiation therapy. The most commonly used cryotherapy 
systems use either liquid nitrogen or argon as the source of freezing. 
Similar  to  the  results  of  radical  prostatectomy  or  radiation  therapy,  outcome  after 
cryotherapy  for  prostate  cancer  correlates  with  cancer  stage  and  grade  (Shinohara  & 
Carroll, 2002). Size of the prostate gland is another determinant of the outcome and hence a 
gland larger than 50 cm
3 may best be treated with neoadjuvant androgen deprivation to 
reduce  target  volume  and  allow  for  more  effective  cryoablation  (Shinohara  &  Carroll, 
1999).   
 
1.6 Treatment of advanced metastatic prostate cancer 
1.6.1 Endocrine treatment of prostate cancer 
Hormonal treatment of prostate cancer was first described by Huggins and Hodges in 1941 
where they showed that either castration or use of diethylstilbestrol (DES) is effective in   30 
improving symptoms of prostate cancer (Huggins & Hodges, 1941). In addition to winning 
the Nobel Prize, this discovery should be credited further for lasting more than 60 years as 
the first-line treatment for locally advanced and metastatic disease. 
The advent of PSA monitoring has led to what is called stage migration and as a result the 
percentage of patients with metastatic disease at the time of diagnosis of prostate cancer has 
decreased enormously. However, the role of hormonal therapy in prostate cancer has been 
reinvented with the emergence of a group of patients with recurrent disease after the failure 
of definitive local treatment with radical prostatectomy or radiotherapy.  
Androgen deprivation or castration is defined by induction of serum testosterone level of 
<20 ng/ml (Scherr et al., 2003). This can be achieved surgically by bilateral orchidectomy 
or  medically  by  estrogen  agonists,  gonadotropin  hormone-releasing  hormone  (GnRH) 
agonists, GnRH antagonists, and androgen antagonists. The aim of endocrine treatment is 
palliation rather than cure as it eliminates symptoms in most symptomatic patients. It also 
prolongs  time  to  clinical  progression  and  possibly  prolongs  survival,  at  least  in  some 
patients (Shroder, 2002). 
1.6.1.1 GnRH agonists  
GnRH is a small peptide that is synthesised in  the hypothalamus and secreted into the 
hypophyseal-portal  blood  circulation  in  a  pulsatile  manner.  GnRH  stimulates  anterior 
pituitary  gland  via  high-affinity  receptors  to  synthesise  and  release  the  gonadotropins, 
leutinising hormone (LH) and follicular stimulating hormone (FSH). The episodic release 
of endogenous GnRH prevents receptor desensitisation and is mandatory for continuing 
androgen production. Continuous stimulation of the pituitary with high concentrations of 
GnRH agonist induces regulatory changes, possibly down-regulation of GnRH receptors 
(Tieva et al., 2003; Wolff & Lederberg, 1994). This results in receptor desensitisation and   31 
inhibition  of  LH  release,  which  further  inhibits  the  production  of  testosterone  by  the 
testicles.  
The development of Depot GnRH agonists which, unlike endogenous GnRH, are resistant 
to peptide degradation have revolutionised the treatment of patients with advanced prostate 
cancer (Tammela, 2004). They are administered by subcutaneous injection at intervals of 1-
3  months.  There  are  several  GnRH  agonists  available  including  goserelin,  leuprorelin, 
buserelin  and  tritorelin.  Co-treatment  with  anti-androgen  should  be  used  during  the 
commencement  of  GnRH  for  2-3  weeks.  This  is  because  GnRH  initially  imposes  an 
increased release of LH production, and therefore, an increase in plasma testosterone levels 
lasting 1-2 weeks (Bubley, 2001) leading to what is called tumour flare effect.  
 
1.2.1.2 Anti-androgens  
Anti-androgens,  steroidal  and  non-steroidal  can  be  used  as  monotherapy,  neoadjuvant 
therapy  prior  to  radical  prostatectomy  or  radiation  therapy,  or  in  combination  with 
castration  (Tammela,  2004).  Anti-androgens  competitively  inhibit  the  binding  and 
interaction of testosterone and DHT to the prostatic androgen receptors.  
Non-steroidal antiandrogens also cross blood-brain barrier and block androgen receptors in 
the  diencephalon,  the  area  that  is  crucial  for  GnRH  production,  and  the  feedback 
mechanism, which regulates plasma testosterone levels through LH. This leads to an LH 
increase  in  endocrinologically  intact  males  and,  therefore,  testosterone  secretion  in  the 
testes (Shroder, 2002). Therefore, treatment with nonsteroidal anti-androgens is the only 
established way to avoid castration in the endocrine treatment of prostate cancer (Tammela, 
2004).    32 
Flutamide, biclutamide and nilutamide are among the recently studied nonsteroidal anti-
androgens for the treatment of advanced prostate cancer. Currently, biclutamide is the best 
tolerated agent in this group. Biclutamide offers quality of life benefits in terms of sexual 
interest, physical capacity and potentially, preservation of bone mineral density (Iversen et 
al., 2000). Therefore, biclutamide monotherapy may be a preferred option for younger, 
sexually  active  men  with  locally  advanced  prostate  cancer  who  wish  to  optimise  their 
physical activity.  
 
1.6.2 Management of hormonal refractory prostate cancer 
Despite the fact that most patients on androgen deprivation demonstrate encouraging initial 
response,  a  large  proportion  of  these  patients  will  eventually  progress  to  hormone-
refractory  prostate  cancer.  Hormone-refractory  prostate  cancer  (HRPC)  is  defined  as 
progressively  increasing  PSA  despite  castrate  range  testosterone.  The  development  of 
hormone-independent state is a categorical and irreversible phenomenon observed in the 
majority of patients and occurs within an almost predictable time frame after the initiation 
of androgen deprivation (Eisenberger & Carducci, 2002).  
The main cause of hormone resistance is alterations in the androgen receptor (AR) in the 
form  of  mutations  and/or  amplification  (Hennequin,  2004).  A  common  site  for  genetic 
gain/amplification in prostate cancer is chromosome X, at the AR locus (Koivisto et al., 
1997). It has been suggested that increased AR copy number could play a role in androgen-
independent tumour progression. In concordance with data obtained with LNCaP cells in 
vitro,  genetic  profiling  of  a  series  of  prostate  cancer  xenografts  revealed  that  the  most 
consistent change during transition to the endocrine-therapy insensitive stage is AR up-
regulation, associated with agonism of AR blockers and changes in relative abundance of   33 
co-activators or co-repressors assembled on the promoters of AR target gene (Chen et al., 
2004). Another postulated mechanism of hormone resistance is based on the concept that 
the growth and survival promoting functions of the androgen receptor can be bypassed by 
alternative signalling pathways, such that the androgen receptor is no longer relevant to 
disease progression. One such example is up-regulation of the anti-apoptotic gene BCL2 in 
late-stage clinical samples (McDonnell et al., 1992; Raffo et al., 1995). 
 
1.6.2.1 Second-line hormonal manipulation  
At  least  four  independent  trials  have  suggested  the  benefit  of  adding  second-line  anti-
androgen, such as flutamide ((Fowler et al., 1995), bicalutamide ((Joyce et al., 1998; Scher 
et al., 1997) or nilutamide (Desai et al., 2001). Although response rates between 20% and 
80% have been reported, the median duration of response is short, ranging between 2 and 4 
months (Eisenberger & Carducci, 2002). 
For  patients  who  develop  HRPC  whilst  on  maximum  androgen  blockade  with  the 
combination of GnRH agonist and anti-androgen, the withdrawal of anti-androgen has been 
reported to result in a a brief decline in PSA level of ≥ 50% in 15 to 30% of patients (Figg 
et  al.,  1995;  Scher  &  Kelly,  1993;  Small  &  Srinivas,  1995).  The  mechanism  of  this 
phenomenon has been attributed to alterations in the androgen signalling cascade, including 
mutations in the androgen receptor, resulting in the anti-androgen behaving as an activator, 
not an inhibitor of the androgen receptor (Taplin et al., 1995).  
Ketoconazole is an antifungal that was found to cause suppression of testicular and adrenal 
androgen production. Recent studies have suggested the benefit of using ketoconazole after 
or at the time of androgen withdrawal (Schlesinger et al., 2005; Small et al., 2004). 
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1.6.2.2 Chemotherapy of prostate cancer 
The combination of mitoxantrone with steroids has been approved by the United States 
Food and Drug Administration (FDA) as an effective regimen for the palliation of painful 
bone metastases based on 2 randomised phase 3 studies evaluating the difference between 
mitoxantrone  plus  steroids  versus  steroids  alone  (Kantoff  et  al.,  1999;  Tannock  et  al., 
1996).  There  was  no  difference  seen  in  survival  between  the  2  arms  in  either  study. 
However, there was significant palliative benefit seen with the combination.  
 
Estramustine phosphate, a combination of nitrogen mustard moiety with estradiol, has also 
been approved by the FDA for use in patients with metastatic prostate cancer(Alexander et 
al., 1979; Hauser & Merryman, 1984). In addition to its estrogenic activity that can cause 
castrate levels of testosterone (Ben-Josef et al., 2001), estramustine exerts cytotoxic effects 
by interfering with the microtubule structure and binding to the nuclear matrix (Hartley-
Asp & Kruse, 1986; Tew & Stearns, 1989). 
Docetaxel is a semi-synthetic drug belonging to the taxoid family, all of which share the 
taxane ring. Docetaxel promotes the assembly of microtubules and also stabilises them, 
preventing their depolymerisation leading to cell death (Ringel & Horwitz, 1991; Rowinsky 
& Donehower, 1991). Docetaxel as a single agent has been tested in a number of phase 2 
clinical trials in metastatic HRPC, with about 40% to 45% of patients having a decrease of 
≥50% in PSA and objective response rates of about 20% to 40% (Beer et al., 2001; Berry et 
al., 2001; Friedland et al., 1999). 
A phase 2 clinical trial using 5-day regimen of estramustine with docetaxel and low-dose 
hydrocortisone showed that 30 of 40 patients (68%) had a ≥ 50% decrease in their PSA   35 
levels, and there were 3 complete responses and 9 partial responses in 24 patients with 
measurable disease (Savarese et al., 2001).  
 
Most  recently,  two  phase  3  trials  have  demonstrated  a  clear  survival  advantage  of 
docetaxel-based  chemotherapy  for  men  with  HRPC.  First,  the  intergroup  study  of  the 
Southwest Oncology Group (SWOG 9916) have compared docetaxel and estramustine with 
mitoxantrone  and  prednisone  (Petrylak  et  al.,  2004).  The  median  overall  survival  was 
greater in the docetaxel and estramustine group versus the mitoxantrone and prednisone 
group (17.5 versus 15.6 months, P = 0.02). The median time to progression was 6.3 and 3.2 
months, respectively (P < 0.001). The PSA response rate was also significantly in favour of 
the docetaxel and estramustine group (50 versus 27%, P < 0.001). 
Second,  an  international,  multicenter  randomised  phase  3  study  (TAX327)  compared 
mitoxantrone and prednisone with either docetaxel and prednisone every 3 weeks or weekly 
docetaxel and prednisone (Tannock et al., 2004).  The overall survival was significantly 
higher in the docetaxel and prednisone every 3 weeks compared with mitoxantrone and 
prednisone group (P = 0.009) but not in the weekly docetaxel and prednisone group (P = 
0.36). Median survival rates were higher in the docetaxel and prednisone 3 weekly group 
(18.9 months) compared with the weekly docetaxel and prednisone group (17.4 months) 
and the mitoxantrone and prednisone group (16.5 months). 
   36 
1.7 Gene therapy of prostate cancer 
1.7.1 Rationale for prostate cancer gene therapy 
The available treatments of locally advanced and hormone refractory prostate cancer are so 
far  mostly  palliative.  Even  the  lately  reported  survival  advantage  of  the  combination 
chemotherapy (Petrylak et al., 2004; Tannock et al., 2004) is modest and offers less than 
two years of disease-specific survival. Therefore, novel treatment modalities are urgently 
sought.  Gene  therapy  has,  undoubtedly,  attracted  considerable  attention  as  a  promising 
novel approach for prostate cancer. 
Gene therapy can be defined as the delivery and expression of genetic information in cells 
of an individual to restore health or to ease the consequence of a disease (Goncalves, 2005). 
Cancer gene therapy may be defined as the transfer of recombinant DNA into human cells 
to achieve an anti-tumour effect. Depending upon the strategy, DNA may be introduced 
either into cells removed from the body “the ex vivo approach” or introduced directly into 
cells in their normal location “the in vivo approach” (Anderson, 1998). Successful gene 
therapy requires an appropriate therapeutic gene that is delivered efficiently, is expressed 
therapeutically for a sufficient amount of time with little effect on tissues other than the 
target tissue, and has few toxic side effects (Foley et al., 2004).  
The prostate gland is an ideal organ for cancer gene therapy because it is an accessory 
organ, easily accessible and it harbours the potential of exploiting several tissue and tumour 
specific promoters. Moreover, multiple biological processes can be targeted and exploited 
for  gene-based  therapeutic  approaches  (McCormick,  2001),  including  induction  of 
cytotoxic  and  apoptotic  responses,  correction  of  aberrant  growth  regulation,  and 
enhancement of anti-tumour immune responses.    37 
1.7.2 Brief history of gene therapy and prostate cancer gene therapy 
The potential for treating a patient using gene transfer started not long after Watson and 
Crick discovered the helical structure of DNA in 1953 (Watson & Crick, 1953). One of the 
earliest indications that gene transfer might be used therapeutically was proposed from a 
plant cell experiment in 1968. Roger suggested that: the next step is to build a modified 
virus…and use the virus to transmit information (Rogers & Pfuderer, 1968). 
Before recombinant DNA techniques emerged, the wild type herpes simplex virus (HSV) 
known to encode a thymidine kinase (TK) activity, was used to convert Ltk
- cells from the 
TK negative to the TK positive phenotype. This was the first instance in which a gene of a 
known function had been stably acquired by a eukaryotic cell line due to virus infection. 
Reports on the construction of recombinant DNA appeared in the early 1970s after the 
finding that linear bacteriophage genomes could be circularised in vitro due to the presence 
of complementary cohesive ends at their termini (Hershey & Burgi, 1965; Watson et al., 
1992). Further demonstration of the existence of sequence specific DNA cutters and the 
isolation  of  class  II  restriction  endonucleases  ((Smith  &  Wilcox,  1970)  and  gel 
electrophoresis technique to dissect large DNA molecules into discrete and manageable 
fragments (Danna & Nathans, 1971), have led the way to complex libraries of  cloned DNA 
segments containing genes and gene clusters from different species. 
Throughout the 1970s and 1980s, similar advances in basic sciences and molecular biology 
pushed the field of gene therapy to its first clinical trial in 1988 (Culliton, 1988). However, 
clinical trials to date have been widely unsuccessful and have led many physicians and 
scientists to doubt the efficacy of this modality (Selkirk, 2004). In 1999, a further set-back 
to the development of human gene therapy protocols emerged following the first death of a   38 
patient directly related to the gene therapy clinical trial in the University of Pennsylvania 
(Marshall, 1999; Vogel, 2000).  
 The reported cure of several young patients with severe combined immunodeficiency was 
welcomed as the first significant clinical step forward for gene therapy (Cavazzana-Calvo 
et al., 2000; Hacein-Bey-Abina et al., 2002). However, recent reports have indicated the 
development of leukaemia syndrome in several of these patients which was discerned to be 
a  direct  result  of  the  therapeutic  intervention  (Hacein-Bey-Abina  et  al.,  2003).  This 
development has again called into question the general safety of the current technology 
available for gene transfer.  
Similarly, gene therapy in oncology has yet to reach phase III trials or show clear cancer 
patient benefits in large statistically powered phase II trials (Anderson, 1998). Currently, 
prostate cancer with its unique PSA tumour marker is probably the best model that exists 
for organ-specific gene therapy. The identification of prostate-specific enhancer/ promoter 
has allowed gene expression to be confined only to cells that express PSA (Pang et al., 
1997; Pang et al., 1995; Schuur et al., 1996).  
In addition, The Prostate Expression Data Base (Nelson et al., 2000) has revealed more 
than  55000  expressed  sequence  tags  (ESTs)  from  43  cDNA  libraries;  of  those 
approximately  500  are  prostate  unique. The  presence  of  this  large  number  of  prostate-
unique-promoters  and  candidate  antigens  promises  to  facilitate  the  design  of  prostate-
specific gene therapy. 
The first National Institute of Health (NIH) and FDA approved phase 1 clinical trial of 
human  gene  therapy  for  prostate  cancer,  was  performed  by  John  Hopkins  using 
granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transduced autologous 
tumour  vaccines  (Simons  et  al.,  1999).  Running  parallel  to  this  trial,  a  range  of  other 
approaches have been investigated preclinically and up to date, to our knowledge, there are   39 
86 approved and/ or ongoing clinical trials of prostate cancer gene therapy worldwide, 8 of 
them  use  suicide  gene  therapy  protocols,  of  which  7  involve  HSV1-TK  gene  transfer. 
(http://82.182.180.141/trials/index.html) (The Journal of Gene Medicine web site)  
 
1.7.3 Strategies for gene therapy in prostate cancer 
Current  prostate  cancer  gene  therapy  research  strategies  include,  in  general  terms, 
corrective approaches (replacing deleted or mutated gene) and cytoreductive approaches 
(immunotherapy and cytolytic/pro-apoptotic) (Mabjeesh et al., 2002)  
 
1.7.3.1 Corrective prostate cancer gene therapy 
Corrective strategies may be designed to prevent tumorigenesis in phenotypically normal 
cells or to induce reversion or regression of transformed cells to non-neoplastic or less 
transformed phenotype (Mabjeesh et al., 2002). Potential candidate genes for corrective 
gene therapy could be identified from the wide variety of genetic and epigenetic changes 
known to occur during the development and progress of prostate cancer (see section 1.2). 
p53: The tumour-suppressor gene p53 encodes a transcription factor involved in regulation 
of the cell cycle and apoptosis. Asgari et al. have demonstrated the ability of overexpressed 
p53  to  inhibit  the  growth  of  primary  cultures  derived  from  radical  prostatectomy 
specimens, surprisingly even when p53 status is normal (Asgari et al., 1997). This was 
confirmed on animal models of prostate cancer using a replication defective adenoviral 
vector encoding CMV driven wild type p53 gene (INGN 201) (Cowen et al., 2000; Ko et 
al., 1996). In a recent phase I clinical trial, thirty patients with high risk early prostate 
cancer were all administered intra-prostatic injections of INGN 201, with no grade 3 or 4   40 
adverse effects, and tumour expression of wild type p53 induced tumour cell apoptosis 
(Pisters et al., 2004). 
BAX: This is a pro-apoptotic gene, which has been targeted in prostate cancer therapy. 
Using  replication  defective  adenoviruses  encoding  BAX,  the  overexpression  of  BAX 
induced therapeutic apoptosis of prostate cancer cells growing in vivo and in vitro (Li et al., 
2001). Honda et al. have shown that BAX induced apoptosis of prostate cancer cells was 
independent of their Bcl-2 status and androgen sensitivity (Honda et al., 2002). 
AR receptor gene: It has been shown that the down regulation of AR receptors using 
antisense oligonucleotide has caused inhibition of mouse prostate cancer xenografts (Eder 
et al., 2002). The antisense oligonucleotides inhibit gene expression by binding to a specific 
target mRNA that has a complementary nucleotide sequence, resulting in degradation and 
inhibition of translation of the target gene. Another approach using ‘decoy’ DNA (a double 
stranded  oligonucleotide  containing  the  same  DNA  sequences  as  androgen  responsive 
element (ARE) of the AR) was found to have an anti-androgen effect and induce apoptosis 
in LNCaP cells (Kuratsukuri et al., 1999). 
 c-Myc: The over-expression of the oncogene c-Myc is frequently observed in advanced 
prostate tumours (Buttyan et al., 1987; Fleming et al., 1986). Disruption of c-Myc over-
expression  using  antisense  oligodeoxynucleotides  transduced  by  a  replication-deficient 
MMTV-promoter-driven retrovirus resulted in a 94% reduction in tumour size of DU145 
prostate cancer cell xenografts (Steiner et al., 1998).  
BCL-2:  This is another oncogene which is frequently overexpressed in androgen refractory 
prostate cancer (Furuya et al., 1996; McDonnell et al., 1992). A hammerhead ribozyme 
designed to disrupt bcl-2 expression in LNCaP prostate cancer cells showed pro-apoptotic 
activity  and  resulted  in  increased  cell  sensitivity  to  secondary  pro-apoptotic  agents 
including  phorbol  ester  (Dorai  et  al.,  1997).  BCL-2  antisense  oligonucleotide  has  been   41 
combined with docetaxel in a phase I trial for hormone-refractory prostate cancer (Tolcher 
et al., 2004). Although dose-limiting toxicity of severe fatigue and severe neutropenia was 
reported, twelve of the 17 taxane-naıve patients were considered evaluable for response. 
Seven of these 12 patients had a ≥ 50% reduction in PSA lasting at least 4 weeks.  
A potential limitation of corrective gene therapy is the requirement that not even a single 
neoplastic clonogen must develop. To achieve this goal would require 100% efficiency of 
gene transfer, as well as sustained transgene expression, or tolerance for repeated vector 
application (Mabjeesh et al., 2002). 
 
1.7.3.2 Immunotherapy strategies  
Tumour cells are poor antigen presenting cells. In prostate cancer in particular, defects in 
human  leukocyte  antigen  (HLA)  system  class  I  expression  were  observed  in  85%  of 
primary  and  100%  of  metastatic  tumours (Blades  et  al.,  1995),  which  implied  that  the 
immune  system  may  have  an  important  role  in  the  progression  of  prostate  cancer. 
Therefore, most of the immunotherapeutic approaches aim to activate the immune system 
to recognise and act against tumour cell antigens systemically. This might be achieved by 
enhancing expression of the tumour cell antigen like PSA, or by transfection/ infection of 
tumour or immune cells with cytokines that stimulate the anti-tumour function of immune 
cells such as interleukin-2 (IL-2), which stimulates T-cells or GM-CSF which stimulates 
macrophages and neutrophils. 
Cytokines  
One means to optimise tumour antigen presentation by gene therapy is through the targeted 
expression of cytokines in tumour cells. The GM-CSF has emerged as a cytokine with 
significant efficacy in the induction of an anti-tumour immune response (Dranoff et al.,   42 
1993).  GM-CSF  may  be  transduced  into  autologous  or  allogeneic  tumour  cells  ex vivo 
using either a retrovirus or other vectors. The transduced tumour cells are then irradiated 
both to minimise malignant potential and to improve immunogenicity (Simons & Mikhak, 
1998). The cells are then re-introduced by vaccination into the patient and tumour response 
monitored. Phase I clinical trials suggested that both T-cell and B-cell immune response to 
human prostate cancer can be generated by this treatment (Simons et al., 1999). 
Intraprostatic administration of IL-2 gene to patients with localised or locally advanced 
prostate cancer in phase I clinical trials has shown evidence of systemic immune activation 
based on an increase in the infiltration of lymphocyte into tumours (Trudel et al., 2003, 
Belldegrun et al., 2001). 
 
Expression of a tumour antigen  
Kim et al. developed a DNA vaccine construct, which encodes for PSA by cloning a cDNA 
for PSA into a mammalian expression vector under the control of a CMV promoter. PSA 
specific immune response was induced in mice after immunisation with this PSA vaccine 
(Kim  et  al.,  1998).  There  were  strong  and  persistent  antibody  response  against  PSA, 
significant  T  helper  cell  proliferation  against  PSA  protein,  and T  lymphocyte  response 
against tumour cell targets expressing PSA. However, a similar PSA vaccine delivered by 
modified vaccinia virus has shown low toxic effects and variable efficacy in phase I clinical 
trials of prostate cancer (Sanda et al., 1999). 
In  2004,  the  Eastern  Cooperative  Oncology  Group  reported  a  phase  II  clinical  trial  to 
evaluate the feasibility and tolerability of a prime/boost vaccine strategy using vaccinia 
virus and fowlpox virus expressing human PSA in patients with biochemical progression 
after local therapy for prostate cancer. Out of 64 treated patients, 45% of men remained free 
of  PSA  progression  at  19.1  months  and  78.1%  demonstrated  clinical  progression-free   43 
survival. 46% of patients demonstrated an increase in PSA-reactive-T cells (Kaufman et al., 
2004). 
1.7.3.3 Cytolytic/ pro-apoptotic strategies 
Cytotoxins 
Diphtheria toxin A chain (DT-A) was amongst a group of cytotoxins screened using a wide 
range of prostate cancer cell lines (Rodriguez et al., 1998). This study demonstrated cell 
cycle- and p53-independent cytotoxic activity of DT-A through both apoptotic and non-
apoptotic  pathways.  Regulated  expression  of  DT-A  has  been  achieved  both in  cultured 
androgen-independent  prostate  cancer  cells  that  express  the  protein  BCL-2  and  their 
xenografts using adenovirus vectors (Peng et al., 2002). Furthermore, Zheng and colleagues 
used human LNCaP prostate xenografts in nude mice to evaluate in vivo anticancer efficacy 
of DT-A gene (Zheng et al., 2003). A single injection of the DT-A gene-encoding lentiviral 
vector into LNCaP prostate tumours caused complete eradication of approximately 75% of 
the tumours in the animals. 
 
Oncolytic viruses  
Viral vectors (see section 1.7.4.1) may themselves be designed to target and kill tumours 
without insertion of a foreign transgene. The adenovirus life cycle includes a lytic phase, 
which can result in host cell death independently of entry into the cell cycle – an important 
advantage in prostate cancer given the low mitotic rate. 
CN706 vector  
CN706  is  an  adenovirus  vector  with  the E1A  gene  placed  under  the  control  of  a  PSA 
minimal promoter enhancer. E1A is one of the adenovirus gene products that may function 
to induce cell death (Rao et al., 1992). In a pre-clinical testing, CN706 infection of PSA-  44 
producing  LNCaP  cells  caused  high  expression  of  E1A  gene.  Furthermore,  a  single 
intratumoural  injection  of  the  CN706  vector  into  LNCaP  mouse  xenograft  models 
destroyed the tumours and abolished PSA production (Rodriguez et al., 1997). 
In a phase I clinical trial, twenty patients with locally recurrent prostate cancer following 
radiation therapy received intraprostatic delivery of a range of doses of CV706 (DeWeese 
et al., 2001). CV706 was found to be safe and was not associated with irreversible grade 3 
or  grade  4  toxicity.  Five  patients  from  the  groups  treated  with  the  highest  two  doses 
achieved ≥ 50% reduction in PSA. 
ONYX-015 
The ONYX-015 vector is an adenovirus designed to preferentially replicate in p53 mutant 
cells.  ONYX-015  was  the  first  genetically  engineered  replication-competent  virus  to 
demonstrate selective intratumoural replication and necrosis in patients (Nemunaitis et al., 
2000). In phase II trial, Nemunaitis and colleagues tested intratumoural and peritumoural 
injection  in  37  patients  with  recurrent  head  and  neck  tumours.  Significant  tumour 
regression (>50%) occurred in 21% of evaluable patients, whereas no toxicity to injected 
normal peritumoural tissues was demonstrated (Nemunaitis et al., 2000). 
1.7.3.4 Suicide gene therapy 
This  strategy  (also  known  as  gene-dependent  enzyme  prodrug  therapy),  involves 
introduction of a gene encoding a drug metabolising enzyme into target cells, followed by 
systemic  administration  of  a  non-toxic  prodrug.  The  enzyme  produced  in  the  target 
(tumour) cells converts the non-toxic prodrug into a cytotoxic form which then kills the 
tumour cells (Macrae et al., 2005). 
Two of the most commonly used enzyme-prodrug combination in gene therapy protocols 
are  the  herpes  simplex  virus  type  1  (HSV1)  thymidine  kinase  (TK)  gene  used  with   45 
ganciclovir (GCV) and the cytosine deaminase (CD) gene used with 5-fluorocytosine (5-
FC). 
Mammalian  cells  unlike  certain  fungi  and  bacteria  do  not  contain the  enzyme  CD  and 
therefore  do  not  ordinarily  metabolise  cytosine  to  uracil.  The  introduction  of  the 
Escherichia  coli  CD  gene  into  eukaryotic  cells  allows  these  cells  to  produce  the  toxic 
antimetabolite 5-fluorouracil from the nontoxic prodrug 5-FC (Mullen et al., 1992). 
The efficacy of this system in prostate cancer gene therapy has been studied in a number of 
preclinical studies. Using subcutaneous LnCaP prostate cancer cells xenografts grown in 
nude mice, an adenovirus encoding the CD gene was injected directly into the tumour and 
the prodrug 5-FC was administered intraperitoneally. There was significant reduction in 
tumour growth compared with untreated tumours (Yoshimura et al., 2002). This strategy of 
prodrug activation has the advantage of being less dependent on efficient gene transfer than 
other therapies owing to the bystander effect from the infected/transfected target cells. 
In the first clinical trial of its type, the CD gene was combined with HSV-tk gene in a 
replication competent adenovirus (Freytag et al., 2002a). The vector was then administered 
intra-prostatically  to  16  patients  with  locally  recurrent  prostate  cancer  after  definitive 
radiotherapy. Two days later 5-FC and GCV were administered systemically. The drug 
combination was well tolerated, with few side effects and nearly half of the patients showed 
a decrease of at least 25% in serum levels of PSA following treatment (Freytag et al., 
2002a) 
A trimodal gene therapy approach has also been developed, in which replication-competent 
adenovirus containing a CD/TK fusion gene was administered with FC and valciclovir as 
well as conventional dose radiotherapy (Freytag et al., 2002a). In the pre-clinical mouse 
models (DU145 xenografts and LNCaP orthotopic tumours in immune deficient mice), this 
trimodal  approach  was  found  to  improve  the  cure  rate  and  decrease  the  frequency  of   46 
metastases compared with radiotherapy alone. Following this, a phase I clinical trial studied 
the safety of this strategy for the treatment of newly diagnosed, intermediate- to high-risk 
prostate cancer patients. There was no dose limiting adverse effects. Patients who received 
longer  treatment  with  prodrug  therapy  showed  a  more  prompt  decline  in  serum  PSA 
concentrations (Freytag et al., 2003). 
 
1.7.4 Gene transfer systems 
Successful gene therapy requires the development of suitable vectors or vehicles for in vivo 
gene  transfer.  The  alternative  ex  vivo  approach  of  gene  therapy  is  complicated,  time 
consuming, and costly, thus limiting its clinical application. An ideal vector should be safe, 
stable, easy to produce in large quantities, and capable of achieving efficient and tissue-
specific gene expression when directly administered in vivo (Li & Ma, 2001). Gene transfer 
systems are generally classified into viral and nonviral vectors.  
1.7.4.1 Viral vectors 
The design of viral vectors involves removal of many virally encoded genes (generating so-
called  gutless  vectors)  and  introduction  of  the  therapeutic  gene  (Foley  et  al.,  2004).  
Vectors from retroviruses, adenoviruses, vaccinia virus, adeno-associated virus, and herpes 
simplex virus are extensively used (Bonnet et al., 2000). Several attributes are considered 
when  choosing  a  viral  vector  as  illustrated  in  Table  1.2.  The  most  relevant  factors for 
prostate  cancer  gene  therapy  include  the  ability  to  transduce  non-dividing  cells, 
transduction efficiency and the ability to produce the vector in high titres. 
To increase their safety, viral vectors may be designed to be replication deficient, with no 
further virus particles generated following infection of the target cells. Alternatively the   47 
viral vectors may be replication-competent or replication-attenuated, in which case viral 
replication can occur in permissive cells (Mabjeesh et al., 2002). 
Adenoviruses  are  one  of  the  most  commonly  used  viral  vectors  for  gene  therapy, 
particularly serotypes 2 and 5 of the subgroup C.  Both replication-deficient (e.g. (Herman 
et al., 1999; Teh et al., 2001)) and attenuated replication-competent (e.g. (Freytag et al., 
2002a; Freytag et al., 2003)) forms of adenoviral vectors have been used in the clinical 
trials of prostate cancer gene therapy. Whilst adenoviruses can transduce both dividing and 
non-dividing cells efficiently (Bonnet et al., 2000), and high titres can readily be prepared 
(Herman  et  al.,  1999),  there  are  still  major  issues  of  potential  immune  resistance  and 
inflammatory response. 
Hence the only death of a patient undergoing gene therapy was attributed to an immune 
response to the adenoviral vector (Bostanci, 2002); (Marshall, 1999), adenovirus vectors 
have been modified extensively to decrease their immunogenicity by deletion of the E1 
gene and other genes including E2 and E3 (Herman et al., 1999; Kubo et al., 2003)  
Retroviruses integrate into the cellular genome after reverse transcription, allowing long-
term  and  stable  gene  expression. This  integration  is  beneficial  for  gene  replacement  in 
disorders such as severe combined immunodeficiency (Hacein-Bey-Abina et al., 2002), but 
it is less important in most strategies of gene therapy for cancer, in which the intention is to 
kill the target cells. Adverse events have been reported in a clinical trial using retroviral 
vector, in which two cases of uncontrolled proliferation of T cells were described among 
patients treated for severe combined immunodeficiency (Hacein-Bey-Abina et al., 2003). 
Protocols for research on use of retroviruses as vectors account for many trials on gene 
therapy for cancer, and retroviruses have been used in two clinical trials for prostate cancer 
(Simons et al., 1999; Steiner et al., 1998).    48 
Vaccinia  virus  have  a  wide  host  range  and  may  transfer  large  inserts  of  up to  25  kb, 
facilitating multi-gene transfer (Peplinski et al., 1998). Vectors derived from vaccinia virus 
elicit a rapid and sustained humoral immune response. Vaccinia virus vectors have been 
used in gene therapy for prostate cancer to deliver a vaccine of PSA (Eder et al., 2000; 
Gulley et al., 2002; Sanda et al., 1999) 
Adeno-associated viruses (AAV) are promising vectors for gene delivery because they can 
integrate into the genome of the host cells (preferentially at chromosome 19 in humans) and 
persist for the life of the host cell (Muzyczka, 1992). Although no adverse events related to 
integration of AAV have been reported in clinical trials on gene therapy, it is nevertheless 
of  a  potential  concern.  AAV  require  additional  genes  from  a  helper  virus  such  as 
adenovirus in order to produce viable viral particles with the packaging cell line (Verma & 
Somia, 1997). A major drawback for use in some gene therapy protocols is their limited 
capacity to accept therapeutic genes (Kremer & Perricaudet, 1995).   49 
Table 1.2: Comparison of available viral vectors for gene transfer   
Virus 
(Type) 
Infection  of 
non-dividing 
cells 
Transduction 
efficiency 
Capacity for 
foreign 
DNA 
Concentration 
ability 
Integration  into 
host 
chromosome 
Risk  of 
insertional 
mutagenesis 
Toxicity at 
high doses 
Immune 
response 
Adenovirus 
(dsDNA) 
Yes  High  Small  
(8 kb) 
Can  concentrate 
at high titres 
No 
(lack  sustained 
expression) 
No  Yes  Yes 
Retroviruses 
(ssRNA) 
No 
(Except 
lentiviruses) 
Low  Small  
(<9-10 kb) 
Low  Yes 
(Sustained 
expression) 
 
Yes  Yes  No 
Vaccinia 
(dsDNA) 
Yes  Low  Large 
(>30 kb) 
High  Yes  (Transient 
expression) 
NK  NK  Yes 
Adeno-
assiciated  virus 
(ssDNA) 
Yes  (needs 
helper virus) 
High  Small 
(4.5 kb) 
Yes  with 
difficulty 
Yes  No  No  Low level 
Herpes  simplex 
(dsDNA) 
Yes  (with  or 
without  helper 
virus) 
Moderate  Large 
(40-150 kb) 
High  for  helper-
independent HSV 
Latency 
expression 
Yes  Yes  Yes   50 
1.7.4.2 Non-viral vectors 
In  contrast  to  viral  vectors,  non-viral  vectors  are  particularly  suitable  with  respect  to 
simplicity, ease of large-scale production and lack of specific immune response. Recently, 
several  novel  non-viral  vectors  have  been  developed  that  approach  viruses  in  terms  of 
transfection efficiency.  
Naked DNA 
The most technically simple form of gene therapy is the use of naked DNA. A plasmid 
containing the gene of interest and appropriate promoter is injected directly into a desired 
site. Administered in this way, the efficiency of transgene uptake/ expression is very low 
(Mabjeesh et al., 2002). The transforming DNA does not integrate into the host genome and 
the duration of expression is short. Of all the sites tested so far, the greatest transduction 
efficiency is observed in muscle (Wolff et al., 1990), where brief low-level expression may 
be sufficient for eliciting therapeutic immune response. 
Attempts to improve the utility of naked DNA plasmid gene transfer include the use of 
electroportation  and  gene  gun.  Elecrtoportation  involves  exposing  cells  to  a  strong 
electronic field that temporarily alters the structure of the cell membrane, facilitating entry 
of  naked  DNA.  Recent  studies  have  shown  that  this  method  facilitates  the  uptake  of 
plasmid DNA to tissues in vivo (Cemazar et al., 2002; Somiari et al., 2000) by applying an 
electric  field  to  the  entire  area  of  interest.  Electroportation  has  been  used  to  deliver 
transgenes to subcutaneous prostate tumours in mice (Mikata et al., 2002). 
Gene guns can be used to propel gold microspheres coated with plasmid DNA into target 
cells,  where  DNA  is  released  into  the  nucleus  (Yang  et  al.,  1990).  The  transfection 
efficiency is generally low and varies from 1% to 20% depending on the type and depth of 
the  tissue  (Johnston  &  Tang,  1994).  In  addition  to  physical  trauma  leading  to  loss  of   51 
viability  of  target  cells,  other  disadvantages  of  this  method  are  short-term  low-level 
expression and shallow penetration of target tissues when the electric pulse is externally 
applied (Greco et al., 2002). 
 
Liposome vectors and cationic polymers 
Liposome vectors are cationic lipids, or more usually a combination of cationic and neutral 
lipids,  which  have  been  used  for  the  cellular  delivery  of  drugs  (Ishida  et  al.,  2001). 
Liposomes are the second most commonly used gene transfer method in current clinical 
trials. Liposome vectors consist of a DNA plasmid surrounded by a liposomal coat. The 
positive charge of liposomes facilitates the formation of complexes with DNA and their 
lipid structure allows them to cross cell membranes. 
Liposome vectors are inexpensive and relatively easy to prepare in large quantities. Their 
large insert capacity permits the transfer of multi-gene cassette of unlimited size. Since they 
lack proteins, they elicit weaker or no immune/inflammatory responses (Mabjeesh et al., 
2002). A disadvantage of liposomal gene transfer is its inefficiency; thousands of liposomes 
are  necessary  per  cell  for  successful  transduction  (Yotsuyanagi  &  Hazemoto,  1998). 
Improved formulations, and formation of complexes with targeting molecules have been 
developed to improve the uptake and decrease the problem of sequestration of liposome 
vectors in endosomes (Meyer et al., 1998; Otomo et al., 2001; Shi et al., 2001). 
Similar  to  cationic  liposome,  the  cationic  polymers  bind  to  nucleic  acids  to  facilitate 
intracellular  delivery.  In  vitro,  the  dendrimer  polyethyleneimine  has  been  used  for 
transfection of prostate cancer cells (Fronsdal et al., 1998) .   52 
1.7.4.3 Hybrid Vectors 
As  a  means  to  circumvent  some  of  the  limitations  of  both  synthetic  and  viral  vectors, 
hybrid  vectors  combining  viral  and  synthetic  approaches  have  been  devised.    DNA 
segments can be complexed to an adenovirus virion with which polylysin or DEAE-dextran 
has been conjugated (Curiel, 1994; Forsayeth & Garcia, 1994; Wagner et al., 1992). These 
conjugates  improve  transfer  efficiency  by  the  orders  of  magnitude  in  comparison  with 
naked DNA. Similar improvements have been noted for an adenovirus-liposome complex, 
which resulted in a 1000-fold increase in gene transfer efficiency relative to naked plasmid. 
(Raja-Walia et al., 1995). The presence of the virion proteins in the DNA-virus complex 
improves  vector  attachment  and  uptake  and  allows  escape  of  the  vector  DNA  from 
endosomes prior to fusion with the lysosomes, where they may be degraded (Cristiano et 
al., 1993). 
 
1.7.5 Prostate-specific gene expression  
The efficacy and safety of prostate cancer gene therapy could be improved with the use of 
prostate-targeted vectors with enhanced transcriptional activity, as well as highly accurate 
cell-specific  discrimination.  An  effective  approach  is  transcriptional  targeting  (i.e., 
restricting expression to prostate-specific tissue by using gene regulatory elements) such as 
the  tissue  and  tumour  specific  promoters.  This  is  particularly  suitable  for  use  to  target 
tissues of prostate origin because the prostate is one of the organs (in addition to pancreas 
and breast) that express an unusually high number of unique genes.    53 
1.7.5.1 Tissue specific promoters 
Prostate tissue-specific promoters include PSA, the human glandular kallikrein 2 (hK2), 
prostate specific membrane antigen (PSMA), rodent prostate promoters and osteocalcin. 
A minimal composite PSA promoter/enhancer element (PSE) was used to drive expression 
of Ad E1A in the attenuated replication-competent vector CN706 (Rodriguez et al., 1997; 
Schuur et al., 1996). The regulation of E1A expression by the PSE element effectively 
limits cytolytic viral replication to PSA-expressing cells, with resulting therapeutic ratio of 
between 20:1 and 3000:1 depending upon the cell line tested. 
Like PSA or hK3, hK2 belongs to a large human kallikrein gene family which is located on 
chromosome  19q13.4  ((Yousef  &  Diamandis,  2002).  DNA  transfection  and  adenoviral 
transduction studies have confirmed the androgen-responsive and cell specific nature of the 
hK2 promoter (e.g. (Mitchell et al., 2000). In addition, the increased hK2 expression in 
carcinoma, as compared to benign tissues, supports its utility as a prostate cancer biomarker 
(Yousef & Diamandis, 2002).  
Although detailed immunohistochemical analysis revealed that PSMA expression is not 
restricted to prostate tissues alone (Silver et al., 1997), PSMA promoter-driven cytotoxic 
gene expression was found to be induced by androgen deprivation and is more effective in 
eradicating androgen-independent prostate cancer cells (O'Keefe et al., 2000). 
Osteocalcin is a bone matrix protein produced exclusively by osteoblasts, and its expression 
is  regulated  by  multiple  elements,  including  the  osteo-specific  OSE2  element  and  the 
vitamin D-responsive element (Hsieh et al., 2002; Lian et al., 1999). Interestingly, primary 
and metastaitc prostate cancer cells were shown to express osteocalcin (Matsubara et al., 
2001). Osteocalcin promoter activated adenoviral replication in an oncolytic strategy was   54 
capable  of  suppressing  growth  of  prostate  tumours  in  animals  (Hsieh  et  al.,  2002; 
Matsubara et al., 2001).  
1.7.5.2 Tumour specific promoters 
Since no gene has yet been identified that is unique for prostate cancer, gene targeting using 
prostate  tumour-specific  promoters  is  not  feasible  at  the  present  time.  Therefore,  it  is 
important  to  uncover  differences  in  protein  and  gene  expression  between  normal  and 
cancerous prostate cells to pinpoint genes whose expression is limited to cancer cells. 
Telomerase  is  an  enzyme  involved  in  the  synthesis  and  maintenance  of  chromosome 
termini that conventional polymerase are unable to replicate fully. Telomerase is composed 
of an integral RNA component hTERC (Feng et al., 1995) and the catalytic activity is 
provided  by  the  reverse  transcriptase  sub-unit  hTERT  (Nakamura  et  al.,  1997).  Both 
components are necessary for telomerase activity. The expression of hTERT is confined 
almost exclusively to tumour cells whereas hTERC gene transcription is less stringently 
limited to malignant cells (Weinrich et al., 1997). 
In  contrast  to  most  tissue  specific  promoter  elements,  the  promoter  of  the  telomerase 
reverse  transcriptase  gene  controls  selective  expression  of  telomerase  in  over  90%  of 
human malignancies, but it is silent in most adult tissues (Kim et al., 1994b). The activity 
of  hTERT  promoter  was  compared  with  that  of  the  strong  ubiquitous  cytomegalovirus 
(CMV)  promoter  to  drive  adenovirus  vector  for  the  gene  of LacZ.  In  cancer  cells,  the 
difference in promoter activity between CMV and hTERT was between 2- and 20-fold, 
while in normal cells the difference was more than 500-fold. In all cells tested, the hTERT 
promoter activity was significantly higher in cancer cells than in normal cells, usually by 
more than 100-fold (Gu et al., 2000a).  Wirth et al. (2003) used a telomerase-dependent 
conditionally replicating adenovirus and demonstrated viral replication in all investigated   55 
telomerase-positive  tumour  cell  lines  but  not  in  telomerase  negative  primary  human 
hepatocytes (Wirth et al., 2003). 
 
1.8 Targeted-radiation cytotherapy (TRC) 
1.8.1 Introduction 
The dream of magic bullet for cancer therapy describes a therapeutic agent that selectively 
targets and kills all primary and metastatic malignant cells anywhere in the body without 
causing significant side effects. Up to date, despite the dramatically improved knowledge of 
cancer molecular and genetic sciences, this dream is yet to be realised. 
Although EBRT retains, beside surgery and chemotherapy, its main role in cancer therapy, 
significant issues regarding EBRT are still to be addressed. One of the disadvantages of 
EBRT is that even the most sophisticated methods fail, to a certain extent, to confine the 
damaging  ionising  radiation  to  tumour  deposits  within  the  boundaries  of  the  affected 
organ(s) and spare the normal tissues of the affected organ and the neighbouring structures. 
This  led  to  the  introduction  of  brachytherapy, whose  main  objective  is  to  improve  the 
confinement  of  the  ionising  radiation  within  the  affected  organ.  Pre-requisites  for  this 
method  include  easy  organ  accessibility,  certain  tumour  volume,  and  most  importantly 
clinically acceptable permanent damage after therapy, which are applicable to localised 
prostate cancer. However, according to the recent clinical trials comparing brachytherapy 
with EBRT of prostate cancer, there is no significant survival advantage of brachytherapy 
compared with EBRT and furthermore, the side effect advantage is still marginal (Ragde et 
al., 2000; Zelefsky et al., 1999).   
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Targeted-radiation  cytotherapy  (TRC)  has  recently  emerged  as  a  promising  alternative 
technique for radiation therapy. TRC selectively limits radiation dose to the targeted cells 
utilising a specific molecular characteristic or structural or functional alteration of these 
cells.  Potential  advantages  of  this  novel  strategy  include  feasibility  of  systemic 
administration,  selectivity,  better  dose  control  and  reproducibility.  In  addition  to  the 
established  and  approved  use  for  thyroid  hyperactivity  and  malignancy,  several  other 
applications of TRC are being explored in terms of mechanism of delivery and the type of 
targeted cells. A number of these applications involve trials to combine TRC with genetic 
manipulation of tumour cells. However, the majority of these applications are still in their 
early stages of development. The following is an overview of the available strategies of 
TRC and their related gene therapy applications.  
  
1.8.2 Monoclonal antibody mediated TRC 
Monoclonal  antibodies  (mAbs)  are  targeting  molecules  capable  of  recognising  small 
differences between molecular groups (epitopes) on the surface of normal and cancer cells 
(Kohler & Milstein, 1975). Radiolabelled mAbs are becoming more widely used in the 
field of clinical radio-immunotherapy.  
90Y-ibritumomab tiuxetan and 
131I-tositumomab are currently the only radiolabelled mAbs 
approved for treatment of cancer (Sharkey & Goldenberg, 2005). Each is registered for 
therapy  of  chemotherapy-refractive,  follicular  (low  grade)  non-Hodgkin’s  lymphoma 
(NHL), with or without transformation. This strategy uses an antibody that is directed to 
CD20,  an  antigen  that  is  abundantly  present  on  a  high  percentage  of  both  normal  and 
malignant B-cells. In an integrated analysis of 5 clinical trials including 250 patients with 
refractory or relapsed NHL, response rates ranged from 47% to 68%, complete response   57 
rate ranged from 20% to 38% with a median follow up of 5.3 years (Fisher et al., 2005). 
Long  term  side  effects  reported  after  radiolabeled  mAbs  treatment  of  cancer  include 
hypothyroidism (with 
131I products), myelodysplasia, and, possibly, secondary neoplasms 
(Goldenberg, 2003). 
It has been encouraging that significant response to radiolabelled mAbs of NHL patients 
was  observed  after  the  delivery  of  considerably  low  absorbed  radiation  dose  (less  than 
1,000 cGy to a tumour) (Koral et al., 2000; Wiseman et al., 2001). In contrast, a variety of 
solid tumours in patients with disease burden similar to those treated in NHL trials has 
failed to elicit responses, even with the delivery of as much as 3,000 cGy to the tumour 
using 
131I- or 
90Y-labeled mAbs (Tempero et al., 2000; Tempero et al., 1997). 
Prostate  cancer  is  an  attractive  target  for  radiolabelled  mAbs  for  numerous  reasons 
including the fact that prostate cancer metastasises almost exclusively to bone marrow and 
lymph nodes, both of which have good access to circulating mAbs. Furthermore, prostate 
cancer metastases are frequently small enough for good antibody penetration (Smith-Jones, 
2004). Various radiolabelled mAbs are in preclinical and clinical development. They are 
targeted against a number of different tumour markers, which are either general tumour 
antigens like TAG72 and CA 170 or prostate specific like PSMA.  
The anti-TAG27 mAbs B72.3 and CC49 have been used to target this antigen in prostate 
cancer patients, initially for radioimmunoguided surgery (Badalament et al., 1993) and as 
radioimmunotherapy for HRPC (Meredith et al., 1994). 
Several  radiolabelled  mAbs  have  been  developed  against  PSMA  including  7E11-C5 
[precursor of 
111In-CYT-356 (prostaScint), a FDA approved imaging agent] and J591. 
Animal  studies  of 
111In-J591  and 
90Y-J591  have  demonstrated  dose-related  increased 
median survival time relative to untreated controls in nude mice bearing PSMA positive 
prostate cancer xenografts (Vallabhajosula et al., 2004). In two reported clinical trials using   58 
DOTA-huJ591 conjugates labelled with 
90Y and 
177Lu, there were dose related antitumour 
activity including both PSA decline and measurable disease response (Bander et al., 2003). 
 
1.8.3 Receptor-mediated (somatostatin) TRC 
Low  doses  of  the  radiolabelled  somatostatin  analogues  like 
111In-octreotide  have  been 
shown to be very useful in detection and staging of the neuroendocrine tumours (Krenning 
et al., 1989). These compounds have been conjugated with DTPA (diethylene-triamine-
pentacetic acid) and more recently with DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic  acide)  (Otte  et  al.,  1997)  as  a  way  of  coupling  somatostatin  analogues  with 
various  radionuclides.  This  strategy  of  somatostatin  receptors  (SSRs)  targeting  with 
diagnostic radiopharmaceuticals utilises the over-expression of SSRs on the cell surfaces of 
a number of neuroendocrine tumours (Kwekkeboom et al., 1993). High therapeutic doses of 
these  radiopharmaceuticals  can  also  be  given  to  patients  with  SSR-positive  tumours,  a 
treatment known as peptide receptor radionuclide therapy (PRRT). In vivo studies have 
shown strong growth inhibition of SSR-positive pancreatic liver metastases in rats treated 
with  370  MBq  [
111In-DTPA]  octreotide.  This  effect  was  abolished  when  the  SSR  was 
blocked,  indicating  that  radiolabelled  octreotide  was  internalised  specifically  by  SSR 
(Slooter et al., 1999). Initial clinical studies with high doses [
111In-DTPA] octreotide in 
patients  with  metastasised  neuroendocrine  tumours  have  been  encouraging  (Van  Eijck, 
2005).  Most  recently,  treatment  with  the  newest  radio  labelled  somatostatin  analogue, 
[(
177Lu-DOTA(0),Tyr(3)]  octreotate,  which  has  a  higher  affinity  for  the  subtype  2 
somatostatin receptor, resulted in complete or partial remissions in 30% of 76 patients with 
inoperable or metastasised neuroendocrine tumours (Kwekkeboom et al., 2005). 
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1.8.4 Transporter-mediated TRC 
The affinity of thyroid tissue for radioactive iodine, a property retained by many thyroid 
carcinomas,  allowing  such  tumours  to  be  successfully  treated  by  administration  of 
radiolabelled  sodium  iodide  (
131I-NaI)  was  arguably  the  very  beginning  of  targeted 
radionuclide  therapy.  The  mechanism  mediating  iodide  uptake  across  the  basolateral 
membrane of thyroid follicular cells has been clarified by the cloning and characterisation 
of the sodium iodide symporter, NIS (Dai et al., 1996). 
Mandell et al. demonstrated in vitro and in vivo iodide accumulation in several cancer cell 
lines, including melanoma, liver, colon carcinoma, and ovarian carcinoma cell lines after 
transfection with the rat NIS gene (Mandell et al., 1999).  
The PSA promoter-directed NIS gene delivery induced tissue specific, androgen-dependent 
iodide  uptake  activity  of  the  prostate  cancer  cell  line  LNCaP,  indicating  functional 
expression of NIS (Spitzweg et al., 2000; Spitzweg et al., 1999). More recently, probasin 
promoter driven adenovirus encoding human NIS was used to achieve high magnitude and 
tissue-specific expression of human NIS in prostate cancer cells (Kakinuma et al., 2003). In 
a  preparation  for  a  phase  I  clinical  trial,  Dwyer  and  colleagues  injected  male  dogs 
intraprostatically with adenovirus-mediated NIS gene followed by i.v. injection of 3 mCi 
123I and serial imaging acquisition and then therapeutic dose of 
131I. SPECT/ CT fusion 
images and dosimetry calculations revealed clear images of the NIS transduced prostates 
and acceptably low doses to other organs. There was no vector-related toxicity or surgical 
complication observed (Dwyer et al., 2005). 
 
The radiopharmaceutical meta-iodo-benzyl guanidine (MIBG) is a catecholamine closely 
related to the adrenergic neuron blocking drugs guanethidine and bretylium which is taken   60 
up actively by cells of the sympathetic nervous system and tumours of neuroendocrine 
origin (neuroblastomas and phaeochromcytomas).  
Radiolabelled  MIBG  allows  the  scintigraphic  imaging  of  neural  crest  tumours  and 
[
131I]MIBG  has  been  used  in  the  treatment  of  neuroblastoma  and  phaeochromocytoma 
(Meller, 1997). The mechanism of uptake and retention of MIBG in tissues and tumours of 
neural crest origin have been studied extensively. 
The cellular uptake of MIBG into adrenomedullary cells and neurobalstoma takes place 
both by a specific uptake system, known as uptake-one, and by a non-specific mechanism, 
presumed to be passive diffusion. Uptake-one is an active process by the noradrenaline 
transmembrane protein (noradrenaline transporter NAT) (Meller, 1997). 
The NAT gene has been sequenced (Pacholczyk et al., 1991) and cloned and it has been 
demonstrated that NAT expression is predictive for MIBG uptake capacity (Mairs et al., 
1994).  Furthermore,  quantification  of  NAT  mRNA  could  be  used  for  the  selection  of 
patients for MIBG therapy (Mairs, 1999). Studies carried out in our department have also 
demonstrated  that  the  introduction  of  exogenous  NAT  gene  into  non-NAT-expressing 
tumour cells is a promising method of gene therapy-assisted MIBG-targeted radiotherapy.  
Amongst the tested cell lines are those derived from glioma (Boyd et al., 2001), prostate 
cancer (Fullerton et al., 2004) and bladder cancer (Fullerton et al., 2005).  
 
The transfection of prostate cancer cell lines DU145 and LNCaP with CMV or telomerase 
promoter-driven NAT gene resulted in expression of a functional NAT. This was confirmed 
by significantly enhanced [
131I]MIBG active uptake and resultant tumour cell kill (Fullerton 
et al., 2004). Fullerton et al. have also reported 36-fold enhanced uptake of [
131I]MIBG by 
the bladder cancer cell line EJ138 transfected with telomerase promoter-driven NAT gene,   61 
compared with the parental cell line. The enhanced uptake correlated with dose-dependent 
cell kill in NAT transfected EJ138 treated with [
131I]MIBG  (Fullerton et al., 2005). 
 
1.8.5 Bone-seeking TRC 
Because  advanced  prostate  cancer  often  metastasises  to  bone,  bone  pain  is  a  common 
symptom  and  often  determines  quality  of  life  in  the  later  stages  of  disease.  Moderate, 
localised  skeletal  symptoms  often  respond  to  conventional  analgesics  and/  or  single-
fraction EBRT. This approach becomes less useful in the context of progressive skeletal 
metastases, which results in poorly localised or migratory multisite pain. 
Selective tumour targeting with bone-seeking radiopharmaceuticals is a suitable option for 
the  management  of  disseminated  disease  because  it  acts  systemically  and  has  reduced 
toxicity  compared  with  other  options  like  wide-field,  hemibody  radiotherapy.  Bone 
targeting relies on selective uptake and prolonged retention at sites of increased osteoblastic 
activity. Some therapeutic radionuclides, such as strontium (
89Sr) and radium (
223Ra), have 
natural  affinity  for  metabolically  active  bone.  Others  including  samarium  and  rhenium, 
form  stable  complexes  with  bone-seeking  cations,  such  as  phosphate  and  diphosphate  
(Lewington, 2005).  
Several studies have demonstrated the efficacy of 
89Sr (e.g. (Firusian et al., 1976; Laing et 
al., 1991; Silberstein & Williams, 1985)). In one retrospective review, 89% of 28 patients 
reported moderate or good relief of pain (Robinson et al., 1993).  Toxicity of 
89Sr treatment 
is limited to temporary myelosuppression, which typically occurs less than 6 weeks after 
therapy (Lewington, 2005).   62 
1.8.6 Cell cycle targeting (IUdR) 
Due to their high proliferation rate compared with normal cells, the DNA of tumour cells 
can be selectively targeted by incorporating therapeutic nucleosides. Several investigators 
tested  this  cycle-specific  treatment  strategy  using  the  thymidine  analogue, 
iododeoxyuridine (IUdR), labelled with an Auger-emitter radioiodide. 
In vitro studies have demonstrated the exquisite toxicity of 
123I- and 
125I-iodinated IUdR to 
dividing  cells  (Kassis  et  al.,  1987;  Makrigiorgos  GM  et  al.,  1989;  Schneiderman  & 
Schneiderman, 1996). Furthermore, the effectiveness of locoregional administration of this 
agent has been shown in rodent models of gliosarcoma, ovarian cancer ascites, and bladder 
cancer  (Kassis  &  Adelstein,  1996b).    The  initial  attempt  to  translate  this  approach  to 
clinical application was disappointing because of the extremely rapid metabolic degradation 
of systemically administered radiolabelled IUdR (biologic half-time less than 5 minutes in 
human (Klecker et al., 1985)). 
However,  based  on  the  promising  results  obtained  with  locoregional  administration  in 
animal models, several studies have been conducted to explore this method in patients with 
cancers suitable for locoregional administration (reviewed in (Bodei et al., 2003)). 
The biodistribution of 
123I-IUdR has been investigated in one patient with a cystic brain 
glioma (Kassis et al., 1996). The overall pharmacokinetic pattern of 
123I-IUdR administered 
locoregionally to a human glioma resembles that observed in a rat glioma model, where 
administration of 
125I-IUdR is therapeutically effective (Kassis & Adelstein, 1996a).  
A major limitation of this strategy is that, in order to achieve its therapeutic effect, the 
Auger  electron  emitter  should  be  incorporated  into  cellular  DNA.  This  is  further 
complicated by the phenomenon of heterogeneous proliferation in tumours.   63 
Means  to  circumvent  this  problem  include  the  use  of  sustained  release  biodegradable 
polymeric implants for controlled release and local delivery of IUdR (Williams et al., 1997) 
and continuous infusion by micro-osmotic pump. Mairs and colleagues have demonstrated 
the superiority of mico-osmotic pump over single intralesional injection and slow release 
biodegradable implants for delivering [
125I]-IUdR to rat models of glioma (Mairs et al., 
2000). Furthermore, previous studies by our group, using a multicellular tumour spheroid 
model,  have  demonstrated  that  prolongation  of  the  incubation  time  increased  cellular 
accumulation of [
125I]IUdR (Neshasteh-Riz et al., 1997). 
Moreover, it has been hypothesised that benefit may be obtained from the use of both short-
range  and  long-range  emitters  or  by  a  combination  of  short-range  emitters  and  EBRT 
(O'Donoghue & Wheldon, 1996). 
 
1.8.7 Enzyme mediated TRC (FIAU)  
Incorporation of Auger electron emitters into DNA is an efficient application of irradiation, 
capable  of  inducing  cell  death  with  virtually  no  damage  to  the  surrounding  cells. 
Radiolabelled  thymidine  (TdR)  analogs,  such  as  IUdR,  represent  the  most  extensively 
explored radiobiologic model for cancer therapy with Auger-electron emitters (Bodei et al., 
2003). However, as discussed previously, systemic administration of radio-iodinated IUdR 
is not feasible in the presence of very efficient hepatic dehalogenation (Calabresi et al., 
1961;  Klecker  et  al.,  1985)  leading  to  a  biologic  half-life  of  only  a  few  minutes. 
Furthermore, cellular retention of this radionuclide relies entirely on its incorporation into 
DNA, which takes place only during the S phase (DNA synthesis) of cell growth.   64 
In an attempt to overcome these obstacles and utilise this strategy more efficiently, this 
thesis proposes a novel candidate for TRC with longer biological half-life and additional 
mechanism of cellular retention.  
 
5-iodo-2’-fluoro-2’-deoxy-1-ß-D-arabino-furonosyluracil (FIAU) is a thymidine analogue 
that has been used as an antiviral agent particularly for chronic hepatitis B virus infection 
(McKenzie et al., 1995; Tennant BC, 1998). FIAU is more stable than IUdR because of the 
high  chemical  and  metabolic  stability  of  the  N-glycosyl  linkage  in  the  pyrimidine 
nuceosides that contains the 2’-fluoro substituent in the arabinosyl configuration. (Philips et 
al., 1983) 
FIAU has also been radiolabelled and used as a viral infection imaging agent (Saito et al., 
1982;  Saito  et  al.,  1984;  Tovell  et  al.,  1987).  FIAU  can  also  be  labelled  with  several 
different radionuclides, including carbon-11, iodine-131, iodine-123 and iodine-124 (Misra 
et  al.,  1986),  enabling  clinical  imaging  with  positron  emission  tomography  (PET)  and 
single  photon  emission  tomography  (SPECT)  (Gambhir  et  al.,  2000).  Due  to  its  viral 
thymidine kinase sensitivity and specificity, radiolabelled FIAU can be used as a reporter/ 
marker  probe  for  the  non-invasive  imaging  of HSV1-tk  gene  expression  (Jacobs  et  al., 
1999; Tjuvajev et al., 1996; Tjuvajev et al., 1995).  
HSV1-TK, like mammalian TK, phosphorylates thymidine. Unlike mammalian TK, HSV1-
TK  has  relaxed  substrate  specificity  and  phosphrylates  acycloguanosines,  e.g.  acyclovir 
(ACV) (Elion et al., 1977; Fyfe et al., 1978), ganciclovir (GCV) (St Clair et al., 1987) and 
penciclovir (PCV) (Larsson et al., 1986) as well as TdR analogues e.g. FIAU (Cheng et al., 
1981).  Cellular  enzymes  then  convert  acycloguanosines  monophosphates  and  the 
monophosphate of FIAU to di- and triphosphates (Furman et al., 1980; Miller & Miller, 
1980), which if present in sufficient concentration will kill cells by incorporating as chain   65 
terminating  derivatives  and/  or  inhibition  of  DNA  polymerase  (Furman  et  al.,  1979; 
Furman et al., 1984). In contrast, in mammalian cells without HSV1-TK, TdR analogues 
are not phosphorylated fast enough to produce toxic concentration of their metabolites. This 
is because HSV1-TK is more than 1000 times as active at substrate phosphorylation as the 
endogenous mammalian cellular kinase (Nasu et al., 2000). 
In  addition  to  the  toxicity  resulting  from  DNA  incorporation,  FIAU  conjugated  to 
radioactive iodine will directly deliver ionising radiation into the nucleus. This will ensure 
precisely localised radiation dose to tumour cells (Fig. 1.1).  
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Figure 1.1: Consequences of the introduction and expression of viral thymidine kinase 
(TK) gene into a mammalian cell followed by exposure to GCV and/ or [
123I]FIAU. 
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1.8.8 The choice of radionuclide     
The Auger electron emitters decay by electron capture (EC) or internal conversion (IC) 
resulting in a vacancy, most commonly in the K shell.  
 
 
 
 
Such vacancies are rapidly filled by electrons dropping in from higher shells. This process 
leads to a cascade of electron transition and results in the emission of characteristic X-ray 
photon or an Auger electron (
0
-1e
-). An atom undergoing EC or IC emits, on average, 5-30 
Auger electrons with energy ranging from an eV to approximately 1 keV. The very low 
energies of Auger electrons have two major consequences. Firstly, these light, negatively 
charged (-1) particles travel in contorted paths, and their range in water is from a fraction of 
a nanometer up to approximately 0.5 ￿ m. Secondly, high linear energy transfer (LET) of 
multiple ionisations (4-26 keV/ ￿ m) occurs in the immediate vicinity of the decay site 
(Table 1.3). 
In contrast, the LET of ￿
--particles, which are energetic and negatively charged, is very 
low (approximately 0.2 keV/￿ m) along their up to a centimeter path (i.e., they are sparsely 
ionising). The energy spectrum of ￿
--particles has continuous spectrum ranging from 0 to 
maximum available energy Q. Subsequently, the use of ￿
--particle emitters, like 
131I, as 
therapeutic agents necessitate the presence of high radionuclide concentration within the 
targeted  tissue  (Kassis  &  Adelstein,  2005).  The  ￿
++-particles,  on  the  other  hand,  are   68 
positively charged with mass and charge equal to a helium nucleus, energies ranging from 
5-9 MeV, and corresponding tissue ranges of 5-10 cell diameters (Table 1.3).  
Table 1.3: General characteristics of therapeutic radionuclides. 
 (Modified from (Kassis & Adelstein, 2005) 
Decay  Particles  E(min)-E(max)  Range  LET  Examples 
￿
—particle  energetic 
electrons 
50-2,3000 keV
*  0.05-12 mm  0.2 keV/￿ m 
131I 
89Sr 
￿ -particle  He nuclei  5-9 MeV
$  40-100 ￿ m  80 keV/￿ m 
211At 
212Bi 
EC/IC 
(Auger) 
Nonenergetic 
electrons  
eV-keV
$  2-500 nm  4-26 keV/￿ m 
123I 
 
125I 
*Average (>1% intensity); continuous distribution of energy. 
$Monoenergetic. 
EC = electron capture; IC = internal conversion 
 
The principle target for the biological effects of ionising radiation is DNA resulting in 
several different lesions. These DNA lesions include steadily repairable lesions like single-
strand breaks (SSB), and more difficult to repair lesions of double-strand breaks (DSB) and 
multiply  damaged  sites (MDS).  These  lesions may  be  produced  by  direct  ionisation  of 
DNA  (direct  effect)  or  by  the  interaction  of  free  radicals  (mostly  hydroxyl  radicals 
produced in water molecules that diffuse a few nanometers) with DNA, an interaction that 
may be modified by radical scavengers (Kassis & Adelstein, 2005). The distribution of 
ionisations within DNA and the type of lesion created depend on the nature of the incident 
particle and its energy. Low energy electrons like Auger electrons generate clusters of high 
ionisation  density  along  an  irregular  path  (Fig.  1.2,  centre),  whereas  for  energetic  ￿
--
particles ionisations along their linear track are infrequent (Fig.1.2, top). For ￿ -particles,   69 
high ionisation densities occur along a linear track (Fig. 1.2, bottom). Therefore, the high 
specific ionisations of ￿ -particles and Auger-electron cascade can induce less repairable 
lesions (e.g. DSB) than those created by the sparsely ionising radiation of ￿
--particles. 
Furthermore,  the  cytocidal  efficiency  of  high  LET  radiation  is  not  affected  by  cellular 
proliferation rate and or the oxygen tension in tissues (Zalutsky & Vaidyanathan, 2000). 
This is advantageous particularly in slow growing tumours and in the presence of hypoxic 
regions within the tumour. 
The physical properties of the available Auger electron emitters are illustrated in Table 1.4. 
The modest decrease in DNA breakage efficiency of 
123I compared to 
125I (smaller number 
of electrons emitted per decay) might be more than compensated by the advantage of the 
much shorter half-life. The 60-day half-life of 
125I imposes severe limitations in terms of 
radiation  protection  (Lobachevsky  &  Martin,  2004).  Therefore,  we  selected  the 
radionuclide 
123I as a conjugate to FIAU for this in vitro study. 
Table 1.4: Physical properties of Auger-electron emitters (From (Kassis & Adelstein, 
2005) 
Rdionuclide  Average number of electrons  
emitted per decay 
Half-life 
125I  20  60.5 d 
123I  11  13.3 h 
77Br  7  57 h 
111In  15  3 d 
193mPt  30  4.3 d 
195mPt  36  4 d   70 
 
 
 
 
Figure 1.2: Local density of ionisation (*) produced along track (___) of energetic ￿
--
particles, Auger electrons, and ￿ -particles. (modified from Kassis & Adelstein, 2005) 
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AIMS OF THE PROJECT  
The main objectives of this study were as follows: 
a)  To transfect cancer cell lines including those derived from prostate cancer with the 
HSV1-tk  gene  and  then  to  evaluate  HSV1-tk  gene  expression  using  three  different 
methods.  
b)  To  test  the  hypothesis  that  radiolabelled  FIAU can  be  used  for  targeted  radiation 
cytotherapy of tumours expressing HSV1-tk gene. 
c)  To explore the response of tumour spheroids to this new strategy in order to assess the 
possibility of enhanced response by bystander or cross-fire effects. 
d)  To investigate the effect of cellular proliferation rate on the response of TK-positive 
tumour cells to radiolabelled FIAU.  
e)  To  determine  the  cell  cycle  changes  resulting  from  the  treatment  of  TK-positive 
tumour cell lines with radiolabelled FIAU and GCV using FACS scan. 
f)  To  evaluate  the  combination  therapy  effect  of  GCV  and  radiolabelled  FIAU  on 
tumour cells expressing the viral TK enzyme using the method of median effect analysis 
and combination index. 
The ultimate objective of this study was to optimise our basic knowledge of this novel 
treatment modality in order to develop an approvable clinical trial protocol.   
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Chapter 2 : General Materials and Methods 
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2.1 Materials 
2.1.1 Cell lines 
2.1.1.1 DU145 
This cell line was established from tumour cells removed from a metastatic central 
nervous system lesion of a 69-year-old man with prostate cancer in 1975(Mickey et al., 
1977).  
The cells are epithelial-like, adherent and grow as monolayers. 
2.1.1.2 PC3 
This is a human prostate carcinoma cell line which was established from the bone marrow 
metastasis  isolated  post-mortem  from  a  62-year-old  Caucasian  man  with  grade  IV 
prostate  cancer  (poorly  differentiated  adenocarcinoma)  after  androgen  suppression 
therapy(Kaighn  et  al.,  1979).  These  cells  are  epithelial-like  and  grow  adherently  in 
monolayers or in multilayer foci. This cell line was purchased from the American type 
Culture Collection (ATCC), Manassas, USA.       
2.1.1.3 UVW  
This is a human glioma cell line, which was established from an anaplastic astrocytoma of 
normal  adult  brain  in  the  Department  of  Medical  Oncology,  University  of 
Glasgow(MacDonald et al., 1985). These cells are fusiform and grow in monolayers or 
multicellular spheroids.  
DU145 and UVW were obtained from our departmental maintained cell lines. 
2.1.1.4 143B-TK- (abbreviated to 143B) 
This is a human osteosarcoma cell line derived from 13-year-old Caucasian female. 
These cells are thymidine kinase deficient (TK-) and are resistant to BUdR (Rhim et al., 
1975). Their morphology is fibroblast-like.   74 
 
 
2.1.1.5 143B PML BK TK (abbreviated to 143B-TK) 
This cell line was derived from the human osteosarcoma cell line 143B by the insertion of 
the  PML  BK  TK  plasmid  carrying  a  viral  thymidine  kinase  gene  (Manservigi  et  al., 
1988). 
The  plasmid  contained  in  these  cells  contains  a  sequence  of  the  plasmid  PML,  a 
derivative of pBR322/BK virus/ herpes thymidine kinase. Deletions created in the viral 
DNA negate the chance of viral infection.  
143B-TK and 143B were purchased from the American type Culture Collection (ATCC), 
Manassas, USA. 
 
2.1.2 Tissue culture media and supplements 
Material    Supplier 
Cell culture plastic dishes (all sizes)  Becton-Dickinson Labware, Cowley, 
Oxfordshire, UK 
Sterile plastic pipettes  Corning Incorporated, Corning, New 
York 
Minimum Essential Medium (MEM) 
PRMI 1640+L-Glutamax 
L-glutamine 
GIBCO, Paisley, UK 
   
BUdR 
FBS 
Sigma, Gillingham, Dorset, UK 
HAT  GIBCO, Paisley, UK   75 
DMSO  Fisher Scientific UK Ltd,  
Loughborough, UK 
Fungizone (amphotericin) 
Penicillin/ Streptomycin 
EDTA-Trypsin 
G418 (geneticin) 
GIBCO, Paisley, UK 
 
GIBCO, Paisley, UK     
Liquid nitrogen  Cryoservice Ltd, Worcester, UK 
 
 
2.1.3 TK plasmids 
 
pcDNA3.1 TK  
This TK encoding plasmid was constructed in our department and transformed utilising 
E-coli strain DH5￿ , see section 2.2.2.2.  
PML BK TK 
This is a TK encoding plasmid, which was originally used to transfect the positive control 
cell line 143B and was purchased from ATCC.  The digestion enzymes used to check the 
construct  of  this  plasmid  were  purchased  from New  England  BioLabs,  Ipswich,  MA, 
USA. The size of this construct was 11.3 Kb and the markers were ampR and TK+ (fig.. 
2.1) 
 
Material   Supplier 
E-coli strain (DH5￿ )  Invirtogen life technology 
QIAGEN plasmid purification minikit   QIAGEN, Germany 
Agar culture medium  Sigma, Gillingham, Dorset, UK 
L-broth culture medium  Central services, BLCR-UK   76 
Ampicillin    Sigma, Gillingham, Dorset, UK 
Effectene transfection reagent  QIAGEN, Germany 
Colony glass rings    Bellco Glass, INC, Vineland, USA 
 
 
Figure 2.1: HSV1-tk encoding pML BK TK plasmid transfection vector. 
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2.1.4 Transfection efficiency  
Material  Supplier 
Radiolabelled FIAU ([
123I]FIAU) 
Department of Radionuclide Dispensary 
at the Western Infirmary of Glasgow, 
Glasgow, UK 
[Methyl-
3H]thymidine 
Amersham Biosciences UK Ltd, 
Buckinghamshire, UK 
Ganciclovir (GCV) 
MTT 
Sigma, Gillingham, Dorset, UK 
Glycine 
NaCl 
NaOH 
Fisher Scientific UK Ltd, 
Loughborough, UK 
Scintillation liquid 
National Diagnostic, Atlanta, Georgia, 
USA 
TCA  Central services, BLCR-UK 
 
2.1.5 RT-PCR 
Material    Supplier 
RNeasy Mini Kit (50)     Qiagen, Germany 
GAP-DH Primers   
Agarose gel           Melford, Ipswich, UK 
TK gene primers      78 
1 Kb DNA ladder        
λ DNA/Hind III ladder 
Invirtogen life technology, Paisley, UK 
Ethidium bromide        Sigma, Gillingham, Dorset, UK 
1XTBE (90 mM tris, 90 mM borate, 3 mM 
EDTA) 
Central Services, BLCR-UK 
 
2.1.6 Cell cycle analysis 
Material   Supplier 
70 % Ethanol 
Fisher Scientific UK Ltd,  
Loughborough, UK  
Propidium iodide   Invirtogen life technology, Paisley, UK 
RNase   Qiagen, Germany 
Cell strainer  BD Biosciences, Bedford, USA 
 
 
2.1.7 Special instruments 
Instrument   Supplier 
Gamma counter     
   
Packard instrument company 
￿ eta counter LS6000IC   
   
Spectrophotometer (DNA concentration) 
Beckman DU-64 
Beckman Coulter, Life Science Reseach 
 
ELISA plate reader      Molecular Devices 
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2.2 Methods 
2.2.1 Tissue culture 
2.2.1.1 Maintenance of cell lines 
The cell lines UVW, 143B and 143B-TK were grown in 90% MEM supplemented with 
Eearle’s BSS, 10% foetal bofine serum (FBS) and 2mM of L-glutamine. 143B medium 
was deficient in L-glutamine and supplemented with 15 ￿ g/ml of the selection nucleotide 
BUdR. 143B-TK medium was supplemented with the selection compound HAT. 
DU145 cell line was maintained in 90% RPMI 1640+L-Glutamax and 10% FBS. 
All  culture  media  were  kept  infection  free  by  the  addition  of  2.5  ￿ g/ml  Fungizone 
(Amphotericin), 10,000 U/ml penicillin and 10,000 ￿ g/mL streptomycin. 
All cell lines were tested for mycoplasma infection every two to three months. Cells were 
cultured in 75 cm tissue culture treated flasks (20ml medium) equilibrated with 5% CO2 
for 20 seconds and sealed tightly and incubated at 37°C. Sub-culturing into new flasks 
and fresh medium was carried out at each sub-confluence stage (approximately 5-8 days). 
Sub-confluent cultures were washed with PBS and disaggregated by treatment with 2ml 
of EDTA-trypsin for approximately 5 min. Fresh medium was added to neutralise trypsin 
and the cell suspension was pipetted up and down 4-5 times to enhance disagreggation 
and transferred to a universal. Cells were counted by Casey 1
® automated cell counter 
(Sharfe System, Germany) and cultured at approximately 10
5 cells per flask. 
 
2.2.1.2 Storage of cells 
Long term storage of cells was in liquid nitrogen. Cells were collected in a universal (as 
described above for subcultures), counted and centrifuged at 1200 rpm in 4K15 centrifuge   80 
(Sigma) for 5 mins. Freezing medium was prepared from 80% fresh medium, 10% FBS 
and 10% DMSO. Cells were resuspended in the freezing medium at a density of 10
6 
cells/ml and transferred to 1 ml cryotubes (Nunc vial) and placed at -70
oC for 24 h to 
allow the cells to freeze slowly. After this time, vials were transferred to liquid nitrogen. 
Fresh  cells  were  defrosted  after  15  to  20  passages  of  the  old  cell  lines.  Cells  were 
defrosted quickly by transferring vials from liquid nitrogen immediately to water at 37
oC. 
Vial contents were then emptied into 75cm flasks containing fresh medium devoid of 
selection additives for the transfected cell lines. 
 
2.2.2 TK plasmid construction and transfection 
 
2.2.2.1 Introduction  
2.2.2.1.1 TK Plasmid 
Plasmids are extrachromosomal molecules of DNA that vary in size from 1 Kb to more 
than 200 Kb. Most of them are double-stranded, covalently closed, circular molecules that 
can be isolated from bacterial cells in superhelical form. They are found in a large variety 
of bacterial species. Most plasmids have a narrow host range and can be maintained in a 
limited set of closely related species. They are extrachromosomal elements that behave as 
accessory genetic units that replicate independently of the bacterial chromosome. 
Plasmids have evolved a variety of mechanisms to maintain a stable copy number of 
plasmids in their bacterial hosts and to partition plasmid molecules accurately to daughter 
cells. They frequently contain genes coding for enzymes that are advantageous to the 
bacterial host. These genes specify a remarkably diverse set of traits, many of which are 
of  great  medical  and  commercial  significance.  Among  the  phenotypes  conferred  by 
plasmids are resistance to and production of antibiotics, degradation of complex organic   81 
compounds  and  production  of  colicins,  enterotoxins  and  restriction  and  modification 
enzymes. 
pcDNA3.1(+)  and  pcDNA3.1(-)  are  vectors  derived  from  the  plasmid  pcDNA3  and 
designed for high level stable and transient expression in mammalian hosts. High level 
stable and non-replicative transient transfection can be carried out in most mammalian 
cells. The vectors contain the following elements: 
1.  Human  cytomegalovirus  immediate-early  (CMV)  promoter  for  high-level 
expression in a wide range of mammalian cells. 
2.  Multiple cloning sites in the forward (+) and reverse (-) orientation to facilitate 
cloning. 
3.  Neomycin resistance gene for selection of stable cell lines. 
4.  Episomal  replication  in  cell  lines  that  are  latently  infected  with  SV40  or  that 
express the SV40 large T antigen (e.g. COS-1, COS-7). 
(www1.qiagen.com/Products) 
 
2.2.2.1.2 Plasmid purification using QIAGEN plasmid Mini Kit 
Transformed plasmids were purified using QIAGEN anion-exchange tips according to the 
manufacturer's instructions.  
Briefly, with QIAGEN plasmid kits, bacterial lysates were cleared by centrifugation. The 
cleared  lysate  was  then  loaded  onto  the  anion-exchange  tip  where  plasmid  DNA 
selectively  binds  under  appropriate  low  salt  and  pH  conditions.  RNA,  proteins, 
metabolites and other low-molecular-weight impurities were remove by a medium salt 
wash,  and  ultrapure  plasmid  DNA  was  eluted  in  high  salt  buffer.  The  DNA  was 
concentrated and desalted by isopropanol precipitation and collected by centrifugation. 
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2.2.2.1.3 Effectene transfection reagent 
Methods for transfection include calcium phosphate (Chen & Okayama, 1987; Wigler et 
al.,  1977),  lipid  mediated  (Felgner  et  al.,  1987;  Felgner  &  Ringold,  1989),  and 
electroportation (Shigekawa & Dower, 1988). 
Effectene transfection reagent is an innovative non-liposomal lipid formulation that is 
used in conjunction with a special DNA condensing enhancer and optimised buffer to 
achieve high transfection efficiencies. The enhancer first condenses the DNA molecules 
and  effectene  reagent  subsequently  coats  them  with  cationic  lipids,  providing  a 
particularly efficient way of transferring DNA into eukaryotic cells. 
Some of the advantages using this transfection reagent are that it is fast and easy with 
high transfection efficiency and minimum toxicity, using small amounts of DNA. 
2.2.2.1. Creating stably transfected cell lines using Geneticin selective antibiotic 
 
The  pcDNA3.1(+)  and  pcDNA3.1(-)  vectors  contain  the  neomycin  resistant  gene  for 
selection of stable cell lines using neomycin (Geneticin). Geneticin selective antibiotic 
blocks protein synthesis in mammalian cells by interfering with ribosomal function. It is 
an aminoglycoside, similar in structure to gentamycin and kanamycin. Expression of the 
bacterial  aminoglycoside  phosphotransferase  gene  (APH)  derived  from  Tn5,  in 
mammalian cells results in detoxification of geneticin (Southern & Berg, 1982).  
   83 
2.2.2.2 TK Gene cloning 
HSV1-tk gene was cloned into the plasmid vector pcDNA3.1 in our department. The 
plasmid was cleaved at the multiple cloning site (MCS) using the restriction enzymes 
EcoR I and Xho I and the HSV1-tk gene was ligated into the MCS (figure 2.2). 
Plasmid construct was then checked by digestion and gel electrophoresis using a standard 
method.    84 
 
 
Figure 2.2: HSV1-tk gene was cloned in the MCS of plasmid vector pcDNA3.1 using 
restriction enzymes EcoR I and Xho I
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2.2.2.3 TK plasmid Transformation 
The TK encoding plasmids pcDNA3.1 HSV-TK and PML BK TK were propagated in the 
E-coli strain DH5￿ . Briefly, 100 ￿ l of freshly thawed bacterial suspension was exposed 
to 1 ￿ g of the plasmid. After 30 min, 50 ￿ l of the suspension was spread on a solid agar 
culture medium supplemented with ampicillin (5 ￿ g/ml) for selection in microbiology 
culture plate and incubated overnight at 37°C. On the following day two discrete colonies 
were selected and transferred to 2 Falcon tubes containing 1ml of fresh L-broth culture 
medium and were incubated for 4-6 h with continuous shaking. Once culture growth was 
established, the entire volume was added to 500 ml of L-broth containing ampicillin and 
incubated overnight at 37
oC
 with continuous shaking. Twenty-four hours later plasmids 
were  purified  utilising  QIAGEN  plasmid  purification  minikit  according  to  the 
manufacturer's instructions. 
2.2.2.4 TK palsmid transfection and selection 
Monolayers  of  the  cell  lines  DU145,  PC3,  UVW  and  143B  were  transfected  with 
pcDNA3.1TK  plasmid  individually  using  effectene  transfection  reagent  (Qiagen, 
Germany) according to the manufacturer's instructions as follows: 
The cells were seeded into 6-well plates at a density of 10
5 cells/ well and incubated until 
they reached 70-90% confluence.  1, 2 and 3 ￿ g of the plasmid were diluted in 150 ￿ l of 
DNA condensation buffer (EC) in 500 ￿ l Eppendorf tubes. 8 ￿ l of the Enhancer was 
added and mixed by vortexing for 1 second, incubated at room temperature for 2-3 min 
and then centrifuged for 10-15 seconds. 
25 ￿ l of the Effectene reagent was then added to each tube, mixed by pipetting up and 
down and incubated at room temperature for 10 min. While waiting for the incubation 
period, monolayers were washed with PBS and supplied with 4 ml of fresh medium.  
Each plasmid mixture was then diluted with 1 ml of fresh medium and added drop-wise to 
one well of the 6-well plate. The other 3 wells were used as negative controls for the   86 
selection efficiency. The cells were then transferred to 37
oC
 and 5% CO2 incubators and 
fresh medium was replaced after 24 h. 
One day later, the selection medium containing 500 ￿ g/ml geneticin (G418) was added. 
Low  power  microscopic  examination  for  selection  was  carried  out  regularly  and  the 
selection medium was replaced every 3-4 days. Once complete clearance of the control 
wells was observed and discrete colonies were formed, several individual colonies were 
transferred  to  25  cm
2 tissue  culture  flasks,  one  colony  per  flask,  using  sterile  colony 
isolating  glass  rings.  Selection  continued  in  the  culture  flasks  until  cell  number  was 
enough to be transferred to the larger 75 cm
2 flasks to perform transfection efficiency 
experiments as described in the following section. 
2.2.3 Transfection efficiency  
 2.2.3.1 GCV sensitivity (MTT assay) 
The clonogenic assay is not suitable for all cell lines and not amenable to automation. 
Contrary to the clonogenic assay, MTT assay is quick and allows a large number of assays 
to be carried out in one batch (Cole, 1986). The use of tetrazolium dye (MTT) as an 
indirect measure of cell number was first reported in the early eighties (Mosmann, 1983). 
Cells in exponential phase of growth are exposed to a cytotoxic drug. The duration of 
exposure is usually determined as the time required for maximal damage to occur but is 
also influenced by the stability of the drug.  
After removal of the drugs the cells are allowed to proliferate for two to three doubling 
times  in  order  to  distinguish  between  cells  which  remain  viable  and  capable  of 
proliferation and those which remain viable but cannot proliferate. Surviving cell numbers 
are then determined indirectly by MTT dye reduction. MTT is a yellow water soluble 
tetrazolium dye that is reduced in the mitochondria of living  but not dead cells to a purple 
formazan product that is insoluble in aqueous solutions (Liu et al., 1997). The amount of   87 
MTT-formazan produced can be determined spectrophotometrically once solubilised. The 
procedure was done according to an optimised assay described by J Plumb, 1999. (Plumb)  
The  MTT  dye  (3-(4,5-dimethylthiazol-2-yl)2,5-diphenylltetrazolium  bromide)  was 
purchased from Sigma and prepared at a concentration of 5 mg/ml in PBS. This was filter-
sterilised, which also removes any reduced MTT, and can be stored at 4°C in the dark for 
1 month. Glycine buffer was prepared by adding 0.1 M glycine to 0.1 M NaCl and its pH 
was adjusted to 10.5 using 1 M NaOH. 
MTT  assay  was  carried  out  in  96-well  plates.  Sub-confluent  monolayer  cultures  were 
trypsinised and diluted to a concentration of 5 × 10
3 cells/ml. Cell suspension was then 
transferred to a Petri dish and using a multi channel pipette, 200 ￿ l of growth medium 
were added to the central 6 wells starting with column 2 and ending with column 11, 200 
￿ l of fresh growth medium were added to the 6 wells in column 1 and 12. Plates were 
incubated in a humidified atmosphere at 37
oC for 2-3 days until cells are in exponential 
phase.  Treatment  was  prepared  in  serial  4-fold  dilutions  of  the  ganciclovir  (GCV)  in 
growth medium to give eight concentrations from 10
3 ￿ g/ml to 61 × 10
-3 ￿ g/ml. 
Growth  medium  from  columns  3-10  was  removed  and  replaced  with  the  medium 
containing  the  drug,  highest  concentration  in  column  3  and  lowest  concentration  in 
column 10. Fresh medium was added only to the wells in columns 2 and 11. Plates were 
incubated at 37
oC and 5% CO2 for 3 days. At the end of the exposure period, medium 
from all wells containing cells was removed and replaced with fresh medium. Cells were 
left to grow for a further two days and MTT assay was performed at the fifth day after the 
beginning of treatment. 200 ￿ l of fresh medium and 50 ￿ l of the MTT solution (5 mg/ml 
in PBS) were added to all wells in column 1 to 11. Plates were wrapped in aluminium foil 
and incubated for 4 h in humidified atmosphere at 37°C and 5% CO2. Medium and MTT 
were removed from the wells. Formazan crystals were dissolved by adding 200 ￿ l of 
DMSO to all wells in column 1 to 11 and glycine buffer 25 ￿ l to all wells containing   88 
DMSO. Absorbance at 570 nm with the wells in column 1, which contains medium, MTT 
but  no  cells  was  used  as  a  blank.  A  graph  of  absorbance  (y  axis)  against  drug 
concentration (x axis) was constructed. The mean absorbance reading from the wells in 
column  2  and  11  was  used  as  a  control  absorbance  and  the  IC50 concentration  was 
determined as the drug concentration required to reduce the absorbance to half of the 
control. 
 
2.2.3.2 [
123I FIAU uptake 
 
2.2.3.2.1 Synthesis of no-carrier-added [
123I]FIAU 
Radio-iodinated  FIAU  was  originally  prepared  by  direct  radio-iodination  of  its 
unsubstituted precursor, 1-(2’-fluoro-2’-deoxy-ß-D-arabino-furonosyl) uracil (Misra et al., 
1986) This involves heating of the precursor at 115
oC
 with nitric acid for 90 min. the 
radiochemical yield ranged from 35-90% and was isotope dependent. This method has 
been  modified  by  Tjuvajev  (Tjuvajev  et  al.,  1996)  for  the  no-carrier-added  (n.c.a) 
synthesis.  Vaidyanathan  &  Zalutsky  have  developed  an  efficient  method  for  the 
preparation  of  n.c.a  FIAU  and  its  astatinated  analogue,  FAAU,  from  a  tin  precursor 
(Vaidyanathan & Zalutsky, 1998). 
In our study, [
123I]FIAU was synthesised at the Department of Rdionuclide Dispensary via 
electrophilic  iododestannylation  of  the  corresponding  trimethylstannyl  precursor  using 
peracetic acid as the oxidant following a procedure modified from the previous method 
described by (Vaidyanathan & Zalutsky, 1998). The final product had a radiochemical 
purity of > 98% (Fig. 2.3). 
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Figure 2.3: HPLC of [
123I]FIAU produced by no-carrier-added method showing 
radiochemical purity of  > 98%. 
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Figure 2.4: Chemical structure of FIAU 
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2.2.3.2.2 Pilot study to determine cellular uptake of [
123I]FIAU 
 
[
123I]FIAU uptake by direct measurement with gamma-counter 
In a pilot study, TK gene expression of the transfected cell lines was assessed by the direct 
measurement of [
123I]FIAU  uptake compared with that of the parental cell lines. 
 Cells in exponential phase were seeded into 6-well plates at a density of 10
5 cells/ well 
and incubated for 24 h at 37
oC in 5% CO2.  Monolayers were then incubated with 7 kBq 
of [
123I]FIAU in 1ml of growth medium for a period of 2 h in triplicate for each cell line. 
Medium was then removed and cells were washed several times with cold PBS until no 
activity could be eluted. Intracellular radioactivity was then extracted by exposing cells to 
1  ml  of  cold  trichloroacetic  acid  (TCA)  for  1  h.  Extracts  were  transferred  to  1  ml 
Eppendorf  tubes  and  activity  was  measured  in  a  gamma  counter  (Packard  Instrument 
Company). Simultaneously, cells in untreated control plates were trypsinised and counted 
to determine intracellular activity relative to cell number. 
This simple method obviously has a clear deficiency, it was not possible to determine non-
specific  uptake  of  [
123I]FIAU  and  its  relation  to  cellular  proliferation.  Therefore,  the 
following method of differential uptake of [
123I]FIAU and  [methyl-
3H] TdR was adopted. 
 
2.2.3.2.3 [
123I]FIAU uptake normalised to [methyl-
3H]thymidine uptake 
 
This procedure was modified from the method originally described by Tjuvajev (Tjuvajev 
et  al.,  1995).  The  intracellular  accumulation  of  [
123I]FIAU  was  normalised  to  that  of 
[methyl-
3H]TdR to account for the differences in cellular proliferation. [
123I]FIAU uptake 
was  plotted  against  [methyl-
3H]TdR  uptake  and  data  were  expressed  as 
[
123I]FIAU/[methyl-
3H]TdR uptake ratio at the time point of maximum uptake. 
 
Monolayers of TK+ and TK- cell lines were grown in 75 cm flasks until they reached 
exponential  phase.  Adherent  cells  were  washed  with  PBS,  trypsinised,  counted  and   92 
transferred to 1 ml Eppendorf’s tubes at a concentration of 10
5 cells/ tube in triplicates for 
each time point of the uptake study. Cells were kept in suspension by intermittent shaking. 
1 ml of fresh medium containing 7 kBq of [
123I]FIAU and 7 kBq of [methyl-
3H] TdR was 
added to each tube. Cells were incubated at 37
oC and 5% CO2. Radioactivity was counted 
at 10 min, 30 min, 60 min, 90 min, 2 h, 4 h and 8 h in the ￿  and ￿  counters as described 
below. 
At each time point, cells were centrifuged for approximately 30 seconds. The resultant 
supernatant  was  removed  carefully  without  disturbing  the  cell  pellet  and  cells  were 
washed at least twice with cold PBS and supernatant wash was removed by the same 
method  to  eradicate  residual  extracellular  activity.  Cell  pellets  were  then  transferred 
immediately to the ￿ -counter to measure the cellular [
123I]FIAU uptake. Contamination 
by  [methyl-
3H]TdR  radioactivity  of  the  counts  assigned  to  [
123I]FIAU  uptake  was 
excluded by measuring 7 kBq of [methyl-
3H]TdR activity separately in the ￿ -counter 
where  no  ￿ -radioactivity  was  detectable.  However,  the  radioactivity  of  the  Auger 
electrons emitted by 
123I was detectable by the ￿  counter.
 123I has a short half-life of 13 h, 
whereas 
3H has a half-life of 12.35 years indicating higher stability than 
123I. 
Therefore,  cell  pellets  were  then  stored  at  4
oC  for  at  least  2  weeks  to  allow  nearly 
complete decay of [
123I]FIAU.
 Cell pellets were then re-suspended in 1 ml PBS, added to 
10 ml of scintillation fluid and transferred to the ￿  counter to measure [methyl-
3H] TdR 
cellular uptake.  
 
2.2.3.3 RT-PCR 
2.2.3.3.1 RT-PCR  reaction 
Transfer of the viral tk gene to the transfected cell lines was further assessed by reverse 
transcription (RT)-PCR. RNA from tumour cells was extracted using RNeasy Mini Kit 
(50) (Qiagen, Germany). 1 ￿ g of RNA was used to synthesise cDNA in 20 ￿ l reaction   93 
mixtures  containing  50  mM  MgCl  and  PCR  buffer  by  a  standard  protocol 
(GeneAmp®RNA  PCR,  Applied  biosystems,  USA)  using  oligo  dT  as  a  primer  and 
Moloney-murine leukaemia virus reverse transcriptase (MML-V RT). RT cycling steps 
were 42
 oC for 15 min, 99
 oC for 5 min and 4
 oC for 5 min.  PCR reactions were carried out 
with 10 ￿ l of RT products in 50 ￿ l reactions using Amp Taq polymerase in PCR buffer 
containing 50 mM MgCl2 with annealing temperature of 63
oC.  
Primers 5’-GGCATGCCTTATGCCGTGACCGAC and 
5’CCAGGTCGCATATCGTCGGGTATGG, were used to amplify the 709-bp tk specific 
fragment (Su et al., 1997). The housekeeping gene GAP-DH was amplified with its 
specific primers and served as an internal control. 
2.2.3.3.2 Agarose Gel electrophoresis 
The  products  of  RT-PCR  reactions  and  restriction  enzyme  digest  were  separated  by 
agarose gel electrophoresis. The gel was made by melting 1.25 g of electrophoresis grade 
agarose in 100 ml 1XTBE (90 mM tris, 90 mM borate, 3 mM EDTA) by heating in a 
microwave  oven.  After  the  solution  had  cooled,  0.4  ￿ g/ml  of  ethidium  bromide  was 
added  and  the  gel  was  then  poured  into  the  electrophoresis  tank.  1kb  and  ￿ HINDIII 
ladders were used as molecular size markers.  2 ￿ l of loading dye (15% ficoll, 0.25% 
bromophenol blue) was added to 10 ￿ l of DNA and the total volume loaded into the 
agarose  gel.  Electrophoresis  was  carried  out  in  a  horizontal  electrophoresis  tank 
containing 1XTBE for approximately 1 h at 100 V. The separated DNA fragments were 
visualised by UV-transillumination of the gel. 
2.2.4 Clonogenic assays for [
123I] FIAU sensitivity 
 
Sub-confluent monolayers of TK+ and TK- clones of each cell line were seeded in 25 cm
2 
flasks at 1-2 ×10
5 cells/ flask. The cells were incubated for 48 h to reach approximately 
50-70% confluence. The medium was removed; cells were washed once with PBS and   94 
incubated with a range of doses of [
123I] FIAU.  Cells were then incubated for 4 h, 8 h or 
for the total period of doubling time of each cell line at 37°C in 5% CO2.  
At the end of the treatment period, [
123I] FIAU containing medium was removed, cells 
washed with PBS until no radioactivity could be eluted (at least twice), trypsinised and 
seeded out for the clonogenic assay.  The cells were counted using a haemocytometer and 
seeded into 60 mm tissue culture dishes containing 5 ml of fresh medium at a density of 1 
or 3 ×10
3 cells/ dish, according to each cell line’s plating efficiency, in triplicate for each 
treatment dose. The dishes were then placed in plastic boxes and incubated at 37
oC in 5% 
CO2 for approximately 10-14 days until discrete colonies were observed macroscopically. 
The colonies were then washed with PBS, fixed gradually with 50% then 100% methanol 
and stained with 10% Giemsa stain or crystal violet. Colonies greater than 50 cells were 
counted manually and surviving fractions were calculated as a percentage of the untreated 
control colony number. 
 
Calculating the surviving fraction 
Surviving fraction = Mean number of colonies of treated cell line 
Mean number of colonies of untreated control 
 
2.2.5 Clonogenic assays for GCV sensitivity  
 
Cells were plated cultured as described for the clonogenic assay for FIAU sensitivity. 
Once the cells reached an exponential phase of growth, they were treated with five to 
eight 4-fold dilution doses of GCV ranging from 10
3 ￿ g/ml to 61 x 10
-3 ￿ g/ml. At the end 
of the treatment period of 72 h, the cells were seeded out in 60 mm tissue culture dishes as 
described for the clonogenic assay for [
123I] FIAU sensitivity. Fixing and staining were 
also performed using the same method. 
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2.2.6 Cell cycle analysis 
The cell cycle analysis was carried out for the cell lines DU145-TK and 143B-TK treated 
with various doses of either [
123I]FIAU or GCV. The cells were seeded in 75 cm flasks at 
a density of 10
6
 cells/ flask and cultured to reach an exponential phase of growth. Single 
treatment with either [
123I]FIAU or
 GCV was given as described in sections 2.2.3 and 
2.2.4. At the end of the exposure period, the cells where washed with PBS, trypsinised and 
then collected by centrifugation at 1200 rpm for 5 min. 
The cells from each treatment dose were then transferred to a universal, fixed and stained 
separately.  The  cells  were  fixed  by  drop-wise  addition  of  cold  70%  ethanol  while 
vortexing to ensure fixation of all cells with minimal clumping. They were then kept at 
4
oC for at least 30 min or until staining. After removal of ethanol and washing twice with 
PBS, cells were recovered by centrifugation at 2000 rpm and discarding the supernatant. 
Cells were then stained with 500 ￿ l of propidium iodide (50 ￿ g/ml). They were treated 
with ribonuclease (50 ￿ l of 100 ￿ g/ml RNase) prior to staining to ensure that only DNA 
was stained. 
Cell  cycle  analysis  was  then  carried  out  by  flow  cytometry  FACS  Scan  (Becton 
Dickinson) and the results were analysed by CELLQUEST program. The minimum cell 
number for each analysis was 10
5 cells/ analysis.  
 
2.2.7 Doubling time of the cells 
Initially cells from exponential phase of growth of the monolayers of each cell line were 
seeded in 24-well plates at a density of 10
4 cells/ well. The cells from each 3 wells were 
collected every 24 hours and counted separately until the growth reached plateau phase, 
manifested by full confluence. The growth curves were constructed using a semi-log plot 
and doubling times were calculated from the linear part of the curve as follows: 
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The general formula that describes the growth of cells:  
    A = A02
n 
Where A is the number of cells at any time, A0 is the number of cells at an initial point, and 
n is the number of cell divisions that have taken place. The value n can also be described 
as: 
    n = T/Tc 
Where T is the time elapsed and Tc is the doubling time of the cells. Thus the proliferation 
formula can be written as: 
    A = A02
T/Tc 
Solving for Tc, by taking the natural log of both sides, the formula becomes:  
    In A/A0 = T/Tc In2 
    2.3 log A/A0 = T/Tc × 0.69 
    Tc = (T  × 0.69/2.3)/log (A/A0) = 0.3T/logA/A0 (Wieder, 1999) 
Where, 
T  =  time elapsed in which the data are linear on the semi-log plot 
A0  =  number of cells at initial point of the linear part of the curve 
A  =  number of cells at the end of the linear part of the curve 
 
 
2.2.7 Statistical analysis 
All data were stored and analysed using Microsoft Excel program (Microsoft Windows 
XP  professional  version  2002).  Results  were,  when  applicable,  reported  as  mean  ± 
standard deviation (s.d.). The statistical significance (P value) of the difference between 
the parental and the TK positive cell lines were evaluated by the Student’s t test of two-
sided  distribution  and  two  samples  with  equal  variance.  The  statistical  significance 
amongst single cell population, for example different incubation periods of the clonogenic   97 
assay of a single cell line, was evaluated using paired two-sided distribution Student’s t 
test. 
IC50 value (the drug concentration that inhibits the growth of 50% of cells) was calculated 
according to the simple linear regression using the formula y = mx + b, where, y is the 
estimated y value, x is the known x value, m is the slope of the curve and b is the y-
intercept of the curve. 
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Chapter 3 : HSV1-tk gene transfection and 
evaluation of transfected cells 
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3.1 Aims  
1. To construct and propagate a plasmid encoding the HSV1-tk gene which can be used 
for in vitro gene delivery to the target tumour cell lines. 
2. To transfect these cell lines with the constructed plasmid and then to evaluate tk gene 
expression using three different methods.  
3. To determine IC50 values of GCV treatment of the cell lines. 
3.2 TK Plasmid construction and transformation 
The tk gene was successfully inserted into the plasmid vector pcDNA3.1 by the method 
described in section 2.2.2.2.  The correct size and orientation of the plasmid construct was 
confirmed by restriction enzyme digestion and gel electrophoresis (Fig. 3.1). 
The  construct  of  the  positive  control  plasmid  PML  BK  TK  was  also  checked  by  the 
restriction enzyme digestion as shown in Fig. 3.2. 
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Figure 3.1: pcDNA3.1TK plasmid digest by the enzymes ECoRI and XholI 
 
 
 
 
 
 
Figure 3.2: PML BK TK plasmid digestion by ECoRI and BamHI enzymes  
 
 
 
 
 
1KB 
LADDER 
5.39 kb 
8.4 kb 
4.0 kb 
6.4 kb 
3.4 kb 
2.6 kb 
1.16 kb 
BamHI 
1KB 
LADDER  ECoRI   101 
3.3 Transfection and selection 
The four cell lines DU145, PC3, UVW and 143B were successfully transfected with the 
plasmid pcDNA3.1TK and the expression of HSV1-TK enzyme was confirmed by the 
transfection efficiency experiments (section 2.2.3). 
3.4 Transfection efficiency 
3.4.1 Introduction 
The  assessment  of  HSV1-tk  gene  transfection  efficiency  in  vitro  has  been  described 
previously in several studies, e.g. (Jacobs et al., 1999; Tjuvajev et al., 1996; Tjuvajev et 
al., 1995) . The most widely used indicators of successful transfection and subsequent 
expression  of  this  gene  are  the  increased  sensitivity  to  acycloguanosine  analogues 
(Tjuvajev et al., 1996; Tjuvajev et al., 1995) and the enhanced intracellular accumulation 
of radiolabelled thymidine analogues  (Jacobs et al., 1999; Tjuvajev et al., 1996; Tjuvajev 
et al., 1995). Other methods include RT-PCR, Northern blot analysis (Tjuvajev et al., 
1995) and Western blot of the TK protein (Jacobs et al., 1999) . 
In this study we have adopted three independent methods for the evaluation of transgene 
expression, namely, normalised uptake of [
123I] FIAU, GCV sensitivity and RT-PCR of 
the HSV1-tk gene. 
 
3.4.2 [
123I]FIAU uptake 
3.4.2.1 [
123I]FIAU uptake by direct measurement with gamma-counter 
The monolayers of HSV1-tk transfected cell lines demonstrated an enhanced [
123I]FIAU 
uptake compared with the parental cell lines (Fig. 3.3). The incubation time was 2 h and 
the radionuclide accumulation was expressed as count per minute (CPM) per 10
5 cells. 
The  enhancement  factors  were  PC3,  3.1  (±0.4)  (P  =  0.004);  DU145,  4.1(±0.5)  (P  = 
0.001); UVW, 2.6(±0.34) (P = 0.003) and 143B, 3.8(±0.7) (P = 0.001)   102 
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Figure 3.3: [
123I] FIAU uptake of Parental and TK transfectants of DU145 and PC3 
(A) and UVW and 143B (B) cell lines after 2 hours incubation with 7 kBq/ ml of 
[
123I]FIAU.  Direct  measurement  by  the  gamma  counter  indicated  2.6  to  4.1  fold 
increase in the uptake after TK transfection (P < 0.005). Data represent means and 
s.d. of triplicate experiments. 
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3.4.2.2 [
123I]FIAU uptake normalised to [methyl-3H] thymidine uptake 
HSV-TK-positive cell lines demonstrated an enhanced uptake of [
123I]FIAU compared 
with the parental cell lines (Fig. 3.4). [
123I]FIAU intracellular accumulation was time-
dependent and strongly correlated with cellular proliferation rate (r = 0.976, 0.97 and 0.91 
for DU145-TK, 143B-TK and UVW-TK, respectively), which was assessed by [methyl-
3H] TdR uptake. For the cell line UVW, the FIAU uptake normalised to the TdR uptake 
reached plateau phase after 4-8 h as indicated in Fig. 3.4C.   
At the uptake study point of 8 h, [
123I]FIAU/ [methyl-
3H] TdR uptake ratios were 4.25 
(±0.15) (P = 0.001),  3.59 (±0.8) (P = 0.01) and 25.52 (±3.68), times higher in the TK-
transfectant than the parental cell lines of DU145, 143B, and UVW, respectively (Table 
3.1).  An  Interesting  observation  was  that  the  difference  between  the  slopes  of  the 
normalised uptake curves of the parental and the TK positive clones of a specific cell line 
was  close  to  the  difference  between  the  uptake  ratios.  For  example,  for  the  cell  line 
DU145, TK transfectant slope divided by the parental cells slope was 0.3057/0.08 = 3.69 
versus 4.25 and for the cell line UVW, 1.74/0.87 = 20 versus 25.52. This implies a similar 
degree  of  correlation  between  the  uptake  of [
123I]FIAU  and [methyl-
3H]  TdR  in  both 
parental and transfected clones of each cell line. 
  
Table 3.1: FIAU/TdR uptake ratio of parental and TK-positive cell lines 
  10 min  30 min  60 min  90 min  120 min  4 h  8 h 
DU145  0.24  0.30  0.091  0.10  0.069  0.080  0.07 
DU145-TK  0.76  0.30  0.22  0.27  0.21  0.35  0.29 
143B-TK-  1.09  0.60  0.83  0.96  0.91  0.72  0.98 
143B-TK   2.78  2.48  2.55  2.96  3.17  3.96  4.77 
UVW  0.45  0.32  0.29  0.29  0.18  0.17  0.053 
UVW-TK  2.22  1.88  1.99  2.08  2.015  1.88  1.36   104 
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Figure 3.4: [
123I]FIAU uptake normalised to the uptake of [methyl-
3H]TdR of DU1451, A; 143B, B and UVW, C. Each spot represents 
specific time point of the uptake study. The TK-positive clones of 
the  three  cell  lines  showed  increasing  [
123I]FIAU  uptake    which 
correlated to the cellular proliferation. In contrast, there was no 
significant [
123I]FIAU uptake by the parental cell lines in spite of 
continuous proliferation as indicated by the rising [methyl-
3H]TdR 
uptake. 
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3.4.3 Ganciclovir Sensitivity  
3.4.3.1 GCV sensitivity by MTT assay 
There was a clear difference in CGV sensitivity between the TK-positive and the parental 
cell  lines.  143B  cells  transfected  by  either  of  the  two  TK  gene-encoding  plasmids 
exhibited a very high sensitivity to GCV with IC50 approximately 3000 (P = 0.0002) times 
lower than that of the TK negative cell line (Fig. 3.5C). In the cell lines DU145 and UVW, 
although  the  sensitivities  were  not  as  high  as  that  of  the  143B  cell  line,  they  were 
significantly greater than those of the untransfected cell lines. The IC50 values were 43 (P 
= 0.009) and 212 (P = 0.0013) fold lower in TK positive than parental clones of DU145 
and UVW, respectively (Fig. 3.5 A and B). 
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Figure 3.5: GCV sensitivity by MTT assay of the parental and TK-
positive clones of the cell lines DU145, A; UVW, B and 143B, C. 
Enhanced GCV sensitivity of the transfected clones, compared with 
the parental clones, of all cell lines indicated successful HSV1-TK 
gene transfection. The enhancement factors (EF) of DU145, UVW 
and 143 were 43, 212 and 3000, respectively. Data represents mean 
and s.d. of triplicate experiments. 
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3.4.3.2 GCV sensitivity by clonogenic assay 
The GCV sensitivity of the TK positive clones was further assessed by the clonogenic 
assay to compare GCV effect on cellular proliferation using two different assays and to 
calculate IC50 values for the subsequent experiments of combination therapy (chapter 5). It 
was  also  found  that  there  was  a  discrepancy  between  the  IC50 values  obtained  by  the 
clonogenic assay and the MTT assay. Therefore, these two assays were compared in this 
section. The results showed approximately a 4-fold underestimation of GCV sensitivity in 
DU145 cell line using MTT assay compared with the clonogonic assays. For example, the 
IC50 of the cell line DU145-TK was 11.39 (±0.3) ￿ g/ml by MTT assay and 3.2 (±0.7) 
￿ g/ml by clonogenic assay (P<0.001) (Fig. 3.6 A). On the other hand, in the cell line 
143B-TK there was a slight overestimation, where the IC50 was 0.025 (±0.001) ￿ g/ml by 
MTT assay and 0.045 (±0.01) ￿ g/ml by clonogenic assay (P>0.05) (Fig. 3.6 B).   
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Figure 3.6: Comparison of GCV sensitivity of parental and TK positive clones of 
DU145 and 143B assessed by MTT and clonogenic assays. Approximately 4 fold 
underestimation of sensitivity by MTT assay was observed in DU145-TK cell line; A, 
and a slight overestimation was observed in 143B-TK cell line; B. Error bars are s.d. 
of 2 experiments performed in triplicates, The correlation coefficient between 2 
assays of each cell line was > 0.9.
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3.4.4 RT-PCR of HSV1-TK gene 
Successful transfer of the HSV1-tk gene to the transfected cell lines was confirmed by 
RT-PCR. As shown in Fig. 3.7 A, the 709 bp fragment of HSV1-tk gene was clearly 
seen in the prostate cancer cell line DU145-TK, the positive control cell line 143B-TK 
and was faint in the cell line UVW-TK. The cell line 143B-pcTK is the osteosarcoma 
cell line 143B transfected by the plasmid pc DNA3.1-TK, which has also shown a clear 
band of HSV1-tk gene.  
3.5 Doubling times of the various cell lines  
Growth curves of the cell lines DU143, 143B, 143B-TK and UVW are shown in Fig. 3.8 
and the calculated doubling times are in Table 3.2. We note that there was a difference 
between the doubling time of the parental cell line 143B and that of the TK-positive cell 
line 143B-TK. This was attributed to the fact that the parental cell line 143B is TK-
negative and therefore it has a different rate of DNA synthesis and as a consequence a 
longer cell cycle. 
 
Table 3.2: The doubling times of various cell lines. Values are means and s.d. of 
triplicate experiments. 
Cell line 
Doubling time 
(hours) 
DU145  26.22 (±1.06) 
143B  29.86 (±3.03) 
143B-TK  20.52 (±2.16) 
UVW  26.29 (±2.64)   110 
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Figure 3.7: RT-PCR products for HSV1-tk gene (A) and the reference gene of 
GAP-DH (B) of parental and transfected cell lines. 709bp and 400bp fragments of 
HSV1-tk and GAP-DH, respectively, were recognised using 1kb DNA ladder (1
st 
column from left)  
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Figure 3.8: Growth curves of the cell lines DU145, 143B, 143B-TK and UVW. Data 
represents mean and s.d. of triplicate experiments. 
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Figure 3.9: The relationship between FIAU accumulation ([123I]FIAU / [methyl-
3H]TdR uptake ratio) and IC50 values of GCV in the different clones of TK positive 
cell lines. Strong correlation was observed with r = -0.904.   112 
3.5 DISCUSSION   
In this study, the first sign of successful transfection of the different cell lines with the 
TK encoding plasmids was the continuous growth of transfected cells in the selection 
medium. For cells transfected with plasmid pcDNA3.1-TK, this indicated co-expression 
of the Geneticin resistance gene and for cells transfected with PML BK TK plasmid, i.e. 
143B-TK, this indicated co-expression of the HGPRT enzyme gene. 
The direct measurement of [
123I]FIAU cellular uptake was chosen as an easy and quick 
method to confirm TK gene transfection. This method showed higher [
123I]FIAU uptake 
in TK positive cell lines compared with the parental cell lines. However, this method 
does not assess the relationship between the accumulation rate and the cellular growth 
rate. Furthermore, the uptake enhancement shown was less than that predicted from the 
GCV sensitivity enhancement by TK gene expression..  
The method of normalised uptake of [
123I]FIAU was modified from the one described by 
Tjuvajev et al(Tjuvajev et al., 1995).  Tjuvajev et al. studied the accumulation of the 
potential HSV1-TK enzyme radiolabelled substrates: IUdR, GCV and FIAU in relation 
to  that  of  radiolabelled  thymidine  (methyl-[
3H]TdR  or  2-[
14C]  to  control  for  cell 
proliferation.  Double  label  studies  were  performed  using  a  beta  spectrometer  and 
standard 
3H  and 
14C  dual  channel  counting  technique.  FIAU  and  IUdR  assays  were 
performed after various incubation periods of 10, 30, 60, 90 and 120 min. The data were 
expressed  as  harvested  cells:  medium  concentration  ratio.  This  study  showed  low 
accumulation by a TK-positive glioma cell line of GCV compared to that of FIAU and 
IUdR and higher but not TK specific accumulation of IUdR compared to that of FIAU. 
In  our  study,  the  FIAU  was  labelled  with 
123I  which  is  an  Auger  electron  emitter 
measurable by gamma counting. Given the ultra-short half-life of 
123I (13 h) and the   113 
long half-life of 
3H, it was necessary to measure FIAU cellular uptake immediately for 
the various incubation periods. Samples were then stored in 4
oC for at least 2 weeks to 
allow for complete decay of 
123I and methyl-[
3H]TdR accumulation was measured by 
liquid scintillation counting.  
The [
123I]FIAU uptake by TK positive clones was found to be time and proliferation 
dependent and was rising up to 8 hours of incubation period (Fig. 3.4). The final data 
were  expressed  as  [
123I]FIAU/  methyl-[
3H]TdR  uptake  ratio  (Table  3.1),  which  was 
significantly  higher  in  HSV1-tk  transfected  clones  than  in  the  parental  cell  lines, 
indicating tk gene expression. 
The  second  method  to  confirm  HSV1-tk  gene  expression  was  by  assessing  GCV 
sensitivity by MTT assay. The MTT assay was selected because it is quick and allows 
large number of assays to be carried out in one batch especially if the range of effective 
doses  for  several  clones  is  unknown.  GCV  has  been  used  in  clinical  gene  therapy 
protocols for treatment of tumours transduced with HSV-tk gene (1994).  
In this study, significant enhancement of GCV sensitivity was noticed in the various cell 
lines after HSV-tk gene transfer. However, the response was variable (Fig. 3.5). The 
most sensitive cell line was 143B-TK.  When the control cell line 143B was transfected 
with the plasmid pcDNA3.1TK, it demonstrated GCV sensitivity similar to the positive 
control 143B-TK, as shown in Fig. 3.5C. This indicated that the difference in GCV 
sensitivity amongst different cell lines, despite expressing similar gene, was due to the 
difference in cell lines’s response rather than the expressed plasmid. This variation has 
been described years ago where the antiherpetic activity of acyclovir (ACV) was shown 
to  be  dependent  upon  the  virus,  cell  type,  exogenous  drug  concentration,  time  of 
exposure to AVC, and the presence of other nucleosides in the surrounding medium 
(Elion et al., 1977; Furman et al., 1981).    114 
Furthermore,  a  highly  significant  relationship  was  observed  between  independent 
measures  of  HSV1-tk  gene  expression,  namely  GCV  sensitivity  and  the  level  of 
[
123I]FIAU accumulation in different cell populations (Fig. 3.8). This was also observed 
in a previous study (Tjuvajev et al., 1995), where there was a linear relationship between 
mRNA and GCV sensitivity on the one hand and the level of FIAU accumulation on the 
other hand.  
Figure 3.6A shows an underestimation of GCV sensitivity of the DU145 cell line using 
MTT assay in contrast to clonogenic assay. This could be attributed to the fact that MTT 
is  performed  at  day  5  of treatment,  following  less  than  4  doubling  times,  while  the 
colonies  in  the  clonogenic  assay  are  usually  counted  approximately  10  days  after 
treatment.  This  means  that  the  MTT  assay  included  all  viable  cells  from  which  a 
proportion will die during subsequent cell divisions and fail to form colonies.  
Chen et al. reported that clonogenic assay is more sensitive than the MTT assay. The 
ID50 values (dose which inhibits 50% of cell population) obtained from the MTT assay 
were approximately 3 to 5 times lower than those from the other two methods (Chen et 
al., 1990). 
 Sobottka  and  Berger  compared  MTT  and  cell  counting  efficiency    to  assess 
antineoplasic agents and concluded that depending on the antitumour agent used, the 
MTT assay can result in slight or even considerable underestimation of the antitumour 
efficacy of certain compounds and may need correction by consideration of the effect of 
the drugs on cell size (Sobottka & Berger, 1992). However, other authors reported a 
high degree of correlation (up to r = 0.939, P < 0.01) (Kawada et al., 2002) between 
MTT  and  clonogenic  assays  results  (Carmichael  et  al.,  1987;  Perez  et  al.,  1993). 
Although we noted a similar degree of correlation, all subsequent sensitivity assays were 
carried out using clonogenic assays for several reasons.    115 
Since it was first described (Hamburger & Salmon, 1977; Salmon et al., 1978), tumour-
colony  assay  has  been  the  gold-standard  for  assessing  in vitro tumour  sensitivity  to 
chemotherapy agents, external beam and targeted-particle radiotherapy. It reflects the 
cytocidal  effect  of  therapy  rather  than  the  possibly  transient  cytostatic  effect  that  is 
provided  by  MTT  assay.  Another  advantage  is  the  reduced  risk  of  radiation 
contamination  associated  with  the  clonogenic  as  opposed  to  the  MTT  assay  when 
investigating response to targeted-particle radiotherapy.  
In summary, in this chapter we have transfected 3 tumour cell lines, DU145, 143B and 
UVW, with a plasmid encoding the gene of HSV-TK enzyme. HSV-tk gene expression 
was then confirmed by three transfection efficiency methods.  
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Chapter 4 : [
123I]FIAU toxicity to tumour cells 
expressing the HSV1-tk gene 
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4.1 Aims 
1.  To  test  the  hypothesis  that  radiolabelled  FIAU  can  be  used  as  a  targeted 
radiotherapy agent for tumours expressing HSV1-tk gene. 
2.  To explore the response of tumour spheroids to this new strategy and to assess 
the possibility of enhanced response by bystander or cross-fire effects. 
3.  To investigate the effect of serum concentration and cellular proliferation rate on 
the response of parental and TK-positive tumour cells to radiolabelled FIAU.  
4.  To determine the effect of cell cycle phase on TK-positive tumour cells treated 
with [
123I]FIAU for two different incubation periods. 
 
4.2 Introduction 
The rationale for using radiolabelled FIAU as targeted radiotherapy agent was built on 
two main foundations. Firstly previous experience with another thymidine analogue 5-
iodo-2’- deoxyuridine (IUdR) (Fig. 4.1), indicated that it can incorporate into the DNA 
of  rapidly  dividing  cells.  When  IUdR  was  labelled  with  Auger  electron-emitter 
radioiodine 
123I or 
125I, it exerted a lethal effect on cells undergoing DNA synthesis, as 
shown  in  several  studies  (Hofer  &  Smith,  1975;  Makrigiorgos  et  al.,  1989; 
Schneiderman & Schneiderman, 1996).  
Secondly, tumour cells expressing viral TK gene can selectively accumulate FIAU by 
virtue of viral TK phosphorylation that could result in significant incorporation into the 
cellular DNA. FIAU was shown to be a substantially better substrate for the HSV1-TK 
enzyme than IUdR or GCV (Tjuvajev et al., 1995). Similar to IUdR, if FIAU is radio-  118 
labelled with an Auger electron-emitter, enhanced cell kill will occur by virtue of Auger 
electron radiation damage. The Auger electron has high ionising radiation and ultra-
short LET with effective range of only few nanometers (Martin & Haseltine, 1981). This 
will ensure delivering intense and localised radiation damage to the targeted tumour 
cells.  However,  in  order  for  the  Auger  electron-emitters  to  kill  cells,  they  must  be 
incorporated into the cellular DNA (Kassis et al., 1987). 
It has been shown that the plasma half life of FIAU in human is about 4 h (Feinberg et 
al.,  1985;  Haubner  et  al.,  2000;  King,  1991)  and  hence  the  first  exposure  period  of 
tumour cells was determined according to this to mimic in vivo kinetics. The second 
period of 8 h is double the plasma half-life. This interval was selected to assess the 
relationship between the exposure period and sensitivity. 
Both FIAU incorporation into cellular DNA and the radio-sensitivity of tumour cells 
depend  on  the  phase  of  cell  cycle.  Mammalian  TK  has  two  isozymes:  a  minor 
mitochondrial isozyme which does not flactuate during the cell cycle and the cellular 
isozyme which reaches a high level in cycling cells (Adler & mCauslan, 1974) .  TK 
activity and hence FIAU phosphorylation increases at or near the G1-S phases (Coppock 
& Pardee, 1985) .Dividing cells are most radiosensitive during mitosis (M phase) and 
late G2 phase of the cell cycle (Sinclair & Morton, 1966; Terasima & L.J., 1963).  
If during this in vitro evaluation of [
123I]FIAU cytotoxicity all treated tumour cells are in 
exponential phase, i.e. all cells are cycling, an exposure period equal to their doubling 
time  will  theoretically  ensure  complete  cell  kill.  Therefore,  we  have  also  evaluated 
tumour cell sensitivity to [
123I]FIAU after an exposure period similar to their doubling 
time. Furthermore, cell cycle analysis was carried out to assess the effect of [
123I]FIAU 
treatment on the cell cycle progress. 
   119 
O
OH
H
H
H
H
O H
N H
N O
I
H
O
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Figure 4.1:  chemical structure of IUdR 
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4.3 Materials and methods 
4.3.1 Cell lines 
The parental clones and clones expressing HSV1-tk gene of three different cell lines 
were used in these experiments. These three cell lines, DU145, 143B and UVW are able 
to grow both in monolayers and multicellular spheroids and their capacity to express the 
HSV1-tk gene was confirmed (see sections 3.4).  
4.3.2 [
123I]FIAU sensitivity of monolayers 
The in vitro sensitivity to
 [
123I]FIAU of the monolayers of parental and TK positive 
clones  of  three  different  tumour  cell  lines  was  determined  by  clonogenic  assay  as 
described in section 2.2.4. Monolayers of the three cell lines were treated with a range of 
concentrations of [
123I]FIAU for a period of 4 h, 8 h, and for a period equal to the total 
doubling time of each cell line.  
The  transfected  cell  lines  were  also  treated  with  equivalent  molar  concentrations  of 
unlabelled  FIAU  to  determine  wether  any  of  the  kill  was  the  result  of  DNA 
incorporation of the unlabelled FIAU. The incubation period for this experiment was 
identical to the doubling time of each cell line. 
4.3.3 [
123I]FIAU Sensitivity of multicellular spheroids 
To investigate the possibility of cross-fire effect of [
123I]FIAU on a three dimensional 
model, multicellular spheroids were prepared and treated as follows:  
Cells in exponential phase were disaggregated into a single cell suspension and counted 
as described previously (section 2.2.1.1). 1, 2 or 3 x 10
6 cells were transferred to a 750 
ml  spinner  flask  containing  75  ml  of  fresh  medium,  equilibrated  with  5%  CO2  and 
incubated at 37
oC. Spheroids formed with continuous spinning for approximately 4 to 5   121 
days  and  the  pretreatment  size  of  the  spheroids  was  determined  by  measuring  two 
perpendicular diameters, using an inverted phase-contrast microscope connected to an 
image analyser.  
Spheroids with average diameter of 200 ￿ m were split between number of universals 
according to the number of doses, dosed and incubated for the determined exposure 
period with continuous spinning. The degree of [
123I]FIAU uptake by these spheroids 
was not determined in this experiment. The spheroids were then washed twice with PBS 
and once with fresh medium, trypsinised for 10 min and disaggregated thoroughly by 
passing  them  up  and  down  a  19G  needle  4-5  times.  Single  cell  suspension  was 
confirmed  microscopically  and  then  counted  using  a  haemocytometer.  Spheroid 
sensitivity was then assessed by clonogenic assay as described in section 2.2.4. 
4.3.4 Cell cycle analysis  
The effect of [
123I]FIAU exposure on cell cycle phase distribution was assessed by the 
method described in section 2.2.5. 
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4.4 Results 
4.4.1 [
123I]FIAU sensitivity of monolayers 
The  clonogenic  survival  curves  of  the  parental  and  transfected  clones  treated  with 
[
123I]FIAU for 4 h are shown in Fig. 4.2. The three cell lines demonstrated enhanced 
sensitivity to [
123I]FIAU when transfected with the tk gene. The data were fitted to a 
curve and the IC50 values calculated from the curve were significantly reduced in the 
TK-positive cell clones compared with the parental cells as shown in Table 4.1. The 
[
123I]FIAU sensitivity enhancement factor by TK transfection (EF) was calculated as the 
IC50 of the parental clone divided by the IC50 of the TK transfected clone of the same 
cell line. The EF for the cell lines DU145 and UVW were 5.2 and 2.8, respectively (P < 
0.005).  
Doubling the treatment period from 4 h to 8 h further enhanced [
123I]FIAU sensitivity of 
the TK positive clones of DU145 and 143B as shown in Fig. 4.3 and Table 4.2. The IC50 
of the cell line DU145 was reduced from 0.8 (±0.05) MBq/ ml to 0.16 MBq/ ml and the 
EF increased to 13.8. For the cell line 143B, it was not possible to determine IC50 of the 
parental cell line and hence similarly the EF. For the TK positive clone 143B-TK, the 
IC50 was reduced from 1.8 (±0.5) MBq/ ml to 0.22 (±0.028) MBq/ ml. 
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Table 4.1: The IC50 values (MBq/ml) and EF of the the parental and TK-positive 
clones of cell lines treated with [
123I]FIAU for 4 h.  Values in parenthesis are s.d. of 
triplicate experiments.  
Cell line  IC50 (s.d.) 
Sensitivity 
enhancement factor 
(EF) by TK 
P value (between 
parental and TK-
positive clones) 
DU145  4.65 (0.67)     
DU145-TK  0.89 (0.05)  5.2  < 0.001 
143B  ND     
143B-TK  1.8 (0.5)  ND   
143B-pcTK  2.6 (0.16)  ND   
UVW  7.03 (0.61)     
UVW-TK  2.46 (0.13)  2.8  <0.0001 
ND, not determined 
 
   124 
0
0.2
0.4
0.6
0.8
1
0 2 4 6 8
123I-FIAU Concentration (MBq/ml)
S
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
DU145 DU145-TK
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6
[123I]FIAU concentration MBq/ mL
s
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
143B 143B-TK 143B-pcTK
 
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6
[123I] FIAU concentration MBq/mL
S
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
UVW UVW-TK
 
 
Figure 4.2: Clonogenic survival for [
123I]FIAU sensitivity of 
parental and TK positive clones of DU145, A; 143B, B and 
UVW, C. Monolayers were treated with increasing doses of 
[
123I]FIAU for 4 h.  Data represents means and s.d. of 
triplicate experiments.
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Figure 4.3: Clonogenic survival of parental and TK positive clones of the cell lines 
DU145, A and 143B, B treated with [
123I]FIAU for 8 hours.  
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Table 4.2: The IC50 values (MBq/ ml) and EF of the parental and TK-positive 
clones of the cell lines DU145 and 143B-TK treated with [
123I]FIAU for 8 h. 
   IC50 (s.d)  EF   P value 
DU145  2.22 (0.11)     
DU145TK   0.16 (0.005)  13.8  0.001 
143B  ND     
143B-TK  0.229 (0.028)  ND  ND 
ND, not determined 
 
4.4.3 The effect of cellular proliferation rate on [
123I]FIAU sensitivity 
There was a strong correlation between the clonogenic survival of the tumour cell lines 
treated with [
123I]FIAU and the degree of cellular proliferation. Fully confluent (plateau 
phase) monolayers of the cell lines DU145-TK and 143B-TK exhibited lower sensitivity 
to increasing concentrations of [
123I]FIAU compared with the monolayers in exponential 
phase  (Fig.  4.4).  For  comparison  purpose,  IC25  values  ([
123I]FIAU  concentration  that 
inhibits the growth of 25% of cells) were determined from the curves.  The IC25 of DU145-TK 
was 1.3 (±0.3) MBq/ml for plateau phase versus 0.4 (±0.009) MBq/ml for exponential 
phase (P = 0.006), and of 143B-TK was 3.9 (±0.4) MBq/ml for plateau phase versus 
0.53 (±0.14) MBq/ml for expopential phase (P < 0.005). 
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Figure 4.4: Clonogenic survival of the cell lines DU145-TK, A and 143B-TK, B 
treated with [
123I]FIAU for 4 h at either plateau or exponential phase. Data 
represent mean and s.d. of triplicate experiments. 
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4.4.4 [
123I]FIAU sensitivity of multicellular spheroid models determined by 
clonogenic assay 
When the spheroids of parental and TK-positive clones of DU145 cell line were treated 
with [
123I]FIAU for 4 h, sensitivity was shown to be similar to the monolayers and hence 
there was no enhanced sensitivity to [
123I]FIAU. The IC50 values were similar to the 
values obtained with the treatment of monolayers of parental and TK positive DU145 
(Fig. 4.5A). The IC50 of the parental cell line monoayers and spheroids were 4.65 (±0.7) 
MBq/ ml and 3.2 (±0.4) MBq/ ml, respectively (P > 0.05) and for the TK-positive clone 
the IC50 were 0.89 (±0.05) MBq/ ml for monolayers and 0.91 (±0.06) for the spheroids 
(P > 0.05). Similar results were obtained with the control cell line 143B-TK for which 
the  IC50  increased  from  1.86  (±0.59)  to  4.3  (±0.61)  MBq/ml  with  no  statistical 
significance (P = 0.069) (Fig. 4.5B). However, the spheroids of the cell line UVW-TK 
showed reduced sensitivity to [
123I]FIAU compared with the monolayers where the IC50 
increased from 2.46 (± 0.13) MBq/ ml  to 6.4 (± 0.23) MBq/ ml  (P = 0.008) (Fig. 4.5C). 
 
 
   129 
0
0.2
0.4
0.6
0.8
1
0 2 4 6
[123I]FIAU concentration MBq/mL
S
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
DU145 (spheroids) DU145-TK (spheroids)
 
 
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6
[123I]FIAU concentration MBq/mL
S
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
143B (spheroids) 143B-TK (spheroids) 
  
 
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6
[123I]FIAU concentration MBq/mL
S
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
UVW (spheroids) UVW-TK (shperoids)
  
 
 
 
Figure 4.5: Clonogenic survival of spheroids of parental and 
TK-positive DU145 (A), 143B (B) and UVW (C) treated with 
increasing  doses  of  [
123I]FIAU  for  4  hours.  Data  represent 
mean and s.d. of triplicate experiments. 
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 4.4.5  [
123I]FIAU  sensitivity  after  treatment  period  equal  to  full  doubling 
time of the treated cell lines. 
When the [
123I]FIAU exposure period of the parental and TK-positive clones of all cell 
lines was increased to a period equal to their doubling times, a two log cell kill was 
observed    (Fig.  4.6).  The IC50  values  were  reduced  significantly  compared  to  those 
obtained by the 4 h exposure. For example, the IC50 for the clone 145-TK was reduced 
from 0.89 (±0.05) MBq/ ml to 0.018 MBq/ ml when the incubation period was increased 
from 4 h to 26 h (P < 0.001). There was also a rise in the TK sensitivity enhancement 
factor (EF) for the cell line DU145-TK from 5.2 after 4 h exposure to 7.67 after 26 h 
exposure (Tables 4.1 & 4.3). The treatment of DU145-TK and 143B-TK with equivalent 
molar concentration of unlabelled FIAU for the same period did not result in any growth 
inhibition (Fig. 4.6).  In view of the short half life of 
123I (13 h), longer incubation 
periods  will  result  in  a  smaller  number  of  disintegrations  towards  the  end  of  the 
incubation period. Because this study did not compare different isotopes of iodine, the 
number of disintegrations was not corrected for the incubation periods. 
Table 4.3: IC50 (kBq/ml) of [
123I]FIAU of parental and TK-positive DU145 after an 
incubation period equivalent to the cellular doubling time.  
Cell line  IC50(s.d)  EF  P value 
DU145  142.08(26.3)     
DU145-TK   18.51(0.41)  7.67  0.0012 
143B   ND     
143B-TK  42 (3.2)  ND  <0.001 
ND, not determined.   131 
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Figure 4.6: Clonogenic survival of the parental and TK-positive clones of the cell 
lines DU145 (A) and 143B (B) treated with various doses of [
123I]FIAU for a period 
equal to their doubling time. Data represents mean and s.d. of triplicate 
experiments. Data also included the treatment of the transfected clones of these two 
cell lines with the unlabelled FIAU.  
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4.4.6 Cell cycle analysis of TK-positive cells treated with [
123I]FIAU  
The figures 4.7 and 4.8 show the cell cycle analysis of the cell line DU145-TK treated 
with [
123I]FIAU for 4 h and 26 h, respectively. The incubation period of 4 h had no 
effect on the cell cycle progression over the whole range of [
123I]FIAU doses (Fig. 4.7 & 
4.9A). For example, the maximum [
123I]FIAU dose of 3 MBq/ml, which resulted in a 
survival fraction (SF) of  0.16 caused insignificant reduction in the percentage of cells in 
G1-phase  from  63.5%  (untreated  cells)  to  62.8%  (P  =  0.9).  In  contrast,  the  26  h 
treatment period induced significant cell cycle arrest at G2/M phase. This cell cycle 
redistribution was evident even with the smallest dose of 62.5 kBq/ml, which resulted in 
a SF of 0.28 (Fig. 4.8 & 4.9B). This dose caused a decrease in the proportion of cells in 
G1-phase  from  63.08%  (untreated  cells)  to  38.95%  (P  =  0.026)  and  a  rise  in  the 
proportion of cells in G2/M-phase from 21.98% to 49.85% (P = 0.002).  
Similar results were obtained from the osteosarcoma cell line 143B-TK as shown in 
figure 4.10. The smallest dose of 62.5 kBq/ml reduced the proportion of cells in G1-
phase from 59% to 43.3% and increased the proportion of cells at G2/M phase from 
26.8% to 44.1%. 
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Figure 4.7: Cell cycle analysis for the cell line DU145-TK treated with increasing 
doses of [
123I]FIAU for 4 hours. There were no significant cell cycle changes even 
with the highest dose of 3 MBq/ ml. 
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Figure 4.8: Cell cycle analysis for the cell line DU145-TK treated with increasing 
doses of [
123I]FIAU for 26 h showing evidence of cell cycle arrest at G2/M phase. 
M1, G0/G1; M2, S; M3, G2/M. 
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Figure 4.9: Cell cycle changes of the cell line DU145-TK treated with increasing 
doses of  [
123I]FIAU for 4 h, A and 26 h, B. Data represent mean and s.d. of 2 
independent experiments.  
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Figure 4.10: Cell cycle changes of the cell line 143B-TK treated with increasing 
doses of  [
123I]FIAU for 4 h, A and 20 h, B.  
A 
B   137 
4.5 Discussion 
The  main  purpose  of  the  experiments  described  in  this  chapter  was  to  explore  the 
potential anticancer effect of radiolabelled FIAU on tumour cells bearing HSV1-tk gene. 
Following the incubation of the three cell lines DU145, UVW and 143B with [
123I]FIAU 
for 4 h, both parental and TK positive clones of all cell lines demonstrated a degree of 
sensitivity except the TK-negative cell line 143B. As shown in previous studies, this 
indicates that [
123I]FIAU sensitivity is TK mediated. The IC50 values ranged from 0.89 ± 
0.05 MBq/ml for the cell line DU145-TK to 7.03 ± 0.61 MBq/ml for the cell line UVW. 
The  transfection  of  tumour  cells  with  HSV1-tk  gene  significantly  enhanced  the 
sensitivity of all cell lines to [
123]FIAU. The EF values ranged from 2.8 to 5.2 after 4 h 
exposure.  This  was  in  agreement  with  the  results  of  our  [
123I]FIAU  uptake  studies 
where,  for  example,  the  [
123I]FIAU/  methyl-[
3H]TdR    uptake ratio  was  4.25  (±0.15) 
times higher in the TK positive than in the parental clone of the cell line DU145 (see 
section 3.4.2.2). However, the EF values for GCV sensitivity were considerably higher, 
as shown in section 3.4.3.1. This is probably due to the longer incubation period of 72 h 
which was planned according to similar experiments carried out by other groups (e.g. 
(Haubner et al., 2000; Makinen et al., 2000) .   
In  contrast,  a  previous  study  of  DU145  cells  transfected  with  the  noradrenaline 
transporter (NAT) gene demonstrated upto 8-fold enhancement of the active uptake of 
the radiopharmaceutical [
131I]MIBG compared to the nontransfected cells.  This resulted 
in dose-dependent toxicity with statistically significant difference in the SF between the 
parental cells and the NAT transfected cells (Fullerton et al., 2004). In this study the 
sensitivity enhancement was not determined by comparing the IC50 values. 
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As shown in Fig. 4.5, the spheroid experiments failed to demonstrate better tumour cell 
kill with crossfire or bystander effect using [
123I]FIAU. The possible reasons for this are 
the short radiation range of the radionuclide 
123I and the relatively short exposure period 
of the spheroids to FIAU. Neshasteh-Riz et al., compared the effect of 
123I-IUdR on 
spheroids  of  the  glioma  cell  line  UVW  with  that  of 
125I-IUdR  and 
131I-IUdR.  The 
survival  curves  showed  a  dose  dependent  region  at  low  concentration  for  all  three 
pharmaceuticals, and a dose-independent region for high concentration of [
125I]IUdR 
and  [
123I]IUdR.  [
123I]IUdR  was  less  effective  than  [
125I]IUdR  over  the  whole 
concentration range (Neshasteh-Riz et al., 1998). In addition, another study suggested 
that  tumour  cells  growing  as  spheroids  manifest  a  reduction  in  division  rate  among 
cycling cells as well as a reduction in the proportion of cells in cycle (Neshasteh-Riz et 
al., 1997). 
The prolongation of [
123I]FIAU exposure of the tumour cell lines to a period equal to 
their doubling times (Fig 4.6) caused a dramatic reduction in the clonogenic survival of 
these cells when the entire cell population goes through a full cell cycle. This, together 
with the reduced [
123I]FIAU sensitivity of cells in plateau phase, supports the evidence 
that this strategy works only on cycling tumour cells and in particular cells undergoing 
DNA  synthesis.  The  clonogenic  survival  curves  of  the  TK  positive  clones  showed 
biphasic pattern of dose-dependent kill at low [
123I]FIAU concentrations and thereafter 
in  the  second  phase  no  further  increase  in  kill  despite  increasing  radioactivity 
concentrations. This implies the presence of resistant subpopulation of clonogens.  
Figure 4.8 shows that this prolonged exposure period has also resulted in cell cycle 
arrest at the G2/M phases, in contrast to the negligible cell cycle changes observed after 
the 4 h exposure (Fig.4.7). This cell cycle arrest was evident even with the lowest dose   139 
of  62  kBq/  ml.  This  event  likely  takes  place  at  the  repair  check  point  after  DNA 
radiation damage and before next cell division.  
The arrest of cells at G2-phase of cell cycle following DNA damage is observed readily 
in  mammalian  cells  and  has  been  studied  by  radiation  biologists  for  decades,  since 
before  checkpoints  were  understood  at  the  molecular  level.  The  function  of  this 
checkpoint  in  normal  cells  is  to  prevent  cells  with  damaged  chromosomes  from 
attempting the complex process of mitosis. The cells are arrested in G2 to allow DNA 
repair to be completed. The controlling genes for this checkpoint have been identified in 
yeast, but not in mammalian cells (Hall, 2000). Further cellular division with damaged 
DNA  will  eventually  result  in  cell  death  within  1  or  2  cell  cycles,  unless  the  cell 
manages to repair the damage before mitosis starts. Once the cells are arrested at this 
phase of the cell cycle, which is the most radiosensitive phase, they become vulnerable 
to  a  second  insult  of  radiation  or  another  TK  substrate  like  GCV.  This  may  have 
important implications for the scheduling of the GCV/FIAU combination therapy.  
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5.1 Aims 
1.  To evaluate the combination therapy effect of GCV and radiolabelled FIAU on 
tumour cells expressing the viral TK enzyme using the method of median effect 
analysis and combination index. 
2.  To determine the best timing schedule that leads to maximum synergism. 
3.  To  highlight  the  possible  underlying  mechanisms  of  the  end  result  of  the 
different schedules of this combination therapy using cell cycle analysis. 
5.2 Introduction 
 
5.2.1 Rationale for the combination therapy 
One of the main goals of any combination therapy in oncology is to reduce the required 
doses of each single treatment agent, thereby minimising the individual adverse effects.  
This is beneficial even if the outcome of the combination therapy is merely an additive 
effect.  As a basic principle in oncology, additive or even synergistic antitumour action 
can be achieved by combining agents that have demonstrated single-agent activity and 
non-cross-resistance to overlap against drug-resistant subpopulation of tumour cells. In 
addition,  these  agents  should  have  non-antagonistic  and  preferably  additive  or 
synergistic mechanisms of actions and non-overlapping toxicity profiles (Balis et al., 
1997). As a proof of effectiveness, we have confirmed that radiolabelled FIAU is lethal 
to tumour cells with and without viral TK expression (chapter 4). GCV is taken up by all   142 
cells but only phosphorylated and retained in cells that express TK gene (Frank et al., 
1989). Both GCV and FIAU are selective substrates of the viral TK enzyme.. However, 
their dose-dependent adverse effects seem to be markedly different in terms of severity 
and affected organs. 
The most serious side effect of the non-radiolabelled FIAU was the fatal hepatotoxicity 
which  was  reported  after  clinical  trials  involving  treatment  of  chronic  active  viral 
hepatitis  B  (Brahams,  1994;  Marshall,  1994).  Systemic  administration  of  GCV, 
however,  was  considerably  safer  when  a  large  dose  of  5  mg/  kg  twice  daily  was 
administered for 14 days in the first 2 clinical trials of HSV1-TK/GCV gene therapy 
(Ram et al., 1997; Sterman et al., 1998).  In both studies the tumour responses were low 
in number or of short duration. 
However, higher doses of GCV may not be tolerated because of its toxic effects on the 
bone marrow, gut and kidneys (Wildner et al., 1999). Furthermore, simply increasing 
HSV1-TK enzyme level per cell above a minimal threshold level is not effective in 
augmenting the HSV1-TK/GCV system (Elshami et al., 1997).  
Therefore, new strategies to circumvent these limitations, such as combination therapy, 
are  urgently  sought.  Radiation  therapy  has  traditionally  played  a  major  role  in  the 
combination  therapy  of  human  cancer  together  with  surgery  and/  or  chemotherapy. 
More recently, encouraging results have been reported from an early phase clinical trial 
combining protocols of suicide gene therapy with external beam radiotherapy of prostate 
cancer (Freytag et al., 2003). We are here aiming to couple the Auger electron particle 
targeted-radiation  cytotherapy  by  [
123I]FIAU  with  the  suicide  gene  therapy  HSV1-
TK/GCV system in treating two different cell lines derived from prostate cancer and 
osteosarcoma. 
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5.2.2 Principle of median effect analysis and combination index 
In 1984 Chou and Talalay introduced the median effect analysis in order to analyse and 
normalise all types of dose-response results by a uniform method (Chou, 1991; Chou & 
Talalay, 1984). This analysis is based on the median effect principle of the mass action 
law (Chou, 1974; Chou, 1976; Chou & Talalay, 1977) and has already been shown to be 
simple to apply and useful in the analysis of complex biological systems. 
5.2.2.1 The Median Effect Equation 
The median effect equation states that  
fa/fu = (D/Dm)
m                  (1) 
Where D is the dose, fa and fu are, respectively, the fractions of the system affected and 
unaffected  by  the  dose  D,  Dm  is  the  dose  required  to  produce  the  median  effect 
(analogous  to  the  more  familiar  IC50,  ED50,  or  LD50  values,  and  m  is  a  Hill-type 
coefficient signifying the sigmoidicity of the dose-effect curve, i.e., m = 1 in hyperbolic 
(first order or Michaelis-Menten) systems. 
Since by definition, fa + fu = 1, an alternative to equation 1 is: 
fa/(1 – fa) = (D/Dm)
m  
and thus:
  
D = Dm[fa/(1-fa)]
1/m  
5.2.2.2 The median effect plot 
The median effect equation (equation 1) may be linearised by taking the logarithms of 
both sides, i.e. 
  log [(fa)
-1 -1]
-1 = m log (D) – m log (Dm) 
or    log (fa/fu) = m log (D) – m log (Dm)   144 
or  log [(fu)
-1 -1] = m log (D) – m log (Dm) 
Thus, in the median effect plot (e.g., Fig. 5.2) 
y = log (fa/fu) 
x = log (D) 
The plot gives the slope, m, and the intercept of the dose effect plot with the x axis of 
log (D) which gives log (Dm) and consequently the Dm value [i.e. when fa = fu, fa/fu = 1 
and hence y = log (fa/fu) = 0]. Any cause consequence relationship that gives a straight 
line for this plot will provide the two basic parameters, m and Dm, and thus, the apparent 
equation  that  describe  such  a  system.  The  linearity  of  the  median-effect  plot  (as 
determined  from  linear  regression  coefficients)  determines  the  applicability  of  the 
present method (Chou & Talalay, 1984). 
 
5.2.2.3 Equations for the effect of multiple drugs 
A systematic analysis in enzyme kinetic systems using the basic principles of mass-
action law has led to the derivation of generalised equations for multiple inhibitors or 
drugs (Chou & Talalay, 1977; Chou & Talalay, 1981). 
For two drugs (D1 and D2) that obey higher order conditions (Hill-type) in which each 
drug has a sigmoidal dose-effect curve (i.e., has more than one binding site or exhibits 
positive or negative cooperativity), if the effect of each drug is mutually exclusive (i.e., 
they have different modes of action or act independently), the generalised equation is:  
[(fa)1,2 / (fu)1,2]
1/m
 = [(fa)1 / (fu)1]
 1/m
 + [(fa)2 / (fu)2]
 1/m 
        = (D)1 / (ED50)1 + (D)2 / (ED50)2          (2) 
Where, ED50 is the concentration of the drug that is required to produce a 50% effect. 
If the effects of two drugs are mutually nonexclusive, then this relationship becomes:   145 
[(fa)1,2 / (fu)1,2]
1/m
 = [(fa)1 / (fu)1]
 1/m
 + [(fa)2 / (fu)2]
 1/m + [ (fa)1 (fa)2 / (fu)1 (fu)2]
1/m 
        = (D)1 / (ED50)1 + (D)2 / (ED50)2 + (D)1 (D)2 / (ED50)1 (ED50)2  (3) 
 
In the special case where (fa)1,2 = (fu)1,2 = 0.5, equation 2 becomes: 
(D)1 / (ED50)1 + (D)2 / (ED50)2 = 1              (4) 
This describes the ED50 isobologram. 
Similarly equation 3 becomes: 
(D)1 / (ED50)1 + (D)2 / (ED50)2 + (D)1 (D)2 / (ED50)1 (ED50)2 = 1      (5) 
Which does not describe an isobologram, because of the additional term on the left. 
5.2.2.4 Quantitation of synergism, summation and antagonism 
When experimental results are entered into equations 2 & 3, if the sum is greater than, 
equal to, or smaller than 1, it may be inferred that antagonism, summation, or synergism 
of  effects,  respectively,  has  been  observed.  Therefore,  from  equations  2  &  3,  if  the 
observed combined effect is greater than the calculated additive effect, (fa)1,2, synergism 
is indicated; if it is smaller, antagonism is indicated. 
It  is,  however,  convenient  to  designate  a  “combination  index”  (CI)  for  quantifying 
synergism, summation and antagonism, as follows: 
CI = (D)1 / (DX)1 + (D)2 / (DX)2              (6) 
for mutually exclusive drugs, and 
CI = (D)1 / (DX)1 + (D)2 / (DX)2 + (D)1 (D)2 / (DX)1 (DX)2        (7) 
for mutually nonexclusive drugs. 
For mutually exclusive or nonexclusive drugs, 
when CI < 1, synergism is indicated. 
CI = 1, summation is indicated.   146 
CI > 1, antagonism is indicated. 
To determine synergism, summation and antagonism at any effect level (i.e. for any fa 
value), the procedure involves three steps: i) construct the median effect plot which 
determines m and Dm values for drug 1, drug 2 and their combination; ii) for a given 
degree  of  effect  (i.e.  a  given  fa  value  represents  x  percent  affected),  calculate  the 
corresponding  doses  [i.e.  (DX)1  (DX)2  and  (DX)1,2]  by  using  the  alternative  form  of 
equation 1, DX = Dm [fa / (1 – fa)]
1/m; iii) calculate the combination index (CI) by using 
equations 6 or 7, where (DX)1 and (DX)2 are from step (ii), and (DX)1,2 [also from step 
(ii)] can be dissected into (D)1 (D)2 by their known ratio, P/Q. Thus, (D)1 = (DX)1,2 X 
P/(P+Q) and (D)2 = (DX)1,2 X Q/(P+Q) (Chou & Talalay, 1984). 
  
 
5.3 Materials and Methods 
 
5.3.1 Cell lines 
Two  HSV1-TK-positive  cell  lines,  the  prostate  cancer  cell  line  DU145-TK  and  the 
osteosarcoma cell line 143B-TK cell line, were used in this study because of the high 
stability of HSV1-TK gene expression. 
5.3.2 Timing schedules of the combination therapy 
For all treatment schedules, cells were treated in 25 cm flasks. Cells in exponential 
phase  were  seeded  at  10
5  cells/  flask,  48  h  before  the  first  dose.  Individual  agent 
therapies  were  also  carried  out  simultaneously  with  each  schedule  and  surviving 
fractions  were  calculated  as  a  percentage  of  the  untreated  control  of  each  schedule 
separately. It has been shown that the plasma half life of FIAU in human is about 4 h   147 
(Feinberg et al., 1985; Haubner et al., 2000; King, 1991) and therefore the treatment 
period with[
123I]
 FIAU of tumour cells was determined according to this to mimic in 
vivo kinetics. The treatment period of GCV of 72 h was selected according to the results 
of previous studies which showed maximum cell kill after 72 h incubation (Haubner et 
al., 2000; Makinen et al., 2000) .  
5.3.1.1 Treatment with GCV before FIAU 
Cells  in  exponential  phase  were  incubated  in  4  ml  medium  containing  various 
concentrations of GCV at 37
oC. After 72 h, medium was removed, monolayers were 
washed with PBS and 1 ml of medium containing the appropriate doses of [
123I]
 FIAU 
was added to each flask and cells were further incubated for 4 h. Following this, cells 
were washed twice with PBS.  
5.3.1.2 Treatment with GCV after FIAU  
1 ml of medium containing various concentrations of [
123I]
 FIAU was added to each 
flask and incubated. After 4 h, medium containing [
123I]
 FIAU was removed; cells were 
washed twice with PBS and treated with the appropriate doses of GCV for 72 h and then 
washed twice with PBS. 
5.3.1.3 Simultaneous Treatment with GCV and FIAU 
Cells were initially incubated in 1 ml of medium containing both GCV and [
123I]
 FIAU 
in  concentrations  appropriate  to  each  combination  dose  for  4  h.  Medium  was  then 
removed and cells washed twice with PBS and 4 ml of medium containing the same 
concentration of GCV was added. Cells were then incubated for another 68 h and then 
washed twice with PBS.   148 
At the end of each schedule, single drug or combination effects were determined by 
clonogenic assay as described in section 2.2.4. 
5.3.3 Cell cycle analysis 
The  effect  of  GCV  and  [
123I]FIAU  exposure  on  cell  cycle  phase  distribution  was 
assessed by the method described in section 2.2.6. 
5.3.4 Statistical analysis 
Median effect plots and combination indexes were generated by entering the data of 
clonogenic  assays  into  a  Microsoft  Excel  template  using  the  method  and  equations 
described in section 5.2.2.4. 
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5.4 Results 
5.4.1  Combination  therapy  of  the  cell  line  143B-TK  using  various  schedules  of 
delivery of GCV and [
123I]FIAU 
5.4.1.1 Calculating the combination doses of GCV and [
123I]FIAU 
Clonogenic assays were carried out to determine the IC50 values of individual therapies 
using  GCV  or  [
123I]FIAU.  The  ratio  of  the  concentrations  of  the  two  drugs  used in 
combination therapy was determined according to the method described in Table 5.1. A 
constant ratio of 1 MBq/ml [
123I]FIAU to 25 ng/ml GCV was used for the whole range 
of doses. The combination ratio was designed to approximate the IC50 of the two agents, 
so that the contribution of the effect for each drug in the mixture would be about the 
same (i.e., equipotency ratio), although any other ratios could also be used (Chou et al., 
1994).  
Table 5.1: Calculating individual and combination doses of GCV and [
123I]
 FIAU 
for the treatment of 143B-TK cell line. The combination doses are the sum of GCV 
and [
123I]
 FIAU doses and therefore they do not have a unit. 
 
 
 
 
 
 
 
 
 
 
 
 
[
123I]FIAU 
MBq/ml 
CGV  
ng/ml 
IC50  1.8  44.89 
Approximate 
ratio  1  25 
      Combination doses 
dose 1  4  100  104 
dose 2  2  50  52 
dose 3  1  25  26 
dose 4  0.5  12.5  13 
dose 5  0.25  6.25  6.5   150 
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Figure 5.1: Clonogenic survival of single agent (A) and combination (B) therapies 
of 143B-TK cell line. Doses correspond to the concentrations determined in Table 
5.1.  Data  represent  the  means  and  s.d  of  6  observations  of  2  experiments. 
Sim,simultaneous treatment. 
B 
A   151 
5.4.1.2 The median effect plots of individual and combination therapies 
Data  obtained  from  the  clonogenic  assays  of  each  single  agent  (Fig.  5.1A)  and  the 
different  schedules  of  combination  therapy  (Fig.  5.1B)  were  used  to  construct  the 
median effect plots shown in figures 5.2 and 5.3 using the logarithm of median effect 
equation  as  described  in  section  5.2.2.  The  dose-effect  relationship  parameters  are 
shown  in  Table  5.2  from  which  the  combination  index  values  were  determined  as 
described in section 5.4.1.3 .  
Table 5.2: Dose-effect relationship parameters of each treatment schedule for 
143B-TK cells treated with GCV or/and FIAU as obtained from the median effect 
plots shown in figures 5.2 and 5.3. 
Dm  Combination 
schedule 
GCV  
ng/ml 
FIAU 
MBq/ml 
m  r 
GCV   44.89    0.969  0.99 
FIAU     0.62  0.432  0.865 
GCV before FIAU  12.8  0.51  0.81  0.914 
GCV+FIAU (sim)  14.61  0.58  1.33  0.936 
FIAU before GCV  12.65  0.508  1.71  0.879 
Dm, IC50 of the individual drug (antilog of x-intercept) 
m, the slope 
r,  linear correlation coefficient of the dose-effect curve  
Sim, simultaneous treatment 
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Figure 5.2: The median effect plots of individual agent treatment of the cell line 
143B-TK.  
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Figure 5.3: The median effect plots of the different schedules of combination 
therapy of 143B-TK cell line. Sim, simultaneous treatment. 
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5.4.1.3 Combination index values of different treatment schedules of 143B-TK cell 
line 
All  combination  therapy  schedules  of  this  cell  line  showed  evidence  of  synergism 
between GCV and [
123I]FIAU at the high toxicity concentration range regardless of the 
exclusivity of their effects. Doses which inhibited the growth of more than 50% of the 
cells caused a synergistic effect substantiated by CI values less than 1. As shown in 
Table 5.3, CI values at the 50% growth inhibition dose were close to 1, except the 
simultaneous GCV+[
123I]FIAU schedule, indicating additivity or summation when the 
effect was assumed to be mutually exclusive.  
 
Table  5.3:  Combination  index  values  obtained  from  the  different  schedules  of 
combination treatment of 143B-TK cell line with [
123I]FIAU and GCV. Values in 
parenthesis are CI generated assuming that the effects of combinations of drugs 
are mutually nonexclusive.  
Combination 
schedule  Combination index (CI) values 
  IC30  IC50  IC70  IC90 
GCV before FIAU  2.272 (2.7)  1.067 (1.26)  0.617 (0.71)  0.454 (0.48) 
GCV+FIAU (sim)  3.9 (5.22)  1.26  (1.56)  0.531 (0.6)  0.256 0.26) 
FIAU before GCV  3.779 (5.18)  0.924 (1.31)  0.334 (0.43)  0.145 (0.157) 
ICx, concentration that inhibits the growth of x percentage of cells 
Sim, simultaneously 
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5.4.2 Combination therapy of the cell line DU145-TK using various schedules of 
delivery of GCV and [
123I]FIAU 
5.4.2.1 Calculating the combination doses of GCV and [
123I]FIAU  
Table 5.4 shows the individual and combination doses for the cell line DU145-TK. The 
maximum combination dose was calculated according to a fixed ratio of 3 MBq/ml to 
[
123I]FIAU 1ug/ml GCV  followed with serial two-fold dilutions for the smaller doses.  
 
 
 
 
Table 5.4: Calculating individual and combination doses of GCV and [
123I]
 FIAU 
for the treatment of DU145-TK cell line 
 
 
 
 
 
 
 
 
FIAU 
MBq/ml 
CGV  
￿g/ml 
IC50  0.88  0.268 
Approximate 
ratio  3  1 
      Combination doses 
Dose 1  0.375  0.125  0.5 
Dose 2  0.75  0.25  1 
Dose 3  1.5  0.5  2 
Dose 4  3  1  4   156 
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Figure 5.4: Clonogenic survival of single agents (A) and combination (B) therapies 
of DU145-TK cell line. Doses correspond to the concentrations illustrated in Table 
5.4. Data represent the means and s.d of 6 observations of 2 experiments. Sim, 
simultaneous treatment. 
 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
0  0.25  0.5  0.75  1 
GCV dose 
￿ g/ml 
S
u
r
v
i
v
i
n
g
 
f
r
a
c
t
i
o
n
 
GCV 
FIAU  A 
B   157 
5.4.2.2 The median effect plots of individual and combination therapies 
The median effect plots for the cell line DU145-TK constructed as described in section 
5.2.2 are shown in Fig. 5.5 & 5.6. 
Table  5.5:  Dose-effect  relationship  parameters  of  each  treatment  schedule  for 
DU145-TK cell line treated with GCV or/and FIAU as obtained from the median 
effect plots shown in figures 5.5 and 5.6. 
Dm 
Combination 
schedule 
GCV 
￿g/ml 
FIAU 
MBq/ml 
m  r 
GCV   0.268    1.96  0.995 
FIAU     0.88  0.599  0.854 
GCV before FIAU  0.142  0.42   1.26  0.992 
GCV+FIAU (sim)  0.229  0.68  0.871  0.831 
FIAU before GCV  0.172  0.51  0.861  0.881 
Dm, IC50 of the individual drug (antilog of x-intercept) 
m, the slope 
r,  linear correlation coefficient of the dose-effect curve 
Sim, simultaneously 
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Figure 5.5: The median effect plots of individual agent treatment of DU145-TK cell 
line.  
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Figure 5.6: The median effect plots of the different schedules of combination 
therapy of DU145-TK cell line. Sim, simultaneous treatment. 
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5.4.2.3 Combination index values of various treatment schedules of DU145-TK cell 
line 
Contrary  to  the  findings  of  the  other  cell  line  143B-TK,  two  of  the  combination 
schedules of this cell line showed evidence of antagonism between GCV and [
123I]FIAU 
with CI values greater than 1 throughout the whole range of doses (Table 5.6). One 
exception is the schedule of GCV before FIAU, where doses that caused 50% or greater 
growth inhibition revealed additive combination effect with CI values close to 1 when 
the combination drug effect was assumed as mutually exclusive. 
 
Table 5.6: Combination index values obtained from the different schedules of 
combination treatment of DU145-TK cell line with [
123I]FIAU and GCV. Values in 
parenthesis are CI generated assuming that the effects of combinations of drugs 
are mutually nonexclusive. 
Combination schedule  Combination index (CI) values 
   IC30  IC50  IC70  IC90 
GCV before FIAU  1.439 (1.87)  1.025 (1.28)  0.92 (1.07)  1.083 (1.15) 
GCV+FIAU (sim)  1.712 (2.32)  1.647 (2.32)  2.004 (2.75)  3.846 (4.73) 
FIAU before GCV  1.274 (1.61)  1.24 (1.62)  1.521 (1.95)  2.947 (3.47) 
ICx, concentration that inhibits the growth of x percentage of cells 
Sim, simultaneous treatment 
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Figure 5.7: Comparison of combination index isobolograms of the cell lines 143B-TK 
(A) and DU145-TK (B). fa, affected fraction; CI, combination index. Solid lines and 
dotted lines indicate CI for mutually exclusive and nonexclusive mechanism of action, 
respectively,  of  the  combination  agents  GCV  and  FIAU.  Part  of  the  curve  above, 
overlapping  or  below  X-axis  (when  CI=1)  indicates  antagonism,  summation  or 
synergism, respectively.   162 
5.4.4 Effect of the treatment schedules on the cell cycle distribution  
The cell cycle analysis of DU145-TK cell line following exposure to a range of GCV 
concentrations for 72h is shown in Figures 5.8 and 5.9A. The treatment with GCV alone 
resulted in a slight and dose-dependent increase in the proportion of cells in S- and G2/M-
phases compared with the untreated cells. The GCV dose of 0.5 ug/ml, which corresponds 
to a SF of 0.21, induced a decrease in the proportion of cells in G1-phase from 64.4% to 
53.3% (P = 0.02) and a rise in the percentage of cells in the S-phase from 13.6% to 18.1% 
(P = 0.061). Similarly, the proportion of cells in the G2/M phase increased from 18.4% to 
23.8% (P = 0.107). 
Similar cell cycle redistribution was observed in the 143B-TK cell line (Fig. 5.9B). For 
example, the GCV dose of 100 ng/ml, which caused a SF of 0.33, reduced the percentage 
of cells in G1-phase of the cell cycle from 65.3% to 56% and raised the percentage of 
cells in S-phase from 10.1% to 13.3% (P = 0.08).  
Cell cycle changes after 4 h exposure to [
123I]FIAU are shown and discussed in chapter 4, 
section 4.4.6. As shown in Figures 4.9A and 4.10A, there was no significant change in the 
cell cycle distribution.    163 
                
 
 
Figure 5.8: Cell cycle analysis for the cell line DU145-TK after treatment with 
increasing doses of GCV for 72 h. M1, M2 and M3 are the cell cycle phases of G1, S 
and G2/M, respectively. 
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Figure 5.9: Cell cycle changes after treating the cell lines DU145-TK (A) and 143B-
TK (B) with a range of doses of GCV for 72h. Data represent means and s.d. of 2 
independent experiments.   165 
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Figure 5.10: Comparison of the clonogenic survival of the individual and 
combination therapy of the cell line 143B-TK with GCV or/ and [
123I]FIAU for the 
combination schedule GCV before FIAU. Data represent means and s.d. of 6 
observations from 2 experiments. 
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5.5 Discussion 
This  study  was  designed  to  assess  the  possibility  of  synergistic  interaction  between 
GCV and [
123I]FIAU in the treatment of tumour cells expressing the gene of HSV1-TK. 
One of the reasons for choosing the method of median effect analysis and combination 
index  was  that  it  requires  a  small  number  of  experiments  compared  with  the  full 
isobologram  analysis.  This  is  particularly  important  if  the  combination  involves  a 
radiopharmaceutical  drug  in  order  to  minimise  the  risk  of  radiation  exposure  and 
contamination.   
We hypothesised that [
123I]FIAU toxicity to tumour cells expressing HSV1-TK would 
occur by two different pathways. The first results from HSV1-TK enzyme-mediated 
phosphorylation and subsequent DNA incorporation of [
123I]FIAU. This is similar to the 
mechanism of action of GCV and would lead to mutually exclusive drug effects in the 
GCV/ [
123I]FIAU combination. The other mechanism of [
123I]FIAU toxicity is the result 
of the ionising radiation due to the Auger electrons emitted by 
123I, leading to mutually 
non-exclusive interaction when these agents are combined. Therefore, CI values were 
generated according to both assumptions of similar and different mode of action. 
 
The  direct  comparison  of  the  clonogenic  surviving  fractions  after  individual  and 
combination therapy of the cell line 134B-TK, for example Fig. 5.10, indicated possible 
dose  dependent  supra-additive  effect  at  the  low  surviving  fractions  (i.e.  at  higher 
concentration  of  GCV/  [
123I]FIAU)  of  all  combination  schedules  in  this  cell  line. 
However, this comparison is not reliable, as it does not consider the sigmoidicity of the 
dose-effect curves and the exclusivity of drug effects. The subsequently generated CI 
values  have  confirmed  synergistic  drug  interaction  between  the  two  agents  in  the 
treatment of 143B-TK by all combination schedules. However, exposure to the smaller   167 
doses  of  all  combination  schedules  resulted  in  CI  values  greater  than  1,  indicating 
antagonism or infra-additive effect. 
Unlike the results obtained in 143B-TK cells, the CI values of the prostate cancer cell 
line DU145-TK were generally higher than 1, indicating antagonism. One exception was 
the high toxicity concentration range of the treatment schedule of GCV before FIAU 
(Fig.  5.7).  Variations  in  cell  lines’s  response  to  combination  therapies  have  been 
reported previously in several in vitro and in vivo studies (Aoe et al., 1999; Engblom et 
al., 1999; Kano et al., 1999; Topaly et al., 2002); (Bollig et al., 2005). One possible 
explanation of the antagonistic interaction observed in the prostate cancer cell line is the 
theoretical  competitive  mutual  inhibition  between  FIAU  and  GCV  for  HSV1-TK 
phosphorylation, which is a critical step for their intracellular retention and subsequent 
cytotoxicity. 
The dose dependent synergism which was observed with the cell line 143B-TK might 
indicate  enhancement  of  tumour  cell  radiosensitivity  to  [
123I]FIAU.  It  has  been 
demonstrated in extensive series of preclinical studies that the HSV1-TK/GCV suicide 
gene system is a potent tumour cell radiosensitiser (e.g. (Elshami et al., 1997; Kim et al., 
1994a;  Kim  et  al.,  1995;  Vlachaki  et  al.,  2001).  A  possible  explanation  for  this 
radiosensitivity enhancement is that HSV1-TK system inhibits DNA sub-lethal repair 
after radiation damage (Kim et al., 1995). Firslty, GCV inhibits DNA polymerase ￿ , the 
enzyme that has been implicated with the repair of potentially lethal damage. Secondly, 
phosphorylated GCV is incorporated into the DNA, making fraudulent DNA, which is 
more susceptible to strand breakage by radiation.  
The limitation of synergism to the higher doses of drug combinations (dose-dependent 
synergism)  is  one  of  the  recognised  phenomena  in  the  preclinical  assessment  of 
combination therapy in oncology (e.g. (Johnston et al., 2003). We attempted to explain   168 
this  and  the  difference  between  cell  lines  response  by  the  analysis  of  cell  cycle 
distribution.  
The cell line DU145-TK response to the combination schedule of FIAU-before-GCV 
showed antagonistic effect throughout the whole concentration range. In contrast, the 
cell  line  143B-TK  exhibited  different  interaction  with  synergistic  effect  at  the  high 
toxicity concentration range and additive effect at the low toxicity concentration range. 
Cell cycle analysis showed negligible changes after 4 h exposure to [
123I]FIAU in both 
cell  lines  to  a  similar  extent  which  does  not  explain  their  different  response  to  this 
combination schedule. However, the similar response of both cell lines to the GCV-
before-FIAU schedule coincided with a similar cell cycle shift to S and G2/M phases as 
shown in Fig. 5.9. Previous in vitro work has shown that HSV1-TK/GCV treatment 
leads to a gradual increase in the proportion of cells in S phase in keeping with the 
mechanism of action of the activated GCV as an anti-metabolite (McNeish et al., 2001).  
Although the evidence of synergism in this study was dose- and schedule-limited it is 
worth supporting these findings by an in vivo work in tumour xenografts or orthotopic 
prostate cancer models. Another issue that might be addressed is the use of other FIAU 
radioiodine conjugates such as the Auger electron emitter 
125I and the ￿ -particle emitter 
131I.  One  advantage  of  these  radionuclides  is  their  longer  half-life.  Furthermore, 
enhanced cell-kill might be achieved by the bystander and cross-fire effect of 
131I. 
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6.1 Conclusion  
The main hypothesis of this study was that there is a therapeutic benefit of delivering 
radiolabelled FIAU, alone or in combination with GCV, to prostate cancer tumour cells 
bearing the HSV-tk gene. As in other novel protocols of gene therapy, the process of 
testing  this  hypothesis  requires  a  series  of  preclinical  laboratory  investigations.  We 
have,  in  this  thesis,  presented  the  results  of  our  in vitro  experimental  work  on  this 
strategy, which we believe is supportive of this hypothesis.  
In our study, the initial HSV1-tk gene transfer into tumour cells using a plasmid vector 
and the cationic lipid effectene transfection reagent was shown to be highly efficient 
method  which  agrees  with  previous  studies,  e.g.  (Uchida  et  al.,  2002).  This  was 
confirmed by the transfection efficiency experiments. Despite a large variation in GCV 
sensitivity,  the  three  cell  lines  used  in  this  study  exhibited  comparable  degrees  of 
[
123I]FIAU uptake and sensitivity. The difference in GCV sensitivity enhancement by 
the thymidine kinase gene transfer was attributed to the variations amongst the cell lines 
rather than to the type of the plasmid vector or the transfection efficiencies as it was 
seen in previous studies, e.g. (Nagy et al., 2000). 
This study has illustrated that [
123I]FIAU was cytotoxic to tumour cells expressing the 
HSV1-tk gene. This cytotoxicity, which was evaluated by clonogenic assay, was dose-
dependent and it was enhanced by the prolongation of the incubation period. 
 There was 
a strong correlation between the proliferation rate and the cellular uptake and sensitivity 
of tumour cells bearing the HSV1-tk gene to radiolabelled FIAU. This confirms the 
notion that cellular proliferation is essential in this treatment modality which will work 
more efficiently for rapidly growing tumours. Moreover, there will be an advantage of   171 
sparing  the  normal  slow  growing  tissues.  This  is  in  agreement  with  the  findings  of 
previous studies (Neshasteh-Riz et al., 1998); (Audouy et al., 1999). 
Optimum tumour cell kill was achieved when the monolayers of the TK-positive clones 
of the DU145 and 143B cell lines were treated with [
123I]FIAU for an incubation period 
equivalent to the cellular doubling time. This will probably have an implication on the 
clinical  application  of  this  strategy  related  to  the  schedule  of  administration  of 
[
123I]FIAU. 
The treatment of the spheroid models of the TK-positive clones of the three cell lines 
failed to elicit a greater cell kill than that observed in the monolayers. For example, the 
IC50 value  for  the  monolayers  the  cell  line  DU145-TK  was  0.89  (±0.05)  MBq/  ml 
compared with 0.91 (±0.06) MBq/ ml for the spheroids (P > 0.05). This was anticipated 
according  to  the  results  obtained  from  previous  work  by  our  group  using  another 
thymidine  analogue  labelled  with 
123I  (Neshasteh-Riz  et  al.,  1998).  As  discussed 
previously, we attributed this to the ultra-short range of the Auger electron emitted as a 
result of 
123I decay. 
 It has been shown previously that suicide gene therapy using HSV1-tk and GCV in 
conjunction with spheroid models revealed even lower cellular toxicity when compared 
with the effect on monolayers of tumour cell lines (Finocchiaro et al., 2004). This was 
suggested to be secondary to compromised prodrug penetration and/ or higher fraction 
of quiescent cells in the spheroids that would be naturally resistant to this cell cycle-
dependent system. 
The final part of this study was a trial to amalgamate the strategy of targeted radiation 
cytotherapy with suicide gene therapy protocol using the transgene encoding the HSV1-
TK  enzyme.  The  combination  treatment  of  the  cell  line  143B-TK  revealed  dose-
dependent synergistic interaction following all treatment schedules. The most favourable   172 
combination schedule of the prostate cancer cell line DU145-TK was the GCV-before-
FIAU  schedule  which  resulted  in  a  dose-dependent  additive  effect.  Both  cell  lines, 
however,  exhibited  an  antagonistic  combination  effect  at  the  low  toxicity  range  of 
concentrations of the two agents. Although the two cell lines responded differently to 
this  combination  therapy,  there  was  an  evidence  of  synergism  in  one  cell  line  that 
warrants further investigation in other cell lines and animal models.  
We  have  also  investigated  the  impact  of  the  individual  treatment  with  GCV  or 
[
123I]FIAU on cell cycle progression in TK-positive clones of the two cell lines DU-145 
and 143B-TK. The treatment of the TK-positive cell lines with [
123I]FIAU for 4 h and 
GCV for 72 h caused no significant cell cycle redistribution. A significant finding was 
the cell cycle arrest at G2/M-phase following the exposure to [
123I]FIAU for a period 
equal to the doubling time of the respective cell lines. Due to the fact that tumour cells 
are most radiosensitive in the G2-phase, one of the implications of this cell cycle arrest 
would be the potential benefit of scheduled combination of this strategy with EBRT for 
the treatment of prostate cancer.  
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6.2 Future work  
 
Contrary to the traditional pharmaceutical preclinical drug research, experimental gene 
therapy involves at least two extra steps such as gene transfer and the assessment of its 
long  term  sequels.  This  is  one  of  the  hurdles  which  are  delaying  the  progress  of 
numerous strategies of gene therapy.   
The main part of our future work will include testing the effect of radiolabeled FIAU on 
other cell lines of prostate cancer and other tumours both with and without the viral tk 
gene expression. Further work is also required to improve the transfection effeciency of 
the viral tk gene. In terms of prostate cancer, this will involve trying different tissue- and 
tumour-specific promoters such as the PSA and the telomerase promoters. Furthermore, 
the results obtained from the spheroid experiments were disappointing and, therefore, 
more work is needed using longer incubation periods and utilising FIAU conjugated 
with different isotopes of the radioactive iodine such as the ￿ -particle emitter 
131I.  
In  concordance  with  the  ethics  of  preclinical  research,  this  experimental  therapeutic 
approach should be tested in animals before any clinical trial could be approved. 
To support the findings of our study, the first step of the experimental animal work 
would aim to confirm the therapeutic potential of the radiolabelled FIAU for tumours 
transfected with the HSV1-tk gene. Most animal studies are currently performed using 
transplanted tumours produced by the subcutaneous or intramuscular implantation of 
cancer  cell  lines  (xenografts).  Subcutaneous  heterotopic  graft models  are  often  used 
because they are relatively easy to generate. Unfortunately, this approach completely 
ignores  the  histological  and  anatomical  specificity  of  the  organ  under  investigation. 
Consequently,  although  they  are  useful  in  a  limited  fashion,  these  studies  do  not 
adequately serve as preclinical trials of human gene therapy (Shimizu et al., 2001). It   174 
will be advantageous; therefore, to investigate this novel approach of gene therapy using 
orthotopic tumour models such as the inoculation of cancer cells into the prostate gland 
of the experimental animal (Freytag et al., 2002b).  
A potential model could initially involve ex vivo transfer of the HSV1-tk gene into a cell 
line derived from prostate cancer and then orthotopic inoculation of these transfected 
cells into the prostate gland of a number of rats or mice. The ability of these cells to 
form orthotopic tumour could be assessed by in situ tk gene expression imaging using 
systemic  administration  of  radiolabelled  FIAU  and  PET  (Tjuvajev  et  al.,  2002)  or 
SPECT scanning (Gambhir et al., 2000)  
Alternatively, these orthotopic prostate tumours could be detected using small animal 
MRI scan (Abdulkadir et al., 2001) or by monitoring serum PSA (Freytag et al., 2002b). 
The other model of orthotopic prostate cancer has an additional step of in vivo transfer 
of the HSV1-tk gene into previously prepared TK-negative orthotopic prostate tumours 
e.g. (Zhang et al., 2002). This model recapitulates better the real clinical scenario when 
treating organ-confined human prostate cancer with this strategy.  
In addition, rodent prostate carcinoma models have been developed, which could also 
serve as preclinical models for this strategy. Methods to develop these rodent models 
include  hormone  treatment  (Noble,  1977),  transgenic  prostate-specific  oncogene 
expression  (Greenberg  et  al.,  1995),  and  knockout  of  tumour  suppressor  genes 
(Podsypanina et al., 1999). 
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